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Abstract 
Classical Hodgkin lymphoma (cHL) is one of the commonest lymphomas in the 
developed world, frequently affecting young adults. The majority of patients 
will be cured of their disease, but the toxicities of the therapy required to 
achieve this can lead to long-term morbidity in survivors. In addition, whilst 
most patients are cured, there remains approximately 15% -20% of patients who 
will not respond to primary therapy and may ultimately die of their disease.   
Approximately one-third of cases of cHL in the developed world are associated 
with the Epstein-Barr virus (EBV), where this association is believed to be causal. 
A ubiquitous herpesvirus, persistently infecting more than 95% of the world’s 
population, precisely how this virus causes malignant disease in a minority of 
immune competent hosts remains ill-understood.  
Epidemiological evidence points to inherited genetic factors. Long-recognised to 
have an association with the class I human leukocyte antigen (HLA) system, 
recent studies have confirmed that risk of EBV-associated cHL is related to an 
individual’s HLA-A* allotype, with HLA-A*01:01 being associated with increased 
risk of disease and HLA-A*02:01 being protective. Heterozygotes are observed to 
have an intermediate risk. HLA plays a central role in the recognition and cell 
killing of virally-infected or malignant cells by the cytotoxic T lymphocytes 
(CTLs) of the cell-mediated immune system. The exact mechanism whereby HLA-
A* exerts its effect on risk of cHL unknown, but CTL responses to EBV in this 
context are hypothesised to be crucial.  
The CTL response to EBV is well-studied. Immunodominant epitopes restricted 
through common class I alleles have been described, many directed towards 
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peptides derived from proteins expressed in the lytic cycle of viral infection. In 
spite of intensive study, no confirmed HLA-A*01:01-restricted EBV-specific CTL 
responses have been described, raising the possibility that absent or weak CTL 
responses specifically to EBV might lead to elevated risk of disease. However, 
particularly given the intermediate risk of disease seen in HLA-A*01:01 
heterozygotes, it remains a possibility the HLA-A*01:01-associated risk might be 
due to qualitative or inhibitory changes to the EBV-specific immune response. 
The work of this thesis set out to address a number of specific questions 
regarding the role of HLA class I in the aetiology and clinical outcome of cHL. 
Firstly, whether an HLA-A*01:01 allele could modify the magnitude of the CTL 
response to HLA-A*02:01-restricted epitopes was examined. In a study of healthy 
adults examining CTL responses using interferon-γ ELISPOT, overall HLA-A 
phenotype did not significantly affect the EBV-specific CTL response restricted 
through HLA-A*02:01. However, exploratory analysis of cytokine levels in 
response to stimulation with EBV peptides demonstrated significantly higher 
secretion of IL-10 (with a nearly 10-fold difference), IL-17 and IL-5 in response to 
stimulation with EBV peptides in HLA-A*02:01/A*01:01 heterozygotes, compared 
to other HLA-A*02:01 phenotype groups. This suggests a possible effect of HLA-
A*01:01 in HLA-A*02:01/A*01:01 heterozygotes which might begin to explain 
some of the HLA-associated differences in risk of developing EBV+ve cHL. 
Secondly, again in a study of healthy EBV-seropositive adults, and using sensitive 
methodologies, HLA-A*01:01-restricted EBV-specific CTL responses were sought, 
and, in an exploratory analysis, cytokine responses were examined. No HLA-
A*01:01-restricted CTL responses to EBV were detected in this study, however, 
exploratory analysis demonstrated statistically significant differences in cytokine 
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levels following simulation with EBV, with HLA-A*01:01 homozygotes generating 
much higher levels of IL-6. 
Lastly, given the importance of class I HLA in determining risk of developing 
EBV+ve cHL, a study of 424 patients with cHL was performed to determine if 
HLA-A*01:01 and A*02:01 alleles are a factor in determining clinical outcome. In 
this study, HLA-A*02:01 was associated with inferior overall survival (OS) and 
disease-specific survival (DSS) in EBV+ve cHL, and was independently prognostic 
in an adjusted analysis. Given the extremely poor outcomes seen in this study in 
HLA-A*02:01 carriers with EBV+ve disease (61.7% 10-year OS), it is possible that 
this group of patients is not currently being well-served by standard first-line 
therapy and may benefit from novel therapies.  
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Symbols and Abbreviations. 
Symbols 
 
α alpha 
β beta 
γ gamma 
Δ delta 
κ kappa 
oC degrees centigrade 
µ micro 
% per cent 
  
Abbreviations (also defined at time of first use in the text). 
 
AA amino acid 
ABCC1 ATP-binding cassette, sub-family C 
ABVD doxorubicin, bleomycin, vinblastine, dacarbazine 
AIDS acquired immune deficiency syndrome 
Akt 
also known as Protein Kinase B (PKB),  a serine/threonine-
specific protein kinase 
BamH1 Bacillus amyloli restriction endonuclease 
BARTS BamHI A rightward transcripts  
BCIP 5-bromo-4-chloro-3'indolylphosphate p-toluidine salt 
bcl-2 B cell lymphoma 2 
BCR B cell receptor 
BD-PBMC B cell depleted PBMC 
BEACOPP 
bleomycin , etoposide, doxorubicin, cyclophosphamide, 
vincristine, procarbazine, prednisolone 
BOB1 B cell Oct binding protein 1 
CCL chemokine (C-C motif) ligand 
CCM complete culture medium 
CD cluster of differentiation 
CEF CMV, EBV, 'flu 
CGH comparative genomic hybridisation 
cHL classical Hodgkin lymphoma 
CI confidence interval 
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CIITA class II, major histocompatibility complex, transactivator 
CM  culture medium 
CMV cytomegalovirus 
CO2 carbon dioxide 
COPP cyclophosphamide, vincristine, procarbazine, prednisolone 
COSHH control of substances hazardous to health 
CR complete response 
CRF clinical research facility 
CSF colony stimulating factor 
CSF1R colony stimulating factor 1 receptor 
CT  computed tomography 
CTL cytotoxic T lymphocyte 
CVID chronic variable immune deficiency 
DLBCL diffuse large B cell lymphoma 
DMSO dimethyl sulfoxide 
DNA deoxy-ribonucleic acid 
DSS disease-specific survival 
EA early antigen 
E2A E2A immunoglobulin enhancer binding factors E12/E47 
EBER EBV virus encoded small RNA 
EBF early B cell factor 
EBNA EBV nuclear antigen 
EBV Epstein-Barr virus 
EBV+ve cHL EBV-associated classical Hodgkin lymphoma 
EBV-ve cHL EBV-negative classical Hodgkin lymphoma 
ECD electron coupled dye, also known as PE-Texas red 
EDTA ethylenediamine tetra-acetic acid 
EFS event-free survival 
ELISA enzyme-linked immunosorbent assay 
ELISPOT enzyme-linked immunospot  
ERK extracellular signal-regulated kinases 
ESR erythrocyte sedimentation rate 
FBS foetal bovine serum 
FCR immunoglobulin constant region 
FDG fluorodeoxyglucose 
FFTF freedom from treatment failure 
FITC fluorescein isothiocyanate 
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FOXP3 forkhead box P3  
Fyn FYN oncogene related to SRC, FGR, YES 
g x gravity 
GC germinal centre 
GEP gene expression profiling 
GHSG German Hodgkin Study Group 
GM-CSF granulocyte-macrophage colony-stimulating factor 
GWAS genome-wide association study 
Gy Gray 
HBSS Hank's Balanced Salt Solution 
HCl hydrochloric acid 
HIV human immunodeficiency virus 
HL Hodgkin lymphoma 
HLA human leukocyte antigen 
HPLC high-performance liquid chromatography 
HRS Hodgkin and Reed-Sternberg 
IARC International Agency for Research on Cancer 
IE Immediate early 
IFN interferon 
Ig immunoglobulin 
IgD immunoglobulin D 
IgG immunoglobulin G 
IgM immunoglobulin M 
IgV immunoglobulin variable 
IHC immunohistochemistry 
IκB IκB kinase 
IL interleukin 
IM infectious mononucleosis 
IPS international prognostic score 
IRAS integrated research application service 
JAK Janus kinase 
LCL lymphoblastoid cell line 
LD linkage disequilibrium 
LDHL lymphocyte deplete Hodgkin lymphoma 
LMP latent membrane protein 
LRF Leukaemia Research Fund 
LRHL lymphocyte rich Hodgkin lymphoma 
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M molar 
MALDI matrix-assisted laser desorption and isolation  
MAPK mitogen-activated protein kinase 
MCHL mixed cellularity Hodgkin lymphoma 
MHC major histocompatibility complex 
MIG macrophage-induced gene, also known as CXCL9 
min minute 
miRNA micro ribonucleic acid 
ml millilitre 
MMB minimacs buffer 
MMP matrix metalloproteinase 
mRNA messenger ribonucleic acid 
MS multiple sclerosis 
MUM1 melanoma associated antigen (mutated) 1 
NaOH sodium hydroxide 
NBT nitro blue tetrazolium chloride 
NF-κB nuclear factor κ B 
NHL non-Hodgkin lymphoma 
NK natural killer 
NLPHL nodular lymphocyte predominant Hodgkin lymphoma 
NPC nasopharyngeal carcinoma 
NSHL nodular sclerosis Hodgkin lymphoma 
Oct2 organic cation transporter 2 
OR odds ratio 
ORF open reading frame 
OS overall survival 
PAX5 paired box 5 
PBMC peripheral blood mononuclear cell 
PBS  phosphate buffered saline 
PCR polymerase chain reaction 
PD progressive disease 
PD-1L programmed death 1 ligand 
PE phycoerythrin 
PEL primary effusion lymphoma 
PET positron emission tomography 
PFS progression-free survival 
PHA phytohaemagglutinin 
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PI3K phosphoinositide-3-kinase 
PML promyelocytic leukaemia gene 
PR partial response 
PTLD post-transplant lymphoproliferative disease 
PU1 transcription factor binding to the PU-box 
QC quality control 
RANK 
receptor activator of nuclear factor-kappa B, also known as 
tumour necrosis factor receptor superfamily member 11A 
RANK-L RANK-ligand 
RANTES 
regulated on activation, normal T cell expressed and 
secreted 
RAS rat sarcoma 
Rel v-rel reticuloendotheliosis viral oncogene homolog 
RNA ribonucleic acid 
RT  room temperature 
s seconds 
SAP SLAM-associated protein 
SD standard deviation 
SEM standard error of the mean 
SFC spot-forming cells 
SHARE Study of Healthy Adult Responses to EBV 
SIR standardised incidence ratio 
SLAM signalling lymphocytic activation molecule 
SNBTS Scottish National Blood Transfusion Service 
SNEHD 
the Scotland and Newcastle epidemiological study of 
Hodgkin's disease  
SNP single-nucleotide polymorphism 
SOCS1 suppressor of cytokine signalling 1 
SP side population 
SSO  sequence specific oligonucleotide 
STAT signal transducers and activators of transcription 
Syk spleen tyrosine kinase 
TAP transporter associated with antigen processing 
TARC Thymus and activation regulated chemokine, CCL17 
TCR T cell receptor 
TE tris-edta 
Th T helper 
TIA-1 TIA1 cytotoxic granule-associated RNA binding protein 
TIMP tissue inhibitor of metalloproteinases 
TNF tumour necrosis factor 
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TNFAIP3 tumour necrosis factor alpha induced protein 3 
TNFR tumour necrosis factor receptor 
Treg T regulatory cell 
Ts T suppressor cell 
UK United Kingdom 
VCA  viral capsid antigen 
VZV varicella zoster virus 
WAS Wiskott-Aldrich syndrome 
WHO World Health Organisation 
x times 
XLP x-linked lymphoproliferative syndrome 
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1.1  Hodgkin Lymphoma - Introduction 
Hodgkin lymphoma (HL) is a B lymphocyte malignancy, characterised by the 
presence of the mononuclear Hodgkin and multinucleate Reed-Sternberg cells, 
collectively known as Hodgkin and Reed-Sternberg (HRS cells). First described in 
1832 by Thomas Hodgkin (Hodgkin, 1832) and subsequently called Hodgkin’s 
disease, it has now been re-named Hodgkin lymphoma following its recognition 
as a clonal lymphoid disease (Stein et al, 2008). HL is unique in a number of 
regards, which presents special challenges to elucidating its complex biology and 
translating this into tangible clinical progress.  
HL is one of the commonest lymphomas in the developed world, occurring with 
an incidence of approximately 3 per 100,000 person-years (Information Services 
Division, 2010) and accounting for approximately 10-30% of new lymphomas 
diagnosed worldwide (Stein et al, 2008). In contrast to non-Hodgkin lymphomas 
(NHLs), HL commonly affects young adults and is the second commonest cancer 
in teenagers and young adults in Scotland (Information Services Division, 2010). 
Approximately 170 individuals in Scotland will be diagnosed with HL per year, 
and the incidence is increasing (Information Services Division, 2010). Moreover, 
HL has served as the paradigm for treatment of malignant disease with 
successful outcomes now reported for the majority of patients presenting with 
the disease. A sizeable minority, however, will relapse or have resistant disease, 
and ultimately succumb to their disease. Identifying and treating this group is 
becoming an increasing priority of the international HL research community. 
HL is one of a small number of cancers recognised by IARC (International Agency 
for Research on Cancer) (IARC Working Group on the Evaluation of Carcinogenic 
Risk to Humans, 2009) to have a viral origin in a proportion of cases. In 
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approximately one third of cases of HL, Epstein-Barr virus (EBV) is present within 
the malignant cell, where its presence is thought to be causal (Jarrett, 2002). 
EBV is itself oncogenic, and the virus plays a central role in HRS cell survival and 
proliferation. Important differences are seen in the epidemiology and biology of 
EBV-associated (EBV+ve) cHL, as compared with EBV-negative (EBV-ve) cHL. The 
interaction of the immune system, particularly cytotoxic T lymphocytes (CTLs), 
with the virus in EBV+ve cHL is being recognised as increasingly important. This 
is reflected in the class I human leukocyte antigen (HLA) associations with risk of 
developing EBV+ve cHL, and is the subject of this thesis. 
1.2  Hodgkin Lymphoma - Pathology 
The World Health Organisation (WHO) in its “Classification of Tumours of 
Haematopoietic and Lymphoid Tumours” defines HL as comprising two disease 
entities, classical Hodgkin lymphoma (cHL) and nodular lymphocyte predominant 
Hodgkin lymphoma (NLPHL), Table 1.1.  
Table 1-1 Classification of Hodgkin Lymphoma 
Sub-type of 
Hodgkin 
Lymphoma 
Abbreviation 
Proportion 
of all cases 
Malignant cell Incidence 
Association 
with EBV 
classical 
Hodgkin 
lymphoma 
cHL 95% 
Hodgkin and 
Reed-Sternberg 
(HRS) cell 
Bimodal age 
distribution (peak 
at 15-35 and > 50 
years) 
Approximately 
1/3 of cases 
associated with 
EBV 
Nodular 
lymphocyte 
predominant 
Hodgkin 
lymphoma 
NLPHL 5% 
Lymphocyte 
predominant 
(LP) cell, also 
known as 
"popcorn cell" 
Unimodal age 
distribution 
(median age 35) 
Not associated 
with EBV 
 
There is increasing evidence that the cell of origin, pathogenesis and clinical 
course of NLPHL are distinct from cHL. Accounting for 5% of all HL diagnoses, 
NLPHL is increasingly recognised as a separate disease entity. It is not associated 
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with EBV. The other 95% of HL diagnoses are cHL. Discussion in the remainder of 
this thesis will be restricted to cHL, unless stated otherwise. 
One striking feature of cHL is the rarity of the malignant cell in the tumour with 
the malignant HRS cell typically accounting for around 1% of the tumour mass 
(range 0.1-10%) (Kuppers, 2009b). Usually diagnosed on excision biopsy or core 
biopsy of a lymph node, a diagnosis of cHL requires the presence of the classical 
Reed-Sternberg cells which are large, with abundant cytoplasm and binucleate, 
or their mononuclear counterpart, the Hodgkin cell, collectively referred to as 
HRS cells. The remainder of the tumour comprises a mixed inflammatory cellular 
infiltrate, thought to be crucial in the survival of the malignant cells. This 
infiltrate includes small lymphocytes, often rosetting the HRS cell, eosinophils, 
neutrophils, plasma cells, and fibroblasts (Figure 1.1). The nature and 
importance of this inflammatory background is discussed in Section 1.3.7.  
 
Figure 1-1 Lymph node biopsy, classical Hodgkin lymphoma  
Haematoxylin and eosin staining (x400 original magnification) showing classical appearance 
of nodular sclerosis Hodgkin lymphoma, with large mononuclear and binucleate Hodgkin and 
Reed-Sternberg cells (black arrows) in a polymorphous background of cells which includes 
small lymphocytes and eosinophils. With thanks to Dr. G. Bryson, Department of Pathology, 
Southern General Hospital, Glasgow. 
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The modern classification of HL is based on the morphological appearances of 
the disease, particularly the composition of the background cellular infiltrate 
(Lukes & Butler, 1966). Within cHL there is further sub-classification into four 
histological subtypes (Table 1.2).  
Table 1-2 Sub-types of classical Hodgkin Lymphoma 
Subtype of cHL Abbreviation 
Proportion of 
cHL 
Association with 
EBV 
Outcome 
Nodular sclerosis 
Hodgkin lymphoma 
NSHL 70% 
Approximately 10-
30% of cases 
associated with 
EBV (depending on 
local patterns) 
No strong 
association with 
outcome 
Mixed cellularity 
Hodgkin lymphoma 
MCHL 20-25% 
More strongly 
associated with 
EBV (approximately 
75% of cases) 
No strong 
association with 
outcome 
Lymphocyte rich 
Hodgkin lymphoma 
LRHL 
Approximately 
5% 
Less commonly 
associated with 
EBV 
Associated with 
better outcome 
Lymphocyte depleted 
Hodgkin lymphoma 
LDHL < 1% 
Strong association 
with EBV 
Associated with 
poor outcome 
 
The four subtypes of cHL continue to be reported to clinicians, and recorded by 
cancer registries. Although they share the same immunophenotype and 
malignant cell, these subtypes vary in their epidemiology, clinical features, sites 
of involvement, degree of fibrosis, cellular microenvironment and frequency of 
association with EBV. There is some evidence that histological subtype is 
associated with outcome; it is recognised that lymphocyte depleted HL (LDHL), 
although rare, has an extremely poor outcome compared with other subtypes 
(Klimm et al, 2011). Lymphocyte rich (LR) histology probably has the best 
outcome, with nodular sclerosis (NS) and mixed cellularity (MC) disease falling 
somewhere in the middle. Histological subtype is also associated with age, with 
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NSHL seen more commonly in young adults, and MCHL seen more commonly with 
increasing age. The increased incidence of MCHL in older adults may, in part, 
reflect the proportion of cases due to EBV. At present, treatment of cHL does 
not vary between histological subtypes. 
Immunohistochemistry (IHC) is crucial to the diagnosis of cHL. The HRS cell has a 
downregulated B cell programme (Section 1.3.3).  Although HRS cells express B 
cell transcription factors, such as melanoma associated antigen (mutated) 1 
(MUM1) and paired box 5 (PAX5), they are typically negative for pan B cell 
markers, such as cluster of differentiation (CD) 19 or CD20, and also the pan-
leucocyte marker CD45 (Hertel et al, 2002; Schwering et al, 2003). Instead, the 
tumour necrosis factor receptor (TNFR) family member CD30 (Figure 1.2) and the 
aberrantly expressed myeloid marker CD15 are present in most cases, and 
provide the basis of diagnosis.  
 
Figure 1-2 Lymph Node Biopsy, classical Hodgkin lymphoma, stained for CD30 
Same case as in Figure 1.1, x200 original magnification, immunohistochemical staining for 
CD30. The tumour necrosis factor receptor family member CD30 is expressed by the 
malignant Hodgkin and Reed-Sternberg cells. With thanks to Dr. G. Bryson, Department of 
Pathology, Southern General Hospital, Glasgow. 
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In approximately 40% of cases (Stein et al, 2008), the B cell marker CD20 is 
expressed, usually on only a minority of cells, and at low surface intensity. 
There is some evidence that CD20 expression may be associated with outcome 
(discussed in Section 1.4.4). In addition, the putative “stem-cell” which has 
been described in cHL (discussed in Section 1.3.2) is also CD20 positive. Although 
the clonal expansion of the HRS cells occurs after the germinal centre (GC) 
(Section 1.3.1), the HRS cells are negative for the plasma cell markers CD138 
and CD38. Diagnostic difficulty can arise in cases of B cell NHL with anaplastic 
morphology and CD30 positivity, or with anaplastic T-cell NHL. True biological 
overlap conditions can arise in the “grey-zone” lymphomas with pathological 
features and phenotype intermediate between cHL and diffuse large B cell 
lymphoma (DLBCL) where outcome is generally poor. Determination of the EBV 
status of the cHL is by in-situ hybridisation for EBV virus encoded small RNA 
(EBER) or IHC for EBV latent membrane protein (LMP) 1, (Gulley et al, 2002).  
1.3  Biology of cHL 
1.3.1 Cellular origin of cHL 
The cell of origin of cHL remained elusive for many years, the rarity of the 
malignant cell contributing to the difficulty in characterising these cells. 
However, in the 1990s, microdissection, coupled with immunoglobulin (Ig) gene 
re-arrangement analysis of single cells revealed that the malignant cell in cHL is 
usually a clonal B cell. HRS cells from nearly all cases have re-arrangements of Ig 
heavy and/or light chain genes, confirming a B cell origin (Kuppers et al, 1994; 
Kuppers et al, 1996). The finding of identical mutations within each case 
confirmed the clonal nature of the disease (Kanzler et al, 1996; Marafioti et al, 
2000). In addition, the variable regions of the immunoglobulin gene (IgV) 
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demonstrate somatic hypermutation, suggesting a GC or post-GC derivation 
(Kuppers, 2002). In the HRS cell, these somatic hypermutations are also clonal, 
suggesting that the HRS cell arises from a relatively late stage of B cell 
differentiation (Brauninger et al, 2006). 
In normal post-GC B lymphocytes, the somatic hypermutations in the IgV genes 
result in cells which recognise antigen with high affinity, and are thus selected 
to proliferate as B-memory lymphocytes and to undergo further differentiation 
to plasma cells (Figure 1.3). B lymphocytes which do not express a functional Ig 
as part of a B cell receptor (BCR) complex, would normally undergo apoptosis 
(Kuppers & Hansmann, 2005). In HRS cells non-functional or “crippling” 
mutations of IgV, e.g. through acquisition of a stop codon, are detected in 
approximately 25% of cHL cases (Kuppers et al, 1994; Kanzler et al, 1996; 
Brauninger et al, 2006; Kuppers et al, 2001). The ability of the HRS cell to 
survive in the face of apoptotic signalling is considered central in disease 
pathogenesis. It was later shown that nearly all cases with such crippling 
mutations are EBV+ve supporting an essential role for EBV in the development of 
HRS cells from germinal centre B cells with these types of unfavourable 
mutations (Brauninger et al, 2006). 
In rare cases (< 2%), HRS cells have been demonstrated to harbour T-cell 
receptor gene rearrangements rather than Ig gene rearrangements. These cases 
appear to represent true/ genuine cases of cHL, and so a T-cell origin in a 
minority of cases remains a possibility (Muschen et al, 2000; Muschen et al, 
2001; Seitz et al, 2000). 
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Figure 1-3 The germinal centre origin of the Hodgkin and Reed-Sternberg cell 
Mature but antigen-naïve B lymphocytes, with re-arranged immunoglobulin (Ig) variable 
genes (V-genes), following encounter with an antigen, are driven into follicles within the 
lymph nodes and spleen. There the cells undergo clonal expansion and somatic 
hypermutation producing an Ig molecule with high affinity for the antigen. Those high-
affinity cells are selected for differentiation, with the help of T-helper (Th) cells and 
dendritic cells (DC) differentiate into antibody-producing plasma cells, or long-lived memory 
B cells. Germinal centre, somatically hypermutated B cells which do not produce a 
functional Ig normally undergo apoptosis. This is the population thought to give rise to the 
Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. 
 
1.3.2 A Hodgkin lymphoma stem cell? 
True stem cells, as in acute leukaemia, are recognised by a capacity for 
unlimited self-renewal and generally a facility to produce progeny of multiple 
lineages. However, malignant lymphomas, including cHL, arise from mature 
lymphocytes. Mononuclear Hodgkin cells are capable of self-replication and 
generation of the multinucleate Reed-Sternberg cells through endomitosis 
(nuclear division without cellular division). The Reed-Sternberg cells are 
generally arrested cells unable to undergo further division (Ikeda et al, 2010). 
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The existence of a “lymphoma stem cell” or, to be more precise, a “lymphoma 
originating cell” has yet to be proved and remains controversial.  
A recent study used flow cytometry for the stem cell marker aldehyde 
dehydrogenase to detect rare populations of small cells within cHL derived cell 
lines (Jones et al, 2009). These small cells were CD20 positive and shown to be 
capable of generating cultures of large HRS cells. They were also demonstrated 
to be present in the peripheral blood of patients with the disease by flow 
cytometry. The presence of rare (0.5%) side population (SP) cells in both cHL 
derived cell lines and primary tissue specimens has also been documented 
(Shafer et al, 2010). SP cells are defined by the capability of the ABC transporter 
to expel chemotherapeutic drugs from the cell; they share features with cancer 
stem cells and may cause disease relapse if not eradicated.  
Much of this work is controversial and criticisms based on technical concerns 
have been raised (Kuppers, 2009a; Kuppers, 2010). No investigator has yet 
proven that these cells are clonogenic. However, one of the strongest pieces of 
circumstantial evidence validating the concept of the CD20 positive “cHL-
originating cell” was the finding in a subsequent clinical study that persistence 
of detectable circulating clonotypic B cells was associated with a greater relapse 
frequency (p < 0.05) (Kasamon et al, 2012). 
1.3.3 Cellular re-programming 
Despite its B cell origin, the HRS cell does not express a typical B lymphocyte 
phenotype. Typical B lymphocyte lineage surface markers, such as CD20, CD19, 
CD79 and surface Ig are not present, and the B lymphocyte transcription factors, 
such as organic cation transporter 2 (OCT2), B cell Oct binding protein 1 (BOB1) 
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and transcription factor binding to the PU-box  (PU1) are downregulated (Hertel 
et al, 2002; Schwering et al, 2003). The B lymphocyte-specific transcription 
factor PAX5 usually continues to be expressed, although often at low levels, but 
when present can be useful to the pathologist in distinguishing cHL from T cell 
NHLs (Foss et al, 1999). As has been discussed, HRS cells classically express 
CD30, normally expressed on activated B and T cells, and the myeloid/monocyte 
lineage marker CD15. HRS cells are observed to aberrantly express other lineage 
markers, such as T lymphocyte markers CD3, CD4 and granzyme B (Drexler, 
1992), and dendritic cell markers, fascin and thymus and activation regulated 
chemokine (TARC) also known as chemokine (CC-motif) ligand (CCL) 17) (Peh et 
al, 2001). This loss of B cell signature may be one of the mechanisms adopted by 
the HRS cell to survive without the tonic BCR signalling normally required to 
prevent apoptosis.  
Epigenetic modification plays an important role in the transcriptional 
downregulation of genes associated with the B cell phenotype. Groups of genes 
are silenced by promoter methylation, suggesting the involvement of a master 
transcriptional regulator(s) (Ushmorov et al, 2004). Activation of Notch1 
signalling may be important as it promotes transcription of genes associated with 
a T lymphocyte phenotype, and suppresses B cell differentiation through 
interference with B cell transcription factors. Notch1 promotes the degradation 
of E2A immunoglobulin enhancer binding factors E12/E47 (E2A) (Nie et al, 2003) 
and blocks the ability of early B cell factor (EBF) to bind to deoxy-ribonucleic 
acid (DNA) (Smith et al, 2005), and has been observed to inhibit PAX5 at a 
transcriptional and post-transcriptional level (Jundt et al, 2008). 
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1.3.4 Survival and proliferation signals 
Cellular re-programming is only one of many survival strategies the HRS cell 
employs. Numerous transcription factors, the most crucial of which is nuclear 
factor-κB (NF-κB), are altered to promote survival and proliferation. NF-κB is a 
collection of transcription factors which comprises RelA (p65), RelB, c-Rel, NF-
κB1 (p50 and its precursor p105) and NF-κB2 (p52 and its precursor p100) which 
are involved in inflammatory responses and cell fate decisions (Ghosh et al, 
1998). NF-κB is constitutively active in HRS cells (Bargou et al, 1997; Bargou et 
al, 1996), where it is required for proliferation and survival.  
NF-κB can be activated in a number of ways in cHL. First, many of the tumour 
necrosis factor (TNF)-family receptors upstream of NF-κB, including CD30, CD40 
and CD95, are upregulated (Fiumara et al, 2001; Carbone et al, 1995). The 
cellular microenvironment in which the HRS cell resides (see below) provides 
ligands of these receptors, resulting in unregulated paracrine stimulation. 
Second, EBV can directly activate NF-κB via LMP1 which mimics CD40 signalling 
(see below). Third, mutations in the genes for inhibitors of NF-κB, IκB (IκB 
kinase) have been described in 10-20% of cases of cHL (Emmerich et al, 1999; 
Jungnickel et al, 2000; Lake et al, 2009; Cabannes et al, 1999), and genomic 
gains of c-Rel have been described in nearly 50% of cases (Barth et al, 2003). 
Lastly, inactivating mutations of the TNF-α induced protein 3 (TNFAIP3) gene, 
which encodes the NF-κB inhibitor A20, have been described in approximately 
40% of cases of cHL (Kato et al, 2009; Schmitz et al, 2009a), particularly EBV-ve 
cases.  
Also implicated in the proliferation and apoptosis resistance of HRS cells is the 
Janus kinase – signal transducers and activators of transcription (JAK-STAT) 
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pathway, one of the central mechanisms of cytokine signal transduction. The 
cytokines which initiate JAK-STAT signalling, including interleukin (IL)-6, IL-9, IL-
13 and granulocyte-macrophage colony-stimulating factor (GM-CSF), are 
produced in the cHL tumour and activate the downstream STAT3, STAT5 and 
STAT6 (Hinz et al, 2002; Skinnider et al, 2002a; Kube et al, 2001). Genomic 
lesions affecting the JAK-STAT pathway have also been described, including 
frequent genomic gains of JAK2 (Joos et al, 2003) and inactivating mutations of 
suppressor of cytokine signalling 1 (SOCS1), a negative regulator of JAK-STAT 
signalling (Weniger et al, 2006). 
Additional pro-proliferation signalling pathways constitutively activated in cHL 
include Notch1 (Jundt et al, 2008; Jundt et al, 2002), the phosphoinositide-3-
kinase (PI3K/Akt) pathway (Dutton et al, 2005) and the mitogen-activated 
protein kinase (MAPK)/ extracellular signal-regulated kinases (ERK) pathway 
(Zheng et al, 2003). The myeloid cell receptor colony-stimulating factor 1 
receptor (CSF1R) functions as an oncogene in cHL and is activated by de-
repression of an endogenous long terminal repeat upstream of the gene 
(Lamprecht et al, 2010).  
Micro ribonucleic acid (miRNAs), small non-coding RNAs that bind to and 
influence translation of messenger RNA (mRNA), have over recent years been 
shown to be important in the development of cancer. A number of miRNAs have 
been shown to be dysregulated in cHL as compared to normal B cells (Kluiver et 
al, 2005; Van Vlierberghe et al, 2009), and many of these could putatively be 
associated with targets linked to proliferation, although functional studies have 
to date not been performed. 
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Thus, multiple signalling pathways and transcriptional regulators are disrupted in 
the HRS cell, where they are thought to cooperate to induce proliferation, 
suppress apoptosis and promote a favourable cellular microenvironment (Section 
1.3.7).  
1.3.5 Chromosomal abnormalities  
In contrast to a number of B cell NHLs, which are characterised by a single 
recurrent chromosomal abnormality, there are no recurrent cytogenetic 
abnormalities which characterise cHL. However, most cHL malignant cells have 
complex cytogenetics. Conventional and array comparative genomic 
hybridisation (CGH) studies (Joos et al, 2003; Kluiver et al, 2007; Chui et al, 
2003; Steidl et al, 2010b) have demonstrated a number of recurrent imbalances 
including gains of 2p (which includes the REL oncogene), 9p (on which is located 
JAK2), 12p, 16p, 17p, 17q, 19p, 19q, 20q, 21q and 22q, and losses of 1p, 6q, 7q, 
8p, 11q and 13q. Minimal regions were defined which harboured genes of 
interest, including REL, IκB, CD40, MAP3K14, TNFAIP3, JAK2, programmed death 
1 ligand (PD-1L) and class II, major histocompatibility complex, transactivator  
(CIITA) (Steidl et al, 2011; Steidl et al, 2010b). 
1.3.6 Genome-wide association studies 
Over recent years a number of genome-wide association studies (GWAS) have 
been performed to look for germ-line variations associated with development of 
cHL (Enciso-Mora et al, 2010; Cozen et al, 2011; Urayama et al, 2012). These 
have shown strong associations with the HLA region (discussed in Section 1.7.2) 
and also identified a number of non-HLA loci associated with risk of disease. 
Susceptibility loci have been described (Enciso-Mora et al, 2010) at 2p16.1 
(rs1432295, REL, odds ratio (OR) = 1.22, p = 1.91 x 10−8), 8q24.21 (rs2019960, 
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PVT1, OR = 1.33, p = 1.26 × 10−13) and 10p14 (rs501764, GATA3, OR = 1.25, p = 
7.05 × 10−8). That the three loci identified are of genes described as functionally 
important in the HRS cell is striking.  
1.3.7 Microenvironment 
Nearly all of the cells present in a cHL tumour are those of a reactive infiltrate, 
which includes T cells, B cells, macrophages, eosinophils, fibroblasts, mast cells 
and plasma cells (Schmitz et al, 2009b). It is likely that this infiltrate in part 
reflects the immune response to the tumour; however, this response is 
ineffective. There is evidence that the HRS cell itself recruits these infiltrating 
cells to the tumour tissue, where the paracrine signals they provide generate a 
favourable environment. This in turn supports cell survival, proliferation and 
immune escape. The symbiotic relationship between the HRS cell and the 
cellular microenvironment therefore appears central to the pathogenesis of cHL. 
Most of the infiltrating cells are CD4+ve T cells, characteristically with a T 
helper (Th) 2 (Th2) type phenotype. These cells secrete a cytokine profile which 
supports the humoral immune response and B cell proliferation. In contrast, Th1 
cells which assist the cellular immune response, CD8+ve CTLs and natural killer 
(NK) cells are notable by their paucity.  The Th2 cells are thought to be drawn in 
to the node by chemokines produced directly by the HRS cell: TARC (van den 
Berg et al, 1999), CCL5 and CCL22 (Skinnider & Mak, 2002). Th2 cells also 
express CD40 ligand, which may engage with and stimulate the CD40 molecules 
on the surface of the HRS cells, triggering the activation of NF-κB as mentioned 
above. 
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Abundant among the infiltrating CD4+ve T cells are CD4+ve, CD25+ve, forkhead 
box P3 (FoxP3)+ve cells T regulatory lymphocytes (Tregs) (Marshall et al, 2004). 
Tregs normal function is in immune homeostasis where they are important in 
inducing peripheral tolerance to autologous antigens and regulating effector 
immune responses. They are increasingly recognised as important in suppressing 
tumour antigen specific cellular immunity, and may therefore be important in 
protecting the HRS cell from attack, particularly in EBV-associated disease 
where viral antigens may be expected to trigger a CTL response (Li et al, 2009a; 
Marshall et al, 2007). The HRS cell is able to attract Tregs via secretion of 
cytokines including galectin 1 (Juszczynski et al, 2007; Gandhi et al, 2007), IL-10 
and transforming growth factor-beta (TGF-β) (Marshall et al, 2004) and 
chemokines TARC, CCL5, CCL20 and CCL22 (Skinnider & Mak, 2002; Aldinucci et 
al, 2008). CD8+ve regulatory T cells, also known as T suppressor (Ts) cells, have 
also been described. Acting via secretion of IL-10 or via direct cell to cell 
contact, several types of Ts cell have been described; the majority originate 
from CD8+ve CTLs and acquire a suppressor phenotype after antigenic 
stimulation. The particular inducers of this phenotype in CD8+ve CTLs are not 
known, but it is postulated that different peptide repertoires may induce a 
suppressor phenotype (Filaci et al, 2011).  
Eosinophils are often present in nodal tissue, bone marrow and peripheral blood 
of patients. The HRS cells and the fibroblasts in the tumour microenvironment 
secrete eotaxin, IL-5, IL-9, CCL5, CCL11 and CCL28, all of which are implicated 
in eosinophil proliferation and recruitment (Teruya-Feldstein et al, 2000; 
Teruya-Feldstein et al, 1999).  
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Further cytokines central in the pathogenesis of cHL include IL-13, which is 
secreted by HRS cells and, as HRS cells also express the IL-13 ligand, may act as 
an autocrine growth factor (Kapp et al, 1999; Skinnider et al, 2002b), IL-6 and 
IL-10. IL-6 has both pro-inflammatory and anti-inflammatory functions, and is 
thought to exert potent anti-viral effects. Elevated levels are noted in patients 
with HL (Gause et al, 1992), and in addition, the HRS cell expresses both IL-6 
and IL-6 receptor, such that the cytokine may function as an autocrine growth 
factor (Jucker et al, 1991). In EBV-associated classical Hodgkin lymphoma 
(EBV+ve cHL), the EBV protein LMP1 leads to higher levels of IL-6 expression 
which may contribute to the proliferation and survival of the malignant cell in 
this setting (Herbst et al, 1997). IL-10 is an anti-inflammatory cytokine secreted 
by Th2 cells and a phenotypically distinct subset of Ts cells (Noble et al, 2006). 
In addition to the immune suppressive role, there is also some evidence that IL-
10 can enhance B cell proliferation (Guedez et al, 2001) and IL-10 has been 
particularly implicated in the pathogenesis of EBV+ve cHL (Ohshima et al, 1995; 
Baiocchi, 2008).  
Systemically, the cellular and cytokine responses can result in a degree of 
immune suppression observed in patients with cHL. cHL patients demonstrate 
anergic responses to skin tests for antigens including tuberculin (Schier, 1954) 
and typhoid (Rottino & Hoffmann, 1950). It is also recognised that patients with 
cHL, even before or after treatment, are at high risk of the almost uniformly 
fatal transfusion-associated graft-versus-host-disease (Spitzer et al, 1990), which 
normally occurs only in the setting of severe cell-mediated immune compromise 
e.g. following allogeneic bone marrow transplant or treatment with purine 
analogues. Such systemic immune suppression most likely contributes to the 
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impairment of an effective EBV-specific immune response at the time of 
oncogenesis.  
An overview of the HRS cell and its interactions in the cHL microenvironment is 
given in Figure 1.4. A summary of the many cytokines, chemokines, receptors 
and ligands (Mani & Jaffe, 2009; Roullet & Bagg, 2007) implicated in the cross-
talk between the HRS cell and the reactive infiltrate is shown in Table 1.3.  
 
 
Figure 1-4 The HRS cell and its interactions with the cellular microenvironment 
A simplified schematic of the HRS cell and its interactions with the reactive infiltrate. The 
HRS cell secretes cytokines and chemokines to recruit cells which result in immune escape 
or provide survival/proliferative signals. The effective CD4+ve Th1 and CD8+ve cytotoxic T 
lymphocyte (CTL) immune response is inhibited directly by the HRS cell and via IL-10 from 
Treg and Th2 cells. Other surrounding cells of physiological importance in providing a 
favourable cellular environment are fibroblasts, eosinophils, mast cells and macrophages. 
Further detail is given in the text. CCL, CC chemokine ligand; CD, cluster of differentiation; 
CSF1R, colony stimulating factor 1 receptor; HRS, Hodgkin and Reed-Sternberg; IL, 
interleukin; PD-1L, programmed death 1 ligand; TGF, transforming growth factor; Th, T 
helper cell; TNF, tumour necrosis factor; Treg, T regulatory cell; TARC, thymus and 
activation-regulated chemokine; MIF, macrophage inhibitory factor. 
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Table 1-3 Cytokines, chemokines and receptors altered in classical Hodgkin 
lymphoma.  
Function 
Cytokine/ Chemokine/ 
Receptor/ Ligand 
Reference 
Promote Th2 
Response 
TARC/CCL17 (van den Berg et al, 1999) 
MDC/CCL22 
(Teruya-Feldstein et al, 1999; Hedvat 
et al, 2001) 
CCL-20 (Baumforth et al, 2008) 
MIG 
(Teruya-Feldstein et al, 1999; Buri et 
al, 2001) 
IP-10 (Teruya-Feldstein et al, 1999) 
IL-13 (Skinnider et al, 2002b) 
GATA-3 
(Kuppers et al, 2003; Atayar et al, 
2005) 
CCR-4 (Ohshima et al, 2003) 
Suppress Th1 
Response 
IL-10 (Aldinucci et al, 2010) 
TGF-  
(Kadin et al, 1993; Newcom & Gu, 
1995) 
PD-1L (Yamamoto et al, 2008) 
Galectin-1 
(Juszczynski et al, 2007; Gandhi et al, 
2007) 
Promote influx of 
eosinophils 
IL-5 (Samoszuk & Nansen, 1990) 
IL-9 (Merz et al, 1991) 
Eotaxin (produced by 
fibroblasts) (Jundt et al, 1999) 
CCL28 (Hanamoto et al, 2004) 
Promote influx of 
mast cells 
IL-9 (Merz et al, 1991) 
RANTES/CCL5 (also 
monocytes, T cells & 
eosinophils) (Aldinucci et al, 2008) 
Promote influx of 
plasma cells IL-6 (Jucker et al, 1991) 
Promote influx of 
neutrophils 
IL-8 (Foss et al, 1996) 
GM-CSF (Byrne et al, 1986) 
Promote influx of 
fibroblasts 
IL-13 (Skinnider et al, 2002b) 
TGF-  
(Kadin et al, 1993; Newcom & Gu, 
1995) 
TNF-  
(Kretschmer et al, 1990; Sappino et al, 
1990) 
MMP (Thorns et al, 2003) 
TIMP1 & 2 (Pennanen et al, 2004) 
Autocrine growth 
factor 
IL-13/IL-13-R (via STAT6 
activation) (Skinnider et al, 2002b) 
TIMP-1 (Pennanen et al, 2004) 
IL-6 (Jucker et al, 1991) 
Activates NF-B  
CD40/CD40-R (O'Grady et al, 1994) 
CD30/CD30-R (Pinto et al, 1996; Horie et al, 2002) 
TNF- 
(Kretschmer et al, 1990; Sappino et al, 
1990) 
RANK/RANK-L (Fiumara et al, 2001) 
Adapted from (Farrell & Jarrett, 2011) with permission, copyright Blackwell Publishing Ltd. 
Abbreviations given at first use in the text or on pages 17-22. 
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1.4  Hodgkin lymphoma – Clinical Aspects 
1.4.1 Clinical Staging 
The vast majority of patients present with painless lymphadenopathy, although 
the disease may be asymptomatic and picked up as an incidental finding e.g. on 
a chest X-ray. Clinical outcome in HL depends partially on clinical stage of 
disease as assessed using the internationally accepted clinical staging system, 
the modified Ann Arbor staging system (Lister et al, 1989) (Table 1.4). 
The B symptoms of HL (night sweats, weight loss of at least 10% of body weight 
or unexplained fever) occur in approximately 40% of patients at presentation and 
are associated with poorer outcome. These are thought largely to be the 
systemic result of cytokines released from the malignant HRS cells. Other 
systemic manifestations of disease such as pruritus, fatigue and alcohol-induced 
pain, are not prognostic and are not included as B symptoms for this reason.  
All clinical stage IA and IIA disease is classified as “early stage” disease. All 
clinical stage III and IV disease, and any patient with stage I or II disease with B 
symptoms or disease bulk (nodal mass ≥ 10 cm or a mediastinal mass ≥ 0.33 of 
the intra-thoracic diameter) is classified as “advanced stage disease”. 
Treatment decisions are based on this classification.  
Further prognostic refinement of early stage disease based on the presence of 
“risk factors” can be used to define “early-stage unfavourable disease” which 
may require consideration for more intensive treatment at baseline. Such factors 
vary worldwide depending on the criteria of the national research group but in 
the United Kingdom (UK) include: erythrocyte sedimentation rate (ESR) > 50 
(units); > 3 nodal areas; age > 50 years; and bulk ≥ 5 cm but < 10 cm.  
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Table 1-4 Ann Arbor staging system for Hodgkin lymphoma (Cotswold modification) 
Stage I 
Involvement of single lymph node region or localised extranodal 
site* 
Stage II 
Involvement of two or more lymph node regions or localised 
extranodal sites*, or both,  on the same side of the diaphragm 
Stage III 
Involvement of lymph node regions or localised extranodal sites*, 
or both, on both sides of the diaphragm 
Stage IV  
Diffuse or disseminated involvement of one or more extra-
lymphatic organ(s), with or without associated lymph node 
involvement. Involvement of liver or bone marrow is considered 
stage IV 
* designated by the suffix E, e.g. stage IE, IIE etc. 
† Subsets A and B are designated by the absence (A) or presence (B) of systemic symptoms, 
namely night sweats, weight loss of at least 10% of body weight or unexplained fever. 
(Lister et al, 1989) 
 
The most common presentation of cHL is with cervical lymphadenopathy (60-70% 
of patients); other common sites of disease include the mediastinum, supra-
clavicular, axillary and para-aortic nodes (Sasse & Engert, 2007). Approximately 
half of patients have a mediastinal mass at presentation. In contrast to NHL, 
disease of the inguinal and pelvic nodes is less common. It is not known if this 
distribution of disease reflects potential antigen exposure e.g. oral exposures to 
antigen, or potentially EBV reactivation in the oropharyngeal mucosa. Primary 
extranodal involvement by cHL is rare and, where it occurs, usually arises as a 
local invasion of nodal disease. Bone marrow involvement is also rare (< 5% of 
cases).  
Clinical staging is performed at diagnosis using computed tomography (CT) 
scanning; a three-dimensional scanning technique which uses x-rays to provide 
detailed cross-sectional imaging at high resolution. Involved anatomical areas 
can be defined and sized, and biopsies targeted to involved areas if necessary. 
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Functional imaging, using positron emission tomography (PET) scanning, which is 
based on the increased uptake of the radiolabelled glucose analogue 18F- 
fluorodeoxyglucose (FDG) in metabolically active cells as compared with 
surrounding tissue, is increasingly being used at baseline for accurate staging. It 
is particularly useful in those patients thought to have early stage disease, and 
in whom the inability to correctly detect stage III or IV disease, particularly bony 
disease, could mean potentially undertreating the patient (Richardson et al, 
2012; El-Galaly et al, 2012).  In a study of 18F-FDG PET scanning in staging (Cerci 
et al, 2011), up to 24% of patients thought to have early stage disease were up-
staged to a higher clinical stage and in 15% clinical management was changed as 
a result. Staging 18F-FDG PET is also useful in providing a baseline against which 
subsequent (interim or end-of-treatment) scans can be compared. 
1.4.2 Therapy  
Treatment of cHL is tailored to the patient’s clinical stage and is generally based 
on combinations of different chemotherapeutic agents, with or without the 
addition of radiotherapy. Neither histological subtype or EBV status influence 
treatment decisions. HL was one of the first malignancies treated successfully 
with radiotherapy in the 1940s and chemotherapy in the 1960s (Kaplan, 1968; 
Kaplan & Rosenberg, 1968). Prior to this, the disease was almost universally 
fatal. Successive improvements in treatment protocols over subsequent decades 
mean that the majority of patients presenting today are cured of their disease. 
Factors involved in the decision regarding which therapeutic approach to take 
include: efficacy in controlling disease; options and prognosis for second-line 
therapy should it be required; and the toxicity, late effects and quality of life 
following treatment. The majority of patients with cHL achieve a lasting CR; 
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hence toxicity & quality of life have increased in importance when choosing 
treatment. 
Most patients with early-stage disease are cured, and modern treatment 
protocols for this group emphasise cure with the lowest toxicity possible 
(Connors, 2005). Successive refinements of chemotherapy and radiotherapy have 
sought to define the minimal level of treatment which will result in an 
acceptable level of disease control. Abbreviated chemotherapy, based on 
doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) (Bonadonna et al, 
1975), followed by involved-field radiotherapy (the combination referred to as 
combined-modality treatment) is the standard of care in this group. The GHSG 
(Engert et al, 2010) have most recently definitively shown that the combination 
of two cycles of ABVD chemotherapy and 20 Gray (Gy) of involved-field 
radiotherapy is sufficient in early-stage favourable disease, and results in an 
event-free survival (EFS) of 91% and OS of 93% at five years. At present, it is not 
considered safe to omit radiation in the treatment of early-stage cHL due to an 
unacceptably high relapse rate (Meyer et al, 2012). Early-stage unfavourable 
disease is also treated with combined modality treatment, but with four cycles 
of ABVD chemotherapy and 30 Gy of involved field radiotherapy (von Tresckow 
et al, 2012). 
The standard management of advanced stage cHL involves combination 
chemotherapy only. In the UK, the United States, and much of the rest of the 
world ABVD (6-8 cycles) is generally used. ABVD delivers high response rates but 
also has the advantages of preserving fertility and a lower risk of secondary 
haematological malignancy when compared with other regimens. It is recognised 
however, that on-going controversy exists as to the best chemotherapeutic 
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regimen to choose in advanced stage patients. The GHSG HD9 trial (Engert et al, 
2009) compared patients receiving eight alternating cycles of ABVD and an 
alternative regimen, COPP (cyclophosphamide, vincristine, prednisolone and 
procarbazine) with patients receiving eight cycles of escalated BEACOPP 
(bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, 
prednisolone, and procarbazine). Both groups received involved field 
radiotherapy to sites of initial disease bulk and residual masses. In this study, 10 
year freedom from treatment failure (FFTF) was 82% and 10-year OS was 86% in 
the BEACOPP arm as compared with 64% 10-year FFTF and 75% 10-year OS in the 
COPP-ABVD arm. These outcomes have led to the adoption of escalated BEACOPP 
as the standard of care for advanced-stage cHL in Germany and some parts of 
Europe (Eichenauer & Engert, 2011; Borchmann et al, 2011). The study has been 
criticised for use of COPP-ABVD as opposed to ABVD in the comparison arm, 
therefore no true comparison with current gold-standard therapy was 
performed. In addition, the study reported a rate of secondary acute myeloid 
leukaemia (AML) of 3% at 10 years in the BEACOPP escalated arm as compared 
with 0.4% in the COPP-ABVD arm. BEACOPP escalated has also been shown to be 
associated with infertility (Behringer et al, 2005). In addition, it was impossible 
to accurately predict in the HD9 study, even using International Prognostic Score 
(IPS), the group of approximately 10% of patients who required treatment at the 
intensity of BEACOPP escalated, as compared with ABVD, to achieve cure.  
A recent Italian study (Viviani et al, 2011) compared OS in patients treated at 
baseline with 6-8 cycles of ABVD and treatment escalation to salvage therapy 
(see below) only when required for relapsed or progressive disease, with 
patients treated with 8 cycles of BEACOPP escalated at baseline. Greater FFTF 
was seen in the BEACOPP escalated arm (7-year, 84% vs. 73%, p = 0.004). 
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However, once the planned treatment was delivered in all patients (including 
salvage for those in whom it was required), there was no difference in OS (89% 
vs. 84% at 7-years, p = 0.39), suggesting that the same outcome could be 
achieved whilst sparing two-thirds of patients unnecessary higher intensity 
treatment. 
For these reasons, ABVD is still currently thought to deliver the best balance 
between treatment efficacy and toxicity, and is therefore regarded as the 
standard of care for advanced-stage cHL (Connors, 2011a; Lim & Johnson, 2011). 
Future refinements to the treatment are likely to be based on the use of novel 
agents (see below) or on the better targeting of intensive therapy to those that 
need it, using improved prognostic tools (see below) (Connors, 2011b). 
For patients who have primary refractory disease, or who relapse, further 
treatment is required to achieve disease control and aim for cure. This is 
delivered in the form of “salvage therapy” which generally consists of multiple 
courses of a non-cross-reacting high-dose multi-agent chemotherapy, 
consolidated by an autologous or allogeneic haemopoietic stem cell transplant. 
There is no consensus on a gold-standard for salvage chemotherapy, and the 
decisions, particularly those regarding consolidation, depend on patient fitness, 
availability of a stem cell donor and other patient-specific features. It is 
recognised that outcomes are particularly poor in patients with primary 
refractory disease (5-year OS 26%) (Josting et al, 2000), or who relapse within 12 
months (5-year OS 43%) (Josting et al, 2002). 
As has been alluded to in the discussions above, both chemotherapy and 
radiotherapy for cHL are associated with both short and long-term toxicities. 
Short-term toxicities include cytopenias, neutropenic sepsis, hair loss, altered 
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taste and pulmonary toxicity associated with bleomycin. Late toxicities of 
therapy range from those affecting quality of life (such as fatigue) to those 
which may be life-threatening (such as cardiovascular disease or secondary 
malignancy). Some of the late effects of treatment for cHL are listed in Table 
1.5.  
Table 1-5 Late effects of therapy for Hodgkin lymphoma 
 Toxicity 
“Minor” Endocrine dysfunction (hypothyroidism, hypo-a-menorrhoea, 
decreased libido) 
Long-term immunosuppression 
Viral infections (Herpes simplex, Varicella zoster, Human 
papillomaviruses) 
More Serious Lung fibrosis from radiation plus bleomycin 
Myocardial damage from anthracyclines and radiation 
Sterility in men and women 
Growth abnormalities in children and adolescents 
Opportunistic infections 
Psychological problems 
Psychosocial disturbances 
Fatigue 
Potentially life-
threatening 
Acute myeloid leukaemia / myelodysplastic syndrome 
Non-Hodgkin’s lymphoma 
Solid tumours (lung, breast, and colon cancers, sarcomas) 
Heart failure & myocardial infarction 
 
Studies have examined the risk of second cancer in some detail. Acute myeloid 
leukaemia risk peaks at 5-9 years following treatment at a rate of approximately 
1-3% (Standardised Incidence Ratio, SIR, 47.1, 95% confidence interval (CI), 28.4-
73.6) (Swerdlow et al, 2011). There is an increased risk of a number of 
malignancies including lung cancer, colon cancer, melanoma and sarcomas, 
when compared with untreated populations. Some groups are particularly 
vulnerable to second malignancy; female patients under the age of 20 years who 
receive radiotherapy to a field which includes breast tissue have an standardised 
incidence ratio (SIR) of breast cancer of 18.2 (95% CI, 8.3 to 33.6) (Swerdlow et 
  Chapter 1: Introduction 
51 
 
al, 2011) and such patients enter mammography screening programmes from the 
age of 25 years. The overall 20-year cumulative risk of a second cancer in this 
study was 13% for patients treated with chemotherapy only and 18% for patients 
treated with combined modality therapy.  
Cardiovascular disease is emerging as a particular concern in survivors of cHL, as 
the effect becomes more apparent with longer follow-up. Long-term survivors of 
cHL are more likely to die from cardiovascular disease than their cHL, and this 
risk increases with time; at 10 years post-diagnosis, survivors have a relative risk 
of death from cardiovascular disease of 6.3 when compared with age matched 
controls, (Figure 1.5) (Aleman et al, 2003).  
 
Figure 1-5 Acturial risk of death by cause (major disease categories), following a 
diagnosis of Hodgkin lymphoma 
HD, Hodgkin lymphoma. Reproduced with permission from (Aleman et al, 2003), Copyright 
American Society of Clinical Oncology. 
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Balancing treatment efficacy and cure versus morbidity & mortality of late 
complications of treatment has led researchers to explore response-adapted 
therapy. This approach aims to identify disease which is not responding to 
therapy at an early stage, in order that treatment intensification can be 
considered with the aim of avoiding primary refractory disease or early relapse 
and the attendant poor survival. Prospective studies using 18F-FDG PET to assess 
metabolic response after 1 or 2 cycles of chemotherapy have been performed, 
and show clinical utility as a prognostic tool. A pivotal study from a joint Italian 
and Danish group (Gallamini et al, 2007) demonstrated the predictive power of a 
18F-FDG PET after two cycles of ABVD; 2-year PFS of 95% was seen in patients 
with a negative PET vs. 12.8% 2-year PFS in those with a positive PET (p < 
0.001). In this study, treatment was not changed on the basis of the PET-scan 
result. Instinctively, it is felt that treatment intensification in the group of PET-
positive patients would improve outcome, but this hypothesis has yet to be 
proven in clinical studies. On-going clinical trials are addressing this question 
(National Cancer Research Initiative Lymphoma Clincal Studies Group, 2013a; 
German Hodgkin Study Group, 2013) and much work regarding standardisation of 
PET scanning will be required before this can be regarded as the standard 
approach. 
Some authors (Connors, 2011b; Younes, 2009; Jona & Younes, 2010) believe that 
the maximal benefit that can be achieved with standard cytotoxic 
chemotherapeutic approaches has been reached and that further improvements 
in outcome will rely on the use of alternative agents which exploit the biology of 
the tumour. In contrast to diseases such as chronic myeloid leukaemia there is 
no single molecular target in cHL. However, the expression of markers on the 
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cell surface, or molecular pathways utilised by the cell (such as NF-κB, see 
Section 1.3.4) can potentially be exploited.  
Agents currently being explored in clinical trials include the anti-CD20 molecule, 
rituximab, which has demonstrated benefit in phase I and II clinical studies 
(Kasamon et al, 2012; Younes et al, 2012), particularly in patients with EBV+ve 
cHL. Larger phase III studies are in progress (German Hodgkin Study Group, 
2013). 
One of the most exciting agents to emerge in recent years is brentuximab 
vedotin, a monoclonal anti-CD30 antibody conjugated to the anti-microtubule 
drug monomethyl auristatin E. Phase I studies in heavily pre-treated patients 
have demonstrated overall response rates of 50% with CR rates of 35% (Younes et 
al, 2010). On this basis, the drug has received a licence for use in relapsed and 
refractory disease, where it is currently being used as a bridge to transplant 
(Younes et al, 2010). Phase III clinical studies are examining the role of the 
agent in primary therapy (National Cancer Research Initiative Lymphoma Clincal 
Studies Group, 2013b).  
1.4.3 Clinical Prognostic Scoring Systems 
The purpose of any prognostic system is the prediction of clinical outcome to 
allow the identification of groups of patients who may benefit from reduced 
treatment, who will respond well to standard treatment, or who will fare badly 
with standard treatment and may well benefit from more intensive approaches. 
Clinical staging as described in Section 1.4.1, when used in isolation, lacks 
sensitivity in such prediction. In the recent HD10 (Engert et al, 2010) and HD11 
(Eich et al, 2010) German Hodgkin Study Group (GHSG) studies of favourable and 
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unfavourable early-stage cHL respectively, clinical stage alone was not able to 
predict the 7% (favourable) or 15% (unfavourable) of early-stage patients who 
would relapse. It is estimated that of advanced stage patients assessed using 
clinical staging only, one third will fail to be cured with standard therapy and 
another third are likely to be over-treated (Borchmann et al, 2012; Hasenclever 
& Diehl, 1998); clinical staging alone offers no way to discriminate these groups. 
For these reasons, factors other than clinical stage are taken into account when 
estimating prognosis and more refined tools have been developed.  
In advanced stage cHL, a clinical scoring system, the International Prognostic 
Score (IPS) (Hasenclever & Diehl, 1998) has been developed. This model, based 
on the multivariate analysis of a number of clinical measures in nearly 5000 
patients with advanced stage cHL treated using the combination chemotherapy 
regimen of ABVD, or ABVD-like regimens, identified seven independent factors 
associated with poor outcome and led to the development of a scoring system 
detailed in Table 1.6. 
Table 1-6 International prognostic score for advanced-stage Hodgkin lymphoma 
Factor Adverse Criteria Score 
Serum albumin < 40 g/L 1 
Haemoglobin < 105 g/L 1 
Sex Male 1 
Clinical stage Stage IV disease 1 
Age ≥ 45 years 1 
White cell count ≥ 15 x 10
9/L 1 
Lymphocyte count ≤ 0.6 x 10
9/L 1 
Also known as the Hasenclever score (Hasenclever & Diehl, 1998). 
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Table 1-7 Clinical outcome by IPS in the original model  
Score 5-year FFP (%) 5-year OS (%) 
0 84 89 
1 77 90 
2 67 81 
3 60 78 
4 51 61 
≥ 5 42 56 
Grouped 0-3 70 83 
Grouped ≥ 4 47 59 
Adapted from (Hasenclever & Diehl, 1998). FFP, freedom from progression; OS, overall 
survival. 
 
Figure 1-6 Use of the IPI to predict clinical outcome 
A) Rates of Freedom from Progression of Disease; and B) Overall Survival in 1618 Patients 
with Advanced Hodgkin’s Disease. Reproduced with permission from (Hasenclever & Diehl, 
1998), Copyright Massachusetts Medical Society. 
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This scoring system was an improvement on clinical staging (see Figure 1.6) but 
still lacked the ability particularly to predict at baseline the 16% patients with 
score 0 who would progress, or indeed the 50% of score ≥ 4 patients who would 
continue in long-term remission (Table 1.7). As a result whilst the IPS is 
currently widely used in clinical practice, it is informative only, and is not used 
to select treatment.  In addition, the scoring system was not validated for use in 
early-stage disease and, when used in this setting, has been shown to lack 
sensitivity (Franklin et al, 2000), therefore in early-stage disease no prognostic 
tools are available to identify those patients who will relapse and require further 
treatment, versus the majority of patients who will do well and may be over-
treated. 
1.4.4 Biological prognostic factors 
Many of the features incorporated into the IPS reflect the biology of the 
underlying disease. It is apparent to pathologists and treating physicians that 
even within the stringent definitions of cHL as defined by the WHO, this is a 
heterogeneous disease. The underlying biology of the tumour is increasingly 
known to be important in determining outcome. Biomarkers, biological markers 
found in the body fluids or tissues of patients with malignancy, have gained 
attention in recent years for their power to predict outcome at time of 
diagnosis, and may be important in determining those patients who will benefit 
from earlier introduction of novel agents.  In cHL, a number of biologically based 
methods have been shown to be prognostic.  
TARC is produced by HRS cells and is elevated in the serum of patients with cHL 
at time of diagnosis (Niens et al, 2008). The level of TARC at time of diagnosis 
has been shown to correlate with clinical outcome (Weihrauch et al, 2005). In 
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this study, TARC levels at diagnosis were higher in those patients who went on to 
have progressive disease (PD) versus those who achieved a complete response 
(CR) (p = 0.068). In addition, a more rapid fall in TARC levels after just one cycle 
of chemotherapy is predictive of chemo-responsive disease (Plattel et al, 2011). 
The GHSG have recently shown that lower serum TARC at baseline is associated 
with negative PET after two cycles of chemotherapy, and with a CR to first-line 
therapy (Sauer et al, 2013). 
Given that the symptoms of cHL are closely linked to the secretion of cytokines 
by the tumour, and that these levels likely reflect tumour bulk, other 
investigators have examined whether this would be helpful prognostically. Early 
studies demonstrated that elevated levels of IL-6 are associated with advanced-
stage disease and adverse prognosis (Kurzrock et al, 1993). Additional studies 
have demonstrated that elevated serum IL-10 was significantly associated with 
early (< 12 months) treatment failure (p = 0.0008) (Rautert et al, 2008) and that 
IL-10 gene polymorphisms were associated with FFTF (Schoof et al, 2013). A 
combined plasma cytokine signature has been developed (Casasnovas et al, 
2007), using levels of IL-1RA, IL-6 and soluble CD30 to prospectively predict EFS 
and OS. High levels of all 3 cytokines were associated with a 5-year EFS of 15% 
(95% C.I., 0% -37%) versus a 92% 5-year EFS (95% C.I., 88%-95%) in those with low 
levels of all three cytokines. 
Given the importance of the tumour microenvironment in cHL (Section 1.3.7), 
there has been much focus in recent years on the prognostic significance of the 
populations of cells which serve to make up the bulk of the tumour. The 
presence of tissue-associated macrophages, as assessed by gene expression 
profiling (GEP) (Steidl et al, 2010a), has been shown to be associated with 
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primary treatment failure. The GEP findings were confirmed using IHC for the 
macrophage associated marker CD68 in formalin-fixed tissue to demonstrate that 
increased numbers of CD68-positive cells were associated with shorter 
progression-free survival (PFS) and increased risk of relapse. The same group 
went on to demonstrate by GEP of microdissected primary HRS cells from 29 
cases target genes with expression levels which correlated with genomic copy 
number changes (Steidl et al, 2012). The authors identified a macrophage-like 
GEP signature, which included CSF1R. This was independently associated with 
poor outcome in an internal validation of 132 cases.  
Studies aiming to validate the use of IHC for CD68 in a clinical setting (Sanchez-
Espiridion et al, 2012; Harris et al, 2012) have not been able to demonstrate 
that it is independently predictive of outcome, and have highlighted technical 
issues which would require to be addressed before such a test could be used 
routinely, such as lack of reproducibility in scoring, even among experts. 
A further study (Scott et al, 2013) used GEP to study formalin-fixed paraffin-
embedded tumour tissue, which is more routinely available. From this large 
study of 290 patients a 23-gene outcome predictor was generated and validated 
in an independent cohort of 78 patients. The group demonstrated 63% 5-year OS 
in the high-risk groups and 92% 5-year OS in the low-risk groups (p < 0.0011). The 
found their predictor to be superior to the IPS and CD68 IHC in multivariate 
analyses. 
As GEP is a technique not routinely available to treating clinicians the 
translational relevance of such studies remains to be proven.  
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It is known that much of the cellular infiltrate in cHL comprises cytotoxic and 
Tregs (Section 1.3.7). Low infiltration of FOXP3+ve Tregs in conjunction with high 
levels of TIA1 cytotoxic granule-associated RNA binding protein (TIA-1)-positive 
CTLs are associated with unfavourable outcome (Alvaro et al, 2005). The 
unfavourable outcome associated with low infiltration of FOXP3+ve Tregs seems 
counterintuitive to the suggestion that these cells suppress local anti-tumour or 
anti-viral responses (Section 1.3.7). Additionally, it has been shown that high 
levels of CTLs assessed by Granzyme B positivity are associated with 
unfavourable outcome (Oudejans et al, 1997). These features of tumour 
microenvironment are probably reflected in the improved OS and PFS of patients 
with an absolute lymphocyte count/ absolute monocyte count ratio of ≥ 1.1 
(Porrata et al, 2011).  
Genome-wide copy number analysis has also identified chromosomal changes 
associated with outcome. Array CGH was used to analyse microdissected HRS 
cells from 53 primary cases and identified a number of recurrent chromosomal 
changes (Steidl et al, 2010b). Gains of chromosome 16p11.2-13.3 were 
significantly associated with unresponsive disease and shortened disease-specific 
survival (DSS), the possible mechanism for this being the presence of the 
multidrug resistance gene ATP-binding cassette, sub-family C (ABCC1) nearby on 
chromosome 16p. Whilst illuminating in terms of underlying biology, this 
technology is not currently available to clinicians and is not impacting on 
treatment decisions at present. 
The expression of CD20 has been reported to be associated with clinical outcome 
although these studies are somewhat contradictory, which may in part be 
accounted for by the localisation of expression. In the 5-10% of cases of cHL in 
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which the HRS cells themselves express CD20, this has been reported to be 
associated with reduction in FFTF and OS (von Wasielewski et al, 1997; Portlock 
et al, 2004). Reduced OS with CD20 expression on the HRS cell was confirmed in 
univariate and multivariate analysis in a third study, which also demonstrated a 
direct relationship of CD20 expression of the HRS cell and EBV-positivity of the 
tumour(Aldred et al, 2008). Other studies have failed to show any association 
(Tzankov et al, 2003; Rassidakis et al, 2002), or have shown an association in the 
opposite direction, i.e. CD20 expression in patients with chemoresponsive 
disease (Greaves et al, 2013). More recently, given the importance of tumour 
microenvironment in determining outcome, authors have shown that higher 
levels of CD20, not on the HRS cell, but in the surrounding cellular milieu, are 
associated with improved OS (Chetaille et al, 2009; Canioni et al, 2009). 
A number of other features of the tumour, including B cell lymphoma 2 (bcl-2) 
expression (Sup et al, 2005), spleen tyrosine kinase (Syk) and FYN oncogene 
related to SRC, FGR, YES (Fyn) expression (Martin et al, 2011) and HLA Class II 
expression (Diepstra et al, 2007) have been shown to be associated with 
outcome.  
Lastly, it has been shown that the EBV status of the tumour is important in 
determining outcome. In independent studies (Jarrett et al, 2005; Keegan et al, 
2005), investigators demonstrated that EBV+ve cHL in older adults (defined as > 
50 years or > 45 years in the two different studies) was associated with a 
significantly poorer outcome. In contrast, in younger patients and children, 
EBV+ve disease was associated with a survival advantage, but in neither study 
did this reach significance. EBV status of the tumour is often reported to 
clinicians but does not yet impact on treatment decisions.  
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There are weaknesses with the prognostic studies to date: some are 
contradictory and some have not adjusted for other recognised prognostic 
factors. An additional weakness of all the biologically based methods explored to 
date is that none has been validated prospectively in independent studies.  
1.5  Epidemiology of HL 
The epidemiology of cHL is unique among malignant diseases and suggests clues 
to the aetiology of this disease. cHL has a bimodal age incidence in developed 
countries, with a peak seen in young adults (age 15-35 years) where it is one of 
the commonest cancers, and a second peak in older adults, over the age of 50 
years. This is in contrast to NLPHL, which does not demonstrate this bimodal 
pattern (Figure 1.7). 
 
Figure 1-7 Age-specific incidence rates of Hodgkin lymphoma  
Demonstrating the bimodal incidence curve for classical Hodgkin lymphoma. HL, Hodgkin 
lymphoma; NLPHL, nodular lymphocyte predominant Hodgkin lymphoma. Incidence per 
100,000 person years. Adapted from (Jarrett et al, 2003) with permission, Copyright BMJ 
Publishing Group.  
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Males have a higher risk of cHL compared to women (Glaser & Jarrett, 1996; 
Landgren & Caporaso, 2007) and account for approximately 60% of cases 
diagnosed (Information Services Division, 2010). In addition, males also have 
higher rates of EBV+ve cHL (Glaser et al, 1997; Cartwright & Watkins, 2004). 
Like NHL, Hodgkin lymphoma is becoming more common. Scottish data 
(Information Services Division, 2010) demonstrate incidence increasing by 43.8% 
in men and 15.8% in women, between 2001 and 2011, and this finding has been 
reported in multiple series worldwide.  
As has been mentioned, overall, approximately one-third of cases of cHL are 
associated with EBV (EBV+ve cHL) (Jarrett & MacKenzie, 1999; Jarrett, 2002; 
Jarrett, 2006; Kuppers, 2009b). Childhood cHL is almost always EBV+ve (Jarrett 
et al, 1991; Flavell et al, 2000), as is cHL in developing countries. In contrast, in 
developed countries, the majority of cases are young-adult cHL, most commonly 
NS-type, which is less likely to be EBV+ve. In older adult cHL (in adults > 50 
years of age), the proportion of cases associated with EBV increases. Within 
developed countries, EBV+ve disease is associated with socio-economic 
deprivation (Flavell et al, 1999). On the basis of these findings, a “4-disease 
model” has been proposed (Figure 1.8). In this model, four entities are defined 
based on age at diagnosis and EBV status of the tumour. The majority of cases 
are EBV-ve cases with a peak in young adulthood. There are three groups of 
EBV+ve cases: EBV+ve cases in childhood; EBV+ve cases in young adults occurring 
following infectious mononucleosis (IM); and EBV+ve cases in older adults. 
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Figure 1-8 Four disease model of classical Hodgkin Lymphoma. 
There are three groups of EBV+ve cases (solid lines) and one group of EBV-ve cases (dashed 
line). Reproduced with permission from (Jarrett, 2002), copyright Oxford University Press. 
 
One of the first clues towards the role of EBV in the aetiology of cHL was an 
observation of an increased risk of cHL occurring after IM (Gutensohn & Cole, 
1980). These cases associated with delayed exposure to EBV probably account 
for the peak of EBV+ve disease in young adults. Primary infection with EBV (see 
Section 1.6.2) occurs most commonly in childhood, when it is generally 
asymptomatic. Early exposure to EBV, or surrogates of early exposure to EBV 
such as oral exposures, shared bedrooms in childhood or early nursery care are 
protective for development of cHL (Alexander et al, 2000; Glaser et al, 2005; 
Cozen et al, 2009). Delayed exposure to the virus resulting in infection in the 
late teenage years or early adulthood is associated with a clinical syndrome of 
fever, pharyngitis, lymphadenopathy, variable hepato-splenomegaly, fatigue and 
debility which is recognised as IM. The pattern of clinical disease seen with IM 
(clinical disease resulting from late exposure to a pathogen) may echo that 
which is seen with EBV+ve cHL.  The peak of young-adult cHL follows the peak of 
IM by approximately five years (Hjalgrim, 2012), and large cohort studies have 
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demonstrated a 3-fold increase in risk in individuals with a history of IM 
(Hjalgrim et al, 2000). This has been verified in case-control studies which have 
again demonstrated a 3-fold increase in risk in individuals with a personal or 
family history of IM (Alexander et al, 2003; Alexander et al, 2000). This risk is 
particularly pronounced for EBV+ve cases (Hjalgrim et al, 2003; Alexander et al, 
2000).  
Further epidemiological evidence of the EBV association with cHL was the 
altered patterns of antibodies to EBV in cHL patients as compared with controls. 
No increased risk was seen with simple EBV seropositivity, indicating prior 
infection (Lehtinen et al, 1993; De Sanjose et al, 2007); instead elevated 
antibodies to EBV early antigen (EA) and EBV nuclear antigen (EBNA) were 
observed in cases as compared with controls. This abnormal EBV serology has 
now been shown to be associated with risk of developing EBV+ve, but not EBV-ve 
cHL (Levin et al, 2012). In addition, higher numbers of EBV-infected B 
lymphocytes are noted in the pre-treatment blood of patients with EBV+ve cases 
of cHL as compared with EBV-ve cases (Khan et al, 2005). Both of these pieces of 
evidence suggest that risk of developing EBV+ve cHL may be associated with 
control of EBV viral infection. 
That inherited genetic factors play a role in susceptibility to cHL is suggested by 
the striking racial and ethnic differences in the incidence of cHL and the 
numerous reports in the literature of familial clustering of disease. It is 
recognised that cHL is more common in Caucasian populations, and less common 
in people of Asian origin (Cartwright & Watkins, 2004). This is not thought just to 
be due to variation in environmental factors as migrants of Asian origin to high –
incidence areas continue to have a lower incidence than the local population 
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(Landgren & Caporaso, 2007), and thus genetic factors are thought to play a 
role. 
Population based studies have described  a 7-fold excess risk of disease in 
siblings of young adults with cHL (Grufferman et al, 1977) and a 4-fold increase 
in deaths due to cHL in first and second degree relatives of patients with cHL 
(Kerzin-Storrar et al, 1983). Recent Swedish registry data suggest that familial 
clustering is stronger for cHL than any other malignancy with a standardised 
incidence ratio of 5.5 in siblings of patients with cHL (Altieri & Hemminki, 2006). 
Even stronger evidence that this risk is due to an inherited factor, as opposed to 
a common environmental exposure, comes from a large twin study which 
demonstrated a 99-fold increase in risk in monozygotic, but not dizygotic, twins 
of patients with cHL (Mack et al, 1995). Much of this genetic susceptibility has 
now been shown to be due to HLA type (discussed in Section 1.7.2). The 
challenge is now to determine how extrinsic environmental factors, such as EBV, 
interact with these genetic factors.   
1.6  Epstein-Barr Virus (EBV)  
1.6.1 The biology of EBV 
EBV was the first virus associated with human malignancy when viral particles 
were observed in cell lines derived from primary Burkitt’s lymphoma in 1964 
(Epstein et al, 1964). EBV is a gammaherpesvirus member of the genus 
herpesviridae, which preferentially infects B lymphocytes(Rickinson & Kieff, 
2007). It is ubiquitous with 95% of the world’s population being infected (Henle 
et al, 1969). EBV is an ancient virus; robust evidence now demonstrates that an 
EBV arose in a common primate precursor around 12 million years ago and has 
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co-evolved synchronously with humans since (Ehlers et al, 2010; McGeoch et al, 
2006).  
 
Figure 1-9 EBV genomic structure 
Diagram showing the location and transcription of the EBV latent genes on the double-
stranded viral DNA episome. The origin of plasmid replication (OriP) is shown in orange. The 
large green solid arrows represent exons encoding each of the latent proteins, and the 
arrows indicate the direction in which the genes encoding these proteins are transcribed. 
The latent proteins include the six nuclear antigens (EBNAs 1, 2, 3A, 3B and 3C, and EBNA-
LP) and the three latent membrane proteins (LMPs 1, 2A and 2B). EBNA-LP is transcribed 
from a variable number of repetitive exons. LMP2A and LMP2B are composed of multiple 
exons, which are located on either side of the terminal repeat (TR) region, which is formed 
during the circularization of the linear DNA to produce the viral episome. The blue arrows at 
the top represent the highly transcribed non-polyadenylated RNAs EBER1 and EBER2; their 
transcription is a consistent feature of latent EBV infection. The long outer green arrow 
represents EBV transcription during a form of latency known as latency III (Lat III), in which 
all the EBNAs are transcribed from either the Cp or Wp promoter; the different EBNAs are 
encoded by individual mRNAs that are generated by differential splicing of the same long 
primary transcript. The inner, shorter red arrow represents the EBNA1 transcript, which 
originates from the Qp promoter during Lat I and Lat II. Reproduced and adapted from 
(Young & Rickinson, 2004) with permission. Copyright Nature Publishing Group. 
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EBV is a large (184 kilobase) double-stranded DNA virus (see Figure 1.9). The 
encapsulated virus particle carries its DNA in a linear form. In the cell, the virus 
does not integrate into the host genome, but instead exists as circular episomes. 
Infection with EBV can either be lytic or latent. The number of EBV episomes 
(and hence genomes) present in any one cell can vary from one to 100 of copies 
in latent infection to many thousand in active lytic infection.  
EBV displays one of the characteristic features of the herpesviridae, namely life-
long persistence of infection in an immune host (Rickinson & Kieff, 2007). EBV 
exists as two strains, 1 and 2 differing by 16-47% in their coding sequences for 
the EBNAs. Type 1 infection is the dominant form in most of the world and 
accounts for 80-90% of EBV infections in the developed world. The B95-8 
reference strain (National Center for Biotechnology Information (NCBI), 2008; 
Miller & Lipman, 1973) is the archetypal strain 1 virus. Type 2 infection is more 
prevalent in central Africa and New Guinea. Co-infection with type 1 and type 2 
EBV is rare other than in immune compromised hosts.  
The viral genome is known to have > 85 open reading frames (ORFs). A selection 
of the functionally more important, or better studied, is given in Table 1.8. 
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Table 1-8 Functionally important open reading frames in the EBV genome 
Open reading frame Protein or more common name  
Latent genes 
BKRF1 EBNA1 
BYRF1 EBNA2 
BERF1 EBNA3A 
BERF2 EBNA3B 
BERF3/4 EBNA3C 
BWRF1 EBNALP 
BNLF1 LMP1 
BNRF1 LMP2A/2B 
BARF0 BARF0 
EBER1/2 EBER1/2 
Lytic genes 
Immediate early genes 
BZLF1 BZLF1 
BRLF1 BRLF1 
BILF4 BILF4 
BMLF1 BMLF1 
BRLF1 BRLF1 
Early genes 
BMRF1 BMRF1 
BMLF2 BMLF2 
BALF2 BALF2 
BALF5 BALF5 
BORF2 BORF2 
BARF1 BARF1 
BXLF1 BXLF1 
BGLF5 BGLF5 
BSLF1 BSLF1 
BBLF4 BBLF4 
BKRF3 BKRF3 
Late genes 
BLLF1 gp350/220 
BXLF2 gp85 
BKRF2 gp25 
BZLF2 gp42 
BALF4 gp110 
BDLF3 gp100–150 
BILF2 gp55–78 
BCRF1 BCRF1 
BHRF1 BHRF1 
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In addition to the viral proteins, the virus expresses two classes of RNA which 
are non-protein coding and not translated (Kieff & Rickinson, 2007). There are 
the two small EBERs and a group of alternatively spliced RNAs of the Bacillus 
amyloli restriction endonuclease (BamHI) A rightward transcripts (BARTs) 
segment of the EBV genome which gives rise to a large number of miRNAs. The 
function of these non-coding RNAs is poorly understood but they have been 
demonstrated to be important in oncogenesis.  
The virus has different expression patterns depending on the stage of infection, 
which reflect the different requirements of the virus at different times to infect, 
persist within and reactivate from B-memory lymphocytes, whilst evading the 
immune system.  
At time of lytic infection, the priority is the generation of daughter genomes, 
and the envelope proteins to coat these to release new virus. A large number of 
viral genes are expressed; there is replication of the genome and, ultimately, 
death of the infected cell. 
During latent infection, the virus evades the immune response and 
downregulates much of its transcription to avoid immune recognition. Restricted 
sets of up to nine EBV proteins are expressed: the EBNAs: EBNA1, EBNA2, 
EBNA3A, EBNA3B, EBNA3C and EBNA-LP; and the LMPs: LMP1, LMP2A and LMP2B; 
together with the EBERs, comprise the different programmes of gene usage 
known as the “latency” patterns of gene expression (Table 1.9).  
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Table 1-9 EBV latency gene expression patterns 
Latency 
Programme 
Genes expressed Function in normal latency 
Occurrence in EBV-
associated disease 
0 EBERs 
EBV viral persistence in memory B 
cells in peripheral blood 
 
I EBERs, EBNA1 
Maintains infection whilst allowing 
peripheral memory B cells to 
divide 
Burkitt’s lymphoma, 
PEL  
II 
EBERs, EBNA1, 
LMP1, LMP2A 
Differentiate activated B cell 
In GC into memory B cell 
Hodgkin lymphoma, 
NPC,  
Peripheral T/NK 
lymphoma 
III 
EBERs, EBNA1, 
EBNA2, EBNA3A, 
EBNA3B, EBNA3C, 
EBNA-LP, LMP1, 
LMP2A, LMP2B 
Activates a resting B cell to 
become a proliferating lymphoblast 
(also pattern expressed in 
lymphoblastoid cell line (LCL)) 
PTLD  
HIV-associated NHL  
PEL, primary effusion lymphoma; PTLD, post-transplant lymphoproliferative disease; NHL, 
non-Hodgkin lymphoma; NPC, nasopharyngeal carcinoma. 
 
1.6.2 Natural history of infection 
The life cycle of EBV consists of primary infection, expansion, establishment of 
in vivo latency and reactivation, replication and dissemination of infection to 
new hosts.  
Infection with EBV usually occurs in early childhood, where primary infection is 
typically asymptomatic or sub-clinical. Exposure to the virus later in life, e.g. in 
adolescence or adulthood, leads to the development of symptomatic disease, IM, 
in up to 25% of cases (Crawford et al, 2006) (Section 1.6.4.4). Infection is usually 
by the oral route, but it is known that other mucosal exposures e.g. sexual 
contact also constitute a viable route of infection (Naher et al, 1992; Sixbey et 
al, 1986; Israele et al, 1991). 
Primary infection most usually occurs via the oropharynx, which is also believed 
to be the site of virus replication (Sixbey et al, 1984). Whether the initial cells 
infected are the oropharyngeal epithelial cells or oropharyngeal mucosal 
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associated B lymphoid tissues remains controversial (Young & Rickinson, 2004). 
EBV lytic infection is difficult to study due to the lack of an in vitro model of 
lytic infection; therefore many questions regarding primary infection and 
oropharyngeal replication remain unanswered. During symptomatic infection, 
high levels of free virus are present in oral and pharyngeal secretions (Young & 
Rickinson, 2004). Oral virus shedding may persist for some time; a median of 180 
days was reported in one study (Balfour, Jr. et al, 2013). At time of acute 
primary infection, up to 50% of circulating B lymphocytes may be infected with 
EBV (Hochberg et al, 2004). Subsequently there is a rapid reduction in numbers 
of infected cells in the weeks following acute infection (Hochberg et al, 2004). 
EBV DNA viraemia is cleared quickly (< 1 week) in most subjects, although 
viraemia is more persistent in a minority of individuals (median 95 days) 
(Balfour, Jr. et al, 2013). The factors determining this remain to be established. 
Much of the work studying primary infection has been in patients with IM. It is 
not known if the same processes occur in asymptomatic primary infection. 
Almost immediately following primary infection, the virus becomes latent in B-
memory lymphocytes where the virus remains for the lifetime of the host 
(Bornkamm & Hammerschmidt, 2001). Polymerase chain reaction (PCR) 
performed on limiting cell dilutions of B cells suggests a frequency of EBV 
infected B cells ranging from 1 in 104 in acutely infected hosts, to 1 – 50 per 106 
B cells in steady state immune competent hosts (Kurth et al, 2000; Rickinson & 
Kieff, 2007; Khan et al, 1996). The frequency of infected cells within an 
individual is stable over time and appears to be tightly regulated (Khan et al, 
1996). 
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There is agreement that memory B lymphocytes are the reservoir of latent 
infection, but the exact process by which this occurs is still the subject of some 
debate. EBV may exploit the normal GC reaction to establish latency: a model 
has been proposed whereby infection with EBV drives a naïve antigen-
independent B cell towards an IgD-, CD27+ memory B cell phenotype, mimicking 
the GC reaction (Thorley-Lawson, 2001). Infected naïve B cells are the only cells 
that express all of the latent EBV genes (latency III), just as in LCLs (Joseph et 
al, 2000). The naïve infected B-cells clonally expand and some will undergo the 
GC reaction, where they express the latency II pattern of gene expression 
(Babcock et al, 2000). Post-GC, these cells differentiate into long-lived memory 
B lymphocytes.  Some controversies to this model exist. The demonstration that 
most EBV infected B memory cells are antigen-selected would suggest that 
instead of only driving naïve cells through to B memory cell differentiation, the 
EBV infected Ig mutated B cell may have a selective advantage in a conventional 
GC reaction (Thorley-Lawson, 2005). Further evidence supports that naïve B 
lymphocytes may not be the only cell type infected (Ehlin-Henriksson et al, 
2003) and studies of tonsillar tissue have demonstrates that EBV-infected B cells 
are only rarely detected in germinal centres (Araujo et al, 1999). The exact 
process of establishment of viral persistence in vivo in primary infection remains 
to be established.  
Most infected memory B lymphocytes do not contain active replicating virus, but 
instead the virus is resting in a latent state. There is complete or near-complete 
down-regulation of EBV antigen expression in these cells (latency 0). This lack of 
viral protein expression allows the virus to evade the immune response. 
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Latent EBV infection is kept in check by the CTL response, discussed in Section 
1.6.5. Viral reactivation occurs intermittently, probably as a result of normal B 
cell homeostasis allowing viral replication (Kuppers, 2003). Such reactivation is 
usually asymptomatic, and does not normally lead to clinical symptoms or signs. 
This periodic reactivation can result in infection of greater numbers of B memory 
cells or in the secretion of infectious virus into saliva where it may be the source 
of infection between contacts. Recent work (Shannon-Lowe & Rowe, 2011) has 
demonstrated that the normally inefficient infection of oropharyngeal mucosal 
epithelial cells can be increased by the formation of cellular synapses with EBV 
infected B memory lymphocytes at the baso-lateral surface of the epithelial cell. 
Whilst this does not explain the mechanism of primary epithelial infection, it 
does provide a means for secretion of virus and onward infection. 
The natural history of EBV in the host is summarised in Figure 1.10. The CTL 
response is important in maintaining this equilibrium between viral latency and 
reactivation.   
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Figure 1-10 The natural history of Epstein-Barr virus infection 
EBV virus is acquired most commonly via the oropharynx. Viral particles in saliva may infect 
epithelial cells of the oropharynx directly where lytic infection can occur. Virus particles 
infect naïve or antigen exposed (Ig V gene mutated) B cells in oropharyngeal lymph tissue. 
The cell is driven into blastic proliferation (latency III pattern). A number of B cells will be 
driven through the germinal centre reaction (latency II pattern) and become differentiated 
to immortalised B memory cells. The EBV persists in the peripheral B cell memory pool for 
the life of the host (latency 0 or I). Intermittently EBV reactivates, exploiting differentiation 
to plasma cells to manufacture large numbers of infectious virus (lytic cycle). These virus 
particles can be secreted into saliva to infect new hosts or can infect further B cells. The 
CTL response is central in controlling infection at all stages. CTL, cytotoxic lymphocyte; 
EBV, Epstein - Barr virus; GC, germinal centre.  
 
1.6.3 The role of the EBV latent proteins in B cell transformation 
EBV has the unique capacity to efficiently transform and immortalise resting B 
lymphocytes (Rickinson & Kieff, 2007; Henle et al, 1967). The immortalised cells 
have features of malignant cells and are known as lymphoblastoid cell lines 
(LCLs). They carry multiple copies of the viral episome and express a latency III 
pattern (Young & Rickinson, 2004). Whilst imperfectly matched to the expression 
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patterns of cHL and Burkitt’s lymphoma, such LCLs do provide an in vivo model 
for studying EBV lymphomagenesis.  
It is the latent infection programme of EBV which is capable of this 
immortalisation, and only a limited number of EBV viral genes are expressed: 
EBNA1, EBNA2, EBNA3A, 3B and 3C, EBNA-LP, LMP1, LMP2 and the EBERs 
(Bornkamm & Hammerschmidt, 2001). The minimal set of genes required for this 
process to occur is still not known, but experiments have demonstrated the 
functional importance in transformation of some of the proteins involved. A 
number of the EBV proteins and the EBERs have been shown to be directly 
oncogenic. EBNA2, EBNA3C and LMP1 when expressed individually in human B 
lymphocyte lines can induce an LCL-like phenotype, suggesting that these three 
proteins may be key in the transformation process (Wang et al, 1990).  
EBNA1 is responsible for the maintenance of the viral genome as an episome 
during cell proliferation and is involved in the transcriptional regulation of the 
EBNAs. In a transgenic mouse model, EBNA1 has been shown to produce B cell 
lymphomas (Wilson et al, 1996). EBNA2 appears essential for transformation with 
EBNA2 deficient strains being incapable of transformation (Young & Rickinson, 
2004). EBNA2 activates transcription of viral LMP1 and LMP2 and also a number 
of cellular genes including the oncogene c-myc (Kaiser et al, 1999; Kuppers, 
2003). ENBA2 also interacts with EBNA-LP to induce cyclinD2 and the cell-cycle 
(Bornkamm & Hammerschmidt, 2001) and may be involved in mimicking Notch 
signal transduction (Hsieh et al, 1996). EBNA-LP has been shown to co-localise 
with a number of proteins associated with proliferation or apoptosis resistance 
such as p53, retinoblastoma and the promyelocytic leukaemia (PML) gene 
product (Szekely et al, 1993; Szekely et al, 1996). EBNA3A and EBNA3C are also 
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essential for transformation, appearing important in transcriptional activation of 
a number of genes implicated in oncogenesis such as cyclin A or histone 
deacetylase 1 (Radkov et al, 1999) and, through co-operation with RAS, in the 
over-riding of cell-cycle check-points (Parker et al, 2000; Parker et al, 1996) 
LMP1 is the main protein in EBV-driven B cell transformation, is essential for 
immortalisation and is directly oncogenic (Wang et al, 1985). LMP1 transgenic 
mice are observed to develop B cell lymphoma (Kulwichit et al, 1998). LMP1 has 
a number of roles in the cell. It inhibits apoptosis through up-regulation of the 
anti-apoptotic proteins A20 and bcl-2 and directly activates the NF- κB pathway 
(Mosialos et al, 1995). Indirect activation of the NF- κB pathway is also observed 
as one of several downstream signals which result from the structural and 
functional resemblance LMP1 has with CD40. This member of the TNFR 
superfamily normally functions to transduce the signal from CD40 ligand, 
resulting in a signal which provides growth, anti-apoptotic and differentiation 
signals to the B cell (Uchida et al, 1999; Kilger et al, 1998). This mimicry is 
thought to be one of the key ways in which LMP1 is oncogenic to B cells. LMP1 is 
also capable of activating PI3K, JAK-STAT and other signalling pathways which 
have been shown to be significant in the oncogenesis of cHL (Young & Murray, 
2003), and can upregulate production of IL-10 (Nakagomi et al, 1994).  
LMP2 is not an essential protein for transformation but does contain a domain 
which can replicate the tonic BCR signal and has been shown in vitro to be 
capable of rescuing and transforming GC B lymphocytes with no functional Ig-
containing BCR (Bechtel et al, 2005; Chaganti et al, 2005; Mancao et al, 2005). 
The RNAs encoded directly by EBV may also play a role in oncogenesis. The 
EBERs are important in determining the transformation efficiency of EBV (Yajima 
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et al, 2005) and have been demonstrated to downregulate p53 and STAT1 and 
therefore increase the ability of the cells to survive an apoptotic signal (Liu et 
al, 2010).  
The specific contribution of these mechanisms to EBV-associated malignancies is 
not well understood, and current evidence would suggest that they are likely to 
be different in the various EBV-associated malignancies (Ambinder, 2007). 
1.6.4 EBV-associated diseases 
EBV infection is associated with a number of different epithelial and lymphoid 
malignant diseases. Although infection with EBV is usually asymptomatic, EBV is 
recognised as a carcinogen by the International Agency for Research on Cancer 
(IARC Working Group on the Evaluation of Carcinogenic Risk to Humans, 2009) on 
the basis of its association with a number of cancers, including cHL. In 2010, it 
was estimated that 1213 cases of cancer in the UK were directly attributable to 
EBV (Parkin, 2011).  
1.6.4.1 Malignant disease - cHL and EBV  
Approximately one third of cases of cHL are associated with EBV, where the virus 
is believed to play a causal role (Jarrett, 2011). Evidence for the involvement of 
EBV in the oncogenesis of cHL comes from a number of strands of evidence.  
In EBV+ve cHL, EBV is detected in all the HRS cells seen (Figure 1.11). In 
addition, it has been demonstrated the virus present is clonal, proving that 
infection occurred prior to clonal expansion and supporting a causative role 
(Gulley et al, 1994; Weiss et al, 1989; Weiss et al, 1987; Jarrett et al, 1991).  
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Figure 1-11 Lymph node biopsy, EBV EBER in situ hybridisation  
x1000 original magnification. Positive staining in the nuclei of all the tumour cells can be 
seen. Reproduced from (Farrell & Jarrett, 2011) with permission, copyright Blackwell 
Publishing Ltd. 
HRS cells express the limited latency II pattern of EBV expression (Section 
1.6.1), which includes EBNA1, LMP1, LMP2, the EBERS and BART RNAs. As 
discussed in Section 1.6.3, these gene products are involved in oncogenesis and 
cell transformation. Functional studies suggest that these same mechanisms may 
be involved in HRS cell survival and proliferation (Jarrett, 2002). Strong 
corroborative evidence for the importance of EBV specifically in rescuing HRS 
cells from an apoptotic death includes the demonstration that cHL cases with 
crippling mutations of Ig genes are restricted almost entirely to EBV+ve cases 
(Brauninger et al, 2006). 
Additional survival mechanisms specific to cHL are also reported. EBNA1 can act 
to upregulate CCL22, attracting Treg cells to the tumour, thus suppressing an 
EBV-specific immune response (Baumforth et al, 2008). Both LMP1 and LMP2 may 
also promote the downregulation of the B cell phenotype by the HRS cell 
(Vockerodt et al, 2008), in particular via the activation of Notch1 (Anderson & 
Longnecker, 2009). 
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EBV is known to harness the cellular methylation machinery to counteract the 
cellular response to methylate viral genes and repress their expression. This has 
recently been shown to be another way in which EBV may contribute to 
oncogenesis in cHL; EBV infection of GC B- lymphocytes altered expression of 
DNA methyltransferases in a pattern identical to that seen in HRS cells (Leonard 
et al, 2011), an effect thought to be due to LMP1 expression (Tsai et al, 2002). 
EBV thus has a plausible role in cHL pathogenesis, although its direct role in 
pathogenesis is difficult to absolutely prove in the absence of an EBV-prevention 
strategy. However, a number of pieces of evidence strongly support the 
causative association of EBV in cHL pathogenesis: the epidemiology of cHL; the 
clonal nature of the infection in the malignant cells; the biologically plausible 
transforming role for the latent proteins expressed in the HRS cell; the ability of 
EBV to rescue B-cells with crippling Ig mutations; the observation of TNFAIP3 and 
Iκ-Bα mutations in predominantly EBV-ve cases (See Section 1.3.4); and the 
temporal association of cHL with another EBV-associated condition, IM.  
1.6.4.2 Other EBV-associated malignant diseases 
EBV-associated malignancies are recognised in immune competent hosts and in 
those with immune compromise(IARC Working Group on the Evaluation of 
Carcinogenic Risk to Humans, 2009), and worldwide account for an estimated 
200,000 cancers per year (Cohen et al, 2011). The malignancies with an 
established EBV association are summarised in Table 1.10. 
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Table 1-10 EBV-associated malignancies 
 Disease Proportion associated with EBV 
Im
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classical Hodgkin lymphoma ~ 35% (varies, see text) 
Burkitt’s lymphoma 
> 95% endemic Burkitt’s lymphoma; 
> 20% sporadic Burkitt’s lymphoma 
Nasopharyngeal carcinoma 
~ 100% (mainly seen in those of Chinese 
and other Asian ethnic origin) 
NK / T cell lymphoma 
> 80% (increased incidence in Asia and 
Central/South America) 
Gastric carcinoma 5-10% 
EBV+ve DLBCL of the elderly † 100% 
Im
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Post-transplant lymphoproliferative 
disease (PTLD) 
> 90% 
AIDS-associated NHL  
100% CNS lymphoma;  
50% other NHL 
HIV-associated cHL > 90% 
Primary effusion lymphoma (PEL)  70-80% 
Leiomyosarcoma 100% 
NHLs associated with inherited  
immune compromise 
> 90% 
† Elderly adults with no recognised immune impairment. There is some suggestion that 
immune senescence may play a role in this condition. DLBCL, diffuse large B cell lymphoma; 
NHL, non-Hodgkin lymphoma; cHL, classical Hodgkin lymphoma; AIDS, acquired immune 
deficiency syndrome. 
 
In immune competent hosts, EBV is associated with a number of malignant 
diseases other than cHL, including the B cell malignancy Burkitt’s lymphoma, 
nasopharyngeal carcinoma (NPC) and others (Table 1.10). Although the 
association is lower, the higher numbers of patients presenting with gastric 
carcinoma make this the commonest EBV-associated malignancy worldwide 
(Cohen et al, 2011). 
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The cell mediated response, particularly the CTL response, in central in 
maintaining equilibrium between stable asymptomatic viral persistence and viral 
reactivation (discussed in Section 1.6.4.3). Clinical situations resulting in a 
reduction of T cell mediated immunity can result in clinically significant EBV-
associated diseases. Examples of causes of T cell immune-suppression associated 
with EBV-driven malignancy include: iatrogenic reduction of T cell immunity 
with immunosuppressive drugs such as methotrexate, cyclosporin, or 
mycophenolate; following haematopoietic stem cell or solid organ transplant; 
HIV/AIDS; and inherited immune deficiencies such as x-linked 
lymphoproliferative syndrome (XLP).  
Acquired immune deficiency syndrome (AIDS) is associated with a recognised 
increase in EBV-associated NHL, particularly primary CNS lymphoma, 
plasmablastic lymphoma and primary effusion lymphoma (PEL) (as a result of co-
infection with Kaposi’s sarcoma herpesvirus).  Patients with HIV infection are 
also at increased risk of cHL, which is almost always EBV+ve, but only when CD4 
levels are reasonably normal, mirroring more the “immune competent” host, 
and probably reflecting the importance of the CD4 cell in forming the cHL 
microenvironment.  
Other diseases associated with a reduction in T cell mediated immunity such as 
the XLP are also associated with symptomatic EBV disease. XLP is an inherited 
disease of young males; most cases being caused by mutations in the XLP or 
SH2D1A gene, which encodes the adaptor molecule Signalling Lymphocytic 
Activation Molecule (SLAM)-associated protein (SAP) (Rezaei et al, 2011). When 
these boys acquire primary EBV infection in childhood, a rapidly progressive 
illness, starting with symptoms akin to IM and developing into 
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haemophagocytosis, takes hold. Subsequently, widespread lymphoid 
proliferations and hepatic infiltration lead to death in two-thirds of cases. 
Survivors remain prone to EBV-driven NHL. Children with other forms of immune 
suppression such as Wiskott-Aldrich syndrome (WAS) and chronic variable 
immune deficiency (CVID) are also prone to EBV-associated NHL. 
Studies have demonstrated that a number of factors can impact on whether or 
not EBV-associated malignancy develops. Co-infection with other pathogens at 
time of primary infection is thought to impact on risk of developing disease; 
higher EBV viral loads have been reported in children co-infected with 
Plasmodium falciparum (Moormann et al, 2005) or HIV (Slyker et al, 2013), and 
the incidence of PTLD is higher in individuals with active cytomegalovirus (CMV) 
infection (Manez et al, 1997). More subtle levels of immune suppression may also 
be linked to the development of EBV+ve cHL. Varicella zoster virus (VZV) 
reactivation resulting in shingles is a surrogate of subtle immune suppression, 
and is a recognised risk factor for development of cHL (Karunanayake et al, 
2009; Tavani et al, 2000). Patients with EBV+ve cHL are more likely to have had 
shingles in the year prior to their diagnosis than patients with EBV-ve disease 
(Jarrett et al, 2005). Such sub-clinical immune suppression, possibly arising as a 
result of immune senescence (shingles being more common with increasing age), 
may account for the greater predominance of EBV+ve cHL in older adults, and 
may suggest an aetiological overlap with EBV+ve DLBCL of the elderly (Nakamura 
et al, 2008). These findings reinforce the importance of the immune response in 
the development of EBV-associated malignancies. 
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1.6.4.3 EBV-specific T cell immunotherapy 
The T cell immune response to EBV has been exploited to treat EBV-associated 
malignancies. A number of studies have used LCL-stimulated cultures of T cells 
to treat cHL (Bollard et al, 2004), PTLD (Haque et al, 2002; McAulay et al, 2009; 
Heslop et al, 2010) and NPC (Straathof et al, 2005a). The clinical trials of these 
cells in the setting of cHL have had limited success which may be due to the 
different latency pattern expressed or the inability of the infused T cells to be 
effective locally due to the immune suppressive microenvironment of the tumour 
(Peggs, 2006).  
1.6.4.4 Non-malignant diseases – IM 
In addition to the EBV-associated malignancies described above, EBV has also 
been implicated in the pathogenesis of a number of non-malignant conditions.  
IM, or glandular fever, is a self-limiting disease characterised by painful 
lymphadenopathy, pharyngitis, fever, malaise and occasionally splenomegaly 
and hepatomegaly. Disease severity can range from asymptomatic disease to 
severe disease leaving individuals essentially bedridden. The median duration of 
illness is approximately 10 days but symptoms can last up to two months in some 
individuals.  
During IM, high titres of infectious EBV viral particles are shed into the 
oropharynx from epithelial cells and local mucosal associated lymphoid tissue. 
Latently infected B cells begin to appear in the local lymph nodes, the tonsils of 
Waldeyer’s ring and the cervical lymph nodes, accounting for the associated 
lymphadenopathy (Kurth et al, 2000). Peripheral blood morphology demonstrates 
“atypical mononuclear” cells which are the oligoclonal CTLs responding to the 
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virus, rather than the infected cells themselves. The disease is associated with 
the development of a heterophile antibody, which can be detected clinically 
using the non-specific Paul-Bunnell test for sheep red cell agglutination, also 
known as the “monospot”. Confirmation is with specific serological testing 
initially for EBV viral capsid antigen (VCA)-IgM and then for the subsequent 
development of VCA-IgG. Disease severity has been reported to be related to the 
magnitude of the CD8+ve lymphocytosis and the level of EBV viraemia (Balfour, 
Jr. et al, 2013). 
The benign disease oral hairy leukoplakia is associated with EBV. Areas of white, 
thickened tissue appear on the lateral surface of the tongue and cannot be 
scraped off. This disease is associated with reduced T cell immunity, most 
commonly in the context of HIV infection, and the lesions demonstrate 
productive infection of EBV (Slots et al, 2006). 
An extremely rare complication of primary EBV infection in previously healthy 
individuals is chronic active EBV (CAEBV). This condition, which is distinct from 
chronic fatigue syndrome, has a duration of greater than 6 months and is 
associated with high peripheral blood viral load and altered antibody responses 
(Macsween & Crawford, 2003). End-organ involvement directly by EBV can result 
in pneumonitis, hepatitis, bone marrow hypoplasia, or uveitis (Cohen, 2000; 
Okano et al, 2005; Kimura et al, 2001). There is a high-risk of development of 
haemophagocytic syndrome and T cell and NK-cell malignancies with attendant 
high mortality rate (> 40%) (Macsween & Crawford, 2003). 
A number of autoimmune conditions are associated with EBV, where an aberrant 
immune response to the virus may be the pathogenic mechanism. Some of these 
associations remain highly controversial, such as the links with rheumatoid 
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arthritis, diabetes mellitus or systemic lupus erythematosus (Thorley-Lawson & 
Gross, 2004; Rickinson & Kieff, 2007).  Other links, such as the association 
between multiple sclerosis (MS) and EBV, are stronger with more evidence in 
support of an aetiological role (Ascherio & Munger, 2007; Habek et al, 2008). 
Whilst genetic, and indeed HLA susceptibility has been suggested (Qiu et al, 
2013; Link et al, 2010; Chao et al, 2008), environmental triggers may be 
important. There is evidence that primary EBV infection is followed by an 
elevated risk of developing MS (Levin et al, 2010), and that EBV-specific 
antibodies are present in the cerebrospinal fluid of patients with MS (Bray et al, 
1992). 
1.6.4.5 EBV vaccination 
The possibility of vaccinating against EBV, ultimately to prevent EBV-associated 
malignancies, has had a resurgence of interest particularly following the 
widespread clinical use of the human papillomavirus vaccine to prevent cervical 
carcinoma (Frazer, 2004). To date, vaccines have generally stimulated a humoral 
immune response to e.g. gp350, which has not been effective in preventing 
either infection or clinical illness in the form of IM (Moutschen et al, 2007; Allen, 
2009; Moss et al, 1998). The ability of any vaccine to prevent EBV-associated 
malignancies has not been studied, although it is hypothesised that any vaccine 
which could decrease the level of persistent infection may help prevent EBV-
associated malignancy even if sterile immunity cannot be achieved. The 
importance of the T cell immune response in maintaining control of EBV 
infection would suggest that any EBV vaccine will have to stimulate a CTL 
response for it to be effective. At present there is no EBV vaccine available.  
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1.6.5 Immune response to EBV 
Given that life-long infection with an oncogenic virus in 95% of the world’s 
population does not result in more disease is testimony to the ability of the 
human immune system to keep this virus in check. 
1.6.5.1 Innate immune response 
In the first few days of EBV infection, before the adaptive immune response can 
react, the innate immune response acts to minimise the impact of the infection. 
Relatively little is understood of this, but the first innate immune response to 
EBV observed is the production of the antiviral cytokines interferon (IFN)-α and 
IFN-β. Further to this, an innate immune response involving the NK cell responds 
to the very early phases of acute infection (Williams et al, 2005). NK cells lyse 
virally infected cells and secrete further antiviral cytokines including IFN-γ. The 
importance of the NK cell response can be appreciated in the context of XLP. 
The SAP gene product (Section 1.6.4.2) associated with this disease is expressed 
by NK cells, acting as a cell activation molecule. NK cells from XLP patients do 
not develop properly and are unable to kill EBV-infected B cells (Parolini et al, 
2000), emphasising the importance of this early response in disease control. 
1.6.5.2 Adaptive immune response - humoral 
EBV also stimulates an adaptive, both serological and cell-mediated, immune 
response. As with other infections, acute infection is associated with generation 
of specific IgM class antibodies to a number of components of the virus, 
particularly those proteins expressed in the lytic phase of infection; viral capsid 
antigen (VCA); immediate early (IE) and early antigen (EA); and membrane 
antigen (MA) comprising gp350 and gp85. Subsequently class-switching to 
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specific IgG antibodies occurs, and in addition, IgG antibodies to EBNA become 
detectable (Moss et al, 2001). These antibodies persist for the lifetime of the 
host, barring any other cause for immune paresis. These antibodies are used in 
the diagnosis of current or prior EBV infection (Henle et al, 1974). The clinical 
significance of these antibodies cannot be known for certain but it is thought 
that their importance is secondary to that of the cell-mediated immune 
response. Evidence in support of the secondary importance of the humoral 
immune response includes the observation that suppression of T cell immunity 
has been shown to lead to an increase in levels of EBV-specific antibody, but 
these are insufficient to prevent clinically significant disease in the face of low 
specific T cell numbers. In addition, trials of EBV vaccines which successfully 
stimulate a neutralising gp350 antibody response do not necessarily prevent 
infection (Khanna et al, 1999a). 
1.6.5.3 Adaptive immune response - cell-mediated 
EBV simulates a particularly vigorous cell-mediated immune response. This 
response is central in controlling both acute lytic and persistent latent EBV 
infection. The importance of the T cell immune system in controlling EBV 
infection can be seen in primary symptomatic infection. The name “infectious 
mononucleosis” derives from the large number of atypical mononuclear cells 
seen on a peripheral blood film. Initially thought to represent the infected cells, 
these are now known to be mainly CD8+ve EBV-specific CTLs. These have been 
shown to be present at levels 5 to 20 times greater than normal (up to 50% of 
CD8+ T cells) and are oligoclonal with a skew in their T cell receptor (TCR) usage 
(Callan et al, 1996; Maini et al, 2000). In the initial response at time of primary 
infection, the response to lytic proteins (principally BRLF1, BZLF1, BMRF1, 
BMLF1 and BALF2) predominates with responses to epitopes derived from EBV 
  Chapter 1: Introduction 
88 
 
latent proteins usually accounting for no more than 2.5% of circulating CD8+ve T 
lymphocytes (Hislop et al, 2002). The magnitude of some of the acute lytic 
responses can be great; studies using major histocompatibility (MHC) tetramers 
(Section 1.6.5.5) (Callan et al, 1998) have demonstrated that as many as 12% of 
circulating T cells during acute infection are specific for a single peptide 
epitope (Section 1.6.5). As the primary infection resolves, the numbers of these 
CTLs gradually falls from approximately 50% of circulating T cells to 
approximately 2% of circulating T cells.  
CTLs specific to latent proteins appear later during infection, and persist at 
steady levels within the host. The CD8 responses to latent proteins develop in 
parallel to developing viral persistence, and are thought to be crucial in immune 
surveillance and maintenance viral latency. The main latent specificities 
detected are to EBNA3-derived epitopes (Rickinson & Moss, 1997; Steven et al, 
1996) with responses also seen to LMP2-derived epitopes. CD8 responses to 
EBNA1 were initially not detected; a glycine-alanine repeat domain in this 
protein prevents HLA class I presentation, most likely through decelerating its 
own synthesis via mRNA interference (Apcher et al, 2010) or via proteasomal 
degradation (Yin et al, 2003). This viral evasion strategy is thought to contribute 
to an escape from CD8+ve T cell immunity, however both CD8 and CD4 T cell 
immune responses to EBNA1 have since been observed at low frequency and are 
thought to arise either through processing of partial defective EBNA1 molecules, 
via a non-proteasomal pathway (Lee et al, 2004; Daskalogianni et al, 2008) or 
possibly inter-cellular antigen transfer (Taylor et al, 2006). 
The population of EBV-specific CD8+ CTL memory cells (or effector memory 
cells) thus consists of cells specific to both lytic and latent specificities. There is 
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no evidence that the CD8+ memory T cell responses detectable in viral 
persistence are different between those who had asymptomatic primary 
infection or those who suffered IM (Callan, 2004). These cells continue to be 
capable of direct cytolytic cell killing and of IFN-γ secretion (Bharadwaj et al, 
2001; Hislop et al, 2001).  
EBV restricted CD4+ve Th responses are present at low levels at time of acute 
infection and then are maintained at a low level (Precopio et al, 2003), 
approximately one-tenth of the CD8+ve CTL response. CD4+ve Th cells function 
to augment antibody responses and to initiate and maintain CD8+ve T cell 
memory. The functional importance of these responses in EBV are less well 
understood, but CD4+ve T cells specific to epitopes from both lytic and latent 
proteins are observed, and have been mapped (Long et al, 2005; Long et al, 
2011a). EBV-specific CD4+ve T cells have been observed to have a Th1 
phenotype. Of note, they recognise a different spectrum of EBV antigens as 
compared with CD8+ve CTLs, with an immunodominance hierarchy skewed 
towards latent proteins, particularly EBNA1, EBNA3B, EBNA3C and LMP1 
(Marshall et al, 2003; Paludan & Munz, 2003). Recent availability of class II MHC 
tetramers have permitted the more detailed study of CD4 EBV-specific 
responses; during acute IM responses to EBNA2, BZLF1, BMRF1, BARF1, and 
BFRF1 were observed (Long et al, 2013) and declined rapidly to the low levels 
previously seen with chronic infection. Responses to EBNA1, previously observed 
to be amongst the most immunodominant antigens in CD4-restricted EBV-specific 
responses (Leen et al, 2001), were seen, but not during acute infection. The 
appearance of CD4+ve Th cells specific for EBNA1 epitopes was delayed, 
probably due to lack of release of EBNA1 from EBV-infected cells (Long et al, 
2013). Most EBV-specific Th cells are Th1 polarised and secrete IFN-γ (Amyes et 
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al, 2003), although some have been observed to secrete IL-10 (Marshall et al, 
2003), suggesting a role in stimulating a Treg response. The functional importance 
of CD4+ve Th cells in EBV immune response remains to be fully determined.  
Any immune suppression in the lifetime of the host is associated with a fall in 
the CD8+ve and CD4+ve EBV-specific T cells and a concomitant rise in numbers 
of EBV infected B cells. The T cell immune response to the virus during the 
lifetime of the host is summarised in Figure 1.12. 
 
Figure 1-12 The T cell response to EBV during the lifetime of the host 
During acute infection, there is a high level of viral replication and large numbers of EBV-
infected B cells (pink shaded area). During the acute infection, the CD8+ve cytotoxic T cell 
(CTL) response to peptides derived from proteins expressed in the lytic phase of infection 
(pale purple line) predominates. Later, CD8+ve CTLs to latent protein specificities (dark 
purple line) appear, but at a lower level. The CD4+ve T-helped cell immune response is of a 
much lower magnitude compared with the CTL responses. During persistent latent infection, 
the magnitude of the CTL response falls but CD8 memory CTL responses particularly are 
maintained and act to help maintain good control of viral latency. Any immune suppression 
in the lifetime of the host is associated with a fall in the CD8+ve and CD4+ve EBV-specific T 
cells and a concomitant rise in numbers of EBV infected B cells.  
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The nature of antigen-presentation to T cells means that the CD8+ve and CD4+ve 
T lymphocyte response generated depends on the antigens available at any given 
time, the ability of those antigens to be presented by the HLA molecule, and the 
host’s HLA type (Section 1.7.1). The epitope specificities and profiles of the 
EBV-specific CTL response in acute and persistent infection have been mapped 
(Hislop et al, 2007; Khanna & Burrows, 2000; Moss et al, 2001). Given the > 85 
ORFs of the virus, one might anticipate a broad response to many EBV proteins. 
However, most individuals have a much more restricted response which focuses 
on a few specificities. What is in fact observed is a marked hierarchy in strength 
and frequency of response, referred to as immunodominance, such that certain 
peptide epitopes via certain HLA-restrictions tend to raise responses more 
commonly, and also elicit responses of greater magnitude (Hislop et al, 2007). 
Such responses during acute infection tend to have specificities for proteins from 
the lytic cycle and include the immunodominant HLA-B*08-restricted BZLF1-
derived peptide RAKFKQLL and the HLA-A*02 restricted BMLF1-derived 
GLCTLVAML (Callan et al, 1998). The magnitude and specificity of the EBV-
specific CTL response are thus directly dependent on the class HLA-phenotype of 
the individual. 
Responses to peptides derived from latency programme proteins appear later in 
acute infection and then persist in viral latency. In most individuals, the 
responses to peptides from proteins expressed in latency are strikingly focused 
on epitopes from the immunodominant EBNA3A, EBNA3B and EBNA3C. 
Subdominant responses to epitopes from LMP2 may be seen, but much less 
commonly observed are responses seen to epitopes from EBNA1, EBNA2, EBNA-LP 
or LMP1 (Murray et al, 1992; Khanna et al, 1992; Hislop et al, 2007). The 
patterns of immunodominance are established early in the individual and, 
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although the magnitude of the response falls, the pattern persists (Khanna & 
Burrows, 2000; Woodberry et al, 2005). Responses can be detected for many 
years, likely for the lifetime of the host (Hislop et al, 2007), and there is some 
evidence that, akin to CMV, the proportion of the CD8+ve immune response 
specific to EBV may actually increase with age (Ouyang et al, 2003; Khan et al, 
2004). Not all specificities raised at time of initial infection persist to the same 
degree; undefined differences in epitope specificity and TCR gene usage may 
play a role in which specificities are long-lived (Greenough et al, 2010), 
phenotypically reflected in differences in PD-1 and IL7-R expression(Sauce et al, 
2009).  
The pattern of immune dominance to latent protein specificities has important 
implications for the CTL response in EBV+ve cHL given its limited latency 
patterns of proteins (Table 1.9). Such hierarchies of immune dominance likely 
reflect the immune escape resulting from viral latency, and may be why class I 
HLA type may be significant. The CTL response to this limited set of proteins is 
important in responding to persistent infection, and probably goes some way to 
explaining why the virus is never fully cleared. When occasional viral 
reactivation occurs, the full spectrum of CD8 and CD4 memory available to an 
individual host is brought to bear on the reactivating virus, and, in a healthy 
host, control is rapidly re-achieved.  
1.6.5.4 Adaptive immune response – cytokines 
Levels of several cytokines are noted to be elevated in response to acute 
primary EBV infection. These include IFN-α, IFN-β and IFN-γ which then initiate a 
cascade of responses including IL-15 and IL-12. Further cytokines which may be 
important include TNF, IL-1 and IL-6. 
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Interestingly, in studies of subjects with IM, only IL-6 levels correlated with 
severity of illness. Plasma IL-6 was also noted to be higher in subjects with a 
higher EBV viraemia. IFN-γ did not correlate with severity of symptoms or 
viraemia (Balfour, Jr. et al, 2013). 
In addition to the cytokines produced by the human immune system in response 
to EBV, the virus also expresses proteins with cytokine functions, most notably 
BCRF1, which is a functional homologue to IL-10 (Hsu et al, 1990) and thus may 
drive a Treg response; and BARF1 which acts as a soluble receptor for colony 
stimulating factor 1 (CSF-1), preventing monocyte proliferation and the further 
release of IFN-γ (Cohen & Lekstrom, 1999). 
1.6.5.5 Measuring the EBV-specific CTL response  
A number of different assays are capable of detecting and enumerating antigen-
specific T cell responses in peripheral blood. Investigators have examined these 
assays for sensitivity and specificity, and have compared their advantages and 
disadvantages for different purposes (Hobeika et al, 2005; Karlsson et al, 2003; 
Kim et al, 2007; Letsch & Scheibenbogen, 2003). These methods are summarised 
in Table 1.11. For the purpose of this project, the ability to screen for novel, 
unrecognised CTL responses with maximal sensitivity meant that IFN-γ enzyme-
linked immunospot (ELISPOT) was the most appropriate method. This is 
described further in Chapter 2. 
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Table 1-11 Comparison of assays of T cell responses 
Method Advantages Disadvantages 
IFN-γ 
ELISPOT 
 High sensitivity and specificity. 
 Does not require a known 
antigen to be able to detect 
response, therefore is suitable 
technique for screening. 
 Cellular responses measured at 
the single cell level. 
 Large number of antigens can be 
screened with comparatively 
lower cell numbers. 
 Lowest “limit of detection” –
ability to enumerate CTLs at low 
numbers. 
 Non-specific background 
reactivity can be seen and may 
be a problem rendering assay 
uninterpretable. 
IFN-γ ELISA  
 Detects bulk response to 
antigen. 
 Cannot detect responses at a 
single cell level, therefore does 
not enumerate antigen-specific 
cells. 
MHC 
Tetramer 
 Good for confirming any 
detected responses. 
 High sensitivity and specificity. 
 Requires known epitopes – not 
generally possible to use as a 
screening method. 
 Costly compared to other 
methods. 
 Cannot detect functional 
responses to any particular 
antigen i.e. cognate cells which 
do not display functional 
cytotoxicity may be recognised. 
Intracellular 
cytokine 
analysis by 
flow 
cytometry 
 Greater dynamic range – better 
at quantifying magnitude of 
response in responding cells. 
 Cellular responses measured at 
the single cell level. 
 Ability to phenotype the 
responding cells. 
 High sensitivity and specificity. 
 Less able to detect low level 
responses. 
 Very labour intensive and 
requires large number of cells 
for screening of large numbers 
of antigens. 
 
 
Chromium 
release 
assay 
 Good method for confirming any 
particular response detected.  
 Require the use of irradiation, 
with recognised hazards to 
health, cost, practical aspects 
regarding use, short half-life 
and training.   
 Method less suitable for 
screening large numbers of 
antigens. 
 High inter-test variability. 
 High background release may 
prevent interpretation of result. 
 Cannot detect responses at a 
single cell level, therefore does 
not enumerate antigen-specific 
cells.  
 Cells cannot be used in 
downstream assays. 
CTL, cytotoxic T lymphocyte; ELISA, enzyme-linked immunosorbent assay; ELISPOT, enzyme-
linked immunospot; MHC, major histocompatibility compatibility. 
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1.7  The HLA system and HL 
The HLA system, encoded by the MHC genes, defines “self” and “non-self” 
recognition by the immune system. First described in the 1950s by Jean Dausset, 
for which he won the 1980 Nobel prize in Physiology or Medicine (Nobelprize.org, 
2013), the HLA system is central in antigen presentation for recognition by the T 
cell immune system.  
Perhaps unsurprisingly given its role in self/non-self discrimination, the HLA 
system is recognised to be associated with at least 40 diseases, particularly 
those with an autoimmune aetiology (Ghodke et al, 2005) such as ankylosing 
spondylitis (Allen et al, 1999; Bowness et al, 1999), rheumatoid arthritis (Bax et 
al, 2011), type 1 diabetes mellitus, coeliac disease (Lie & Thorsby, 2005) and 
Behçet’s disease (de Menthon et al, 2009). In addition, as the HLA system 
presents pathogen-derived antigen for immune recognition, it is again 
unsurprising that associations between HLA-type and susceptibility to infectious 
diseases, such as malaria (Hill et al, 1991) and HIV (McNeil et al, 1996) have 
been described.      
The physiology and genetics of the HLA system will be described first, followed 
by a description of the studies demonstrating the association between class I 
HLA and cHL, and lastly, how this may be of significance in EBV+ve cHL.  
1.7.1 The HLA system 
1.7.1.1 Structure and function  
The HLA molecules are encoded by a region on the short arm of chromosome 6 
(6p21.3) called the MHC. This region of the genome is very gene-dense and is 
divided into three “class” sub-regions based on the function of the genes. The 
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class I and class II regions contain the HLA genes (Figure 1.13). Every human has 
three class I genes: HLA-A, B and C on each copy of chromosome six. The class I 
genes are co-dominant, i.e. all are expressed, and thus every individual has 6 
class I alleles. 
 
Figure 1-13 The major histocompatibility complex.  
The approximate position of the complex on the short arm of chromosome six is indicated, 
along with the three class regions. The approximate location of the class I genes, HLA-A, 
HLA-B and HLA-C are given as are the three main class II genes, HLADP, -DQ and –DR. 
 
HLA class I genes are expressed by all nucleated cells in the human body, and 
also on platelets. HLA class II genes are expressed only on professional antigen-
presenting cells of the immune system such as B lymphocytes, dendritic cells and 
macrophages. The class III region does not contain HLA genes, but many of the 
genes within this region have an immune function and include TNF-α and the 
complement genes C2 and C4. A more detailed map of the MHC is given in Figure 
1.14. 
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Figure 1-14 Gene map of the human leukocyte antigen (HLA) region.  
The regions separated by arrows show the HLA sub-regions extended class I, classical class I, 
class III, classical class II and extended class II regions from telomere (left and top side) to 
centromere (right and bottom side). White, grey, striped and black boxes show expressed 
genes, gene candidates, non-coding genes and pseudogenes, respectively. HLA-A is 
highlighted in red. Reproduced and adapted from (Shiina et al, 2009) with permission. 
Copyright Nature Publishing Group. 
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The function of both class I and class II HLA molecules is to present peptides 
derived from pathogens to T cells, initiating or re-activating a cellular immune 
response. HLA class I molecules present endogenously derived peptides including 
non-self peptides e.g. those derived from viruses or altered self peptides. 
CD8+ve CTLs recognise peptides bound to HLA class I. Class II molecules present 
peptides derived from extracellular proteins which are internalised. Class II 
presents peptides for recognition by CD4+ Th cells, thus stimulating T cell help 
and initiation of a humoral immune response.  
HLA class I genes encode a membrane-bound glycoprotein, the variable α-
polypeptide chain. The α-chain is non-covalently bound to a constant β2-
microglobulin molecule (encoded on chromosome 15) to form the HLA class I 
molecule (Figure 1.15).  
  
Figure 1-15 HLA class I molecule 
A. The HLA molecule comprises the HLA class I coded α-chain non-covalently bound to a 
molecule of β2-microglobulin. The α3 domain of class I HLA is constant. The α1 and α2 
domains of the protein are variable and together form the peptide binding groove, which 
faces out from the cell to present the peptide to the T cell receptor for recognition.          
B.  View of the HLA-binding groove of HLA-A*01:01 from above. Figure drawn using the 
sequence of HLA-A*01:01 (Uniprot Consortium, 2008) using Swissprot protein modelling 
programme (Bordoli et al, 2009). 
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The three-dimensional structure of HLA class I has been determined. The first 
two domains, α1 and α2 fold to form a β-pleated sheet bound by two α-helices, 
forming a groove (Figure 1.15). The α1 and α2 regions of the HLA-molecule are 
highly variable leading to the different class I HLA types. The greatest variation 
is seen in the regions which form the binding groove (coded by exons 2 and 3), 
and which ultimately determine which antigenic peptides can bind. 
In an infected cell, viral proteins are digested into small peptides which are 
transported to the endoplasmic reticulum (ER) via the transmembrane pump 
transporter associated with antigen processing (TAP). A peptide which “fits” the 
binding groove of a given HLA class I molecule is bound into the forming HLA 
molecule by the enzyme tapasin, stabilising the structure. Class I bound peptides 
are usually 8 – 10 amino acids (AA) in length, with the majority being 9 AA in 
length. The HLA molecule with bound peptide leaves the ER and is transported 
to the cell surface via the Golgi apparatus. On the cell surface, the HLA-peptide 
complex is free to interact with a cogent T cell, via the TCR, initiating the 
process of cell killing. There are thought to be roughly 105-106 HLA class I 
molecules per cell and, although not all HLA molecules are occupied at any one 
time, potentially tens of thousands of class I-bound peptides could be available 
at the cell surface.  In addition, it has been shown that “naked” HLA, i.e. empty 
HLA molecules without bound peptide, can bind exogenously provided peptide 
(Kubitscheck et al, 1992). Such “naked” HLA in alternative conformations can 
reach the cell surface via the conventional ER route, or can be endocytosed into 
the cell via endosomes for recycling to the cell surface (Jondal et al, 1996). As 
few as 100 copies of a peptide per cell have been shown to be able to stimulate 
a CTL response (Marsh et al, 2000). 
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The selection of any given peptide for presentation in the binding groove of the 
HLA molecule depends on the affinity within binding pockets of the HLA 
molecule for AA (known as anchor residues) within the peptide. This affinity is 
defined by the ability of the cell to digest the viral protein and by the physical 
and chemical properties (size, polarity and acid/basic properties) of the AA 
within the resultant peptides. Thus the ability of any single peptide to bind to a 
particular HLA molecule is a function of both the viral protein and the HLA 
molecule present, and the resultant peptide presented by the HLA molecule is 
referred to as an epitope. 
For many years it has been possible to systematically study the epitopes 
presented from any given antigen and their HLA-restriction. Investigation into 
which epitope from a given antigen stimulates a T cell response usually starts 
with studying the T cell response. The most reliable approach is to use libraries 
of synthetic peptides which fully span every protein in an organism/ virus. Once 
a response is detected, the HLA-restriction is identified, and the epitope is then 
characterised using smaller peptides until a minimum core sequence epitope can 
be defined. Functional studies as described in Section 1.6.4.5 can then be used 
to further analyse the response stimulated e.g. for immunodominance, strength 
of response etc. Using these techniques, HLA-restrictions to EBV peptides have 
been described. Small numbers of healthy donors of known HLA type have 
generally been used in these experiments; therefore HLA-restrictions through 
common alleles are described more frequently.  
The properties of the HLA class I binding groove mean that certain patterns of 
the characteristics of peptides (e.g. anchor residues, binding motifs etc.) can be 
used to study HLA-binding affinities (Chelvanayagam, 1996). A number of 
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epitope prediction software programmes use these properties to predict which 
antigen-derived epitopes might bind to a particular HLA molecule. These are 
summarised in Table 1.12.  
Table 1-12 HLA-binding peptide prediction software used in this project 
Software Method Reference 
SYFPEITHI 
Uses a database of more than 7000 known 
epitopes and their physio-chemical 
characteristics, such as anchor points and 
allele-specific binding ligands.   
Epitopes that would be predicted to bind 
in the peptide groove of an HLA molecule 
with a functional binding strength are 
identified from full-protein sequences. 
http://www.syfpeithi.de.
home.htm (accessed 
19/11/08)  
(Rammensee, 2008) 
RANKPEP 
Predicts peptides predicted to bind to 
Class I and Class II HLA molecules from 
protein sequence or sequence alignments 
using Position Specific Scoring Matrices 
(PSSMs) derived from tables listing the 
observed sequence-weighted frequency 
of all AAs in every column of a sequence 
alignment. In addition RANKPEP takes 
into account whether the C-terminus of 
the epitope resulted from cleavage by the 
proteasome.  
http://imunax.dfci.harva
rd.edu/Tools/rankpep.ht
ml (accessed 19/11/08) 
(Bioinformatic Cancer 
Vaccine Center Harvard 
University, 2008) 
ProPred 
Predicts peptides predicted to bind to 
Class I and Class II HLA molecules from 
protein sequence or sequence alignments 
using Position Specific Scoring Matrices 
(PSSMs) derived from tables listing the 
observed sequence-weighted frequency 
of all AAs in every column of a sequence 
alignment. 
http://www.imtech.res.i
n/raghava/propred1, 
(accessed 19/11/08) 
(Singh & Raghava, 2003; 
Singh & Raghava, 2008) 
BIMAS 
Ranks potential 8 to 10 AA length 
peptides based on a predicted half-time 
of dissociation from HLA class I 
molecules, based on coefficient tables of 
AA binding strength deduced from the 
published literature 
http://www.bimas.cit.ni
h.gov/molbio/hla_bind/, 
(accessed 19/11/08) 
(NIH BioInformatics and 
Molecular Anaysis 
Section, 2008; Parker et 
al, 1994) 
 
These software programmes were used in this study to predict EBV-restricted 
epitopes; this is discussed further in Chapter 4. Note that none of the methods 
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available in 2008 used the ability of peptide to be processed via the TAP system 
in the endoplasmic reticulum in their algorithm. 
1.7.1.2 HLA inheritance 
One of the striking features of HLA genes is their remarkable level of 
polymorphism when compared to other somatic genes. At each of the genes (in 
the case of class I, A, B and C), there are multiple possible variants, called 
alleles. The nucleotide differences at gene level are translated into protein 
sequencing differences, and thus differences in the binding affinity for different 
peptides. The HLA region is the most variable part of the human genome 
studied; at the most recent review by the HLA informatics group of the World 
Health Organization (WHO), there were 2244 HLA-A, 2934 HLA-B and 1788 HLA-C 
alleles at the DNA level, resulting in 1612, 2211 and 1280 different proteins 
respectively (Robinson et al, 2013), each of which can bind many thousands of 
epitopes. As discussed above, each individual has six class I HLA alleles (two 
each of A, B and C) which together these define an individual’s HLA phenotype. 
This variability means that, at the MHC region, humans are enormously diverse 
and are, outside the case of identical twins, genetically unique.  
The extraordinary diversity at HLA allows, at a population level, the capacity to 
respond to a wide range of pathogens. That the bulk of variation in the HLA 
molecule is in the peptide binding groove of HLA suggests that HLA molecules 
have evolved as a result of natural selection (Little & Parham, 1999). 
Populations which have more limited HLA diversity e.g. due to small founding 
populations, such as the Native peoples of North and South America, face 
difficulties when faced with new antigenic challenges such as the introduction 
into the New World of measles by the conquistadors (Black, 1992). An HLA 
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diverse population, whilst still encountering morbidity and mortality in the face 
of an epidemic, is likely to have a greater proportion of individuals surviving 
such an event (de Vries et al, 1979).  
The evolution of HLA is therefore assumed to be predicated on maintenance of 
diversity. HLA class I heterozygotes are more frequent in populations than would 
be expected by chance. Heterozygosity increases the number of possible 
epitopes which can be presented, referred to as heterozygote advantage (Little 
& Parham, 1999). There is even some evidence that mate selection in humans 
may be influenced by HLA haplotype, with individuals less likely to choose a 
partner with a similar HLA type than would be expected by chance alone (Ober 
et al, 1997; Wedekind et al, 1995). 
The HLA molecules first appear in the jawed vertebrates, demonstrating the 
importance to a species of an adaptive immune system (Parham, 1999). It is 
likely that human HLA molecules derived from a common ape ancestor, most 
likely the HLA-A locus. There is evidence that the common chimpanzee (Pan 
troglodytes) HLA-A shares features with human HLA-A*03, suggesting divergence 
from an allele in a common ancestor approximately 5 million years ago (Little & 
Parham, 1999). The class I B and C alleles are thought to have arisen through 
duplication events (and class II from duplication of class I alleles) and have then 
undergone divergence through point mutation and recombination. Class I allele 
lineages, also known as “supertypes”, can be defined based on this sequence 
divergence.  
HLA-class I genes are also remarkable in that they are often inherited as 
“blocks” of genes which do not undergo recombination during meiosis – a 
phenomenon referred to as “linkage disequilibrium” (LD) (Yunis et al, 2003).  A 
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combination of alleles encoded by different HLA loci on the chromosome, when 
found together at higher frequencies than would be expected by chance, is 
referred to as a haplotype. Single-nucleotide polymorphisms (SNPs) are 
associated with HLA haplotypes such that HLA-alleles can be imputed from 
knowledge of the SNPs (de Bakker et al, 2006; Miretti et al, 2005; Leslie et al, 
2008). Such haplotypes also encompass the non-HLA genes which sit between the 
classical HLA genes. In some studies of disease association, the haplotype 
association has been demonstrated to be in an intermediate gene such as TNF-α 
(Abraham et al, 1993; Abdou et al, 2010). Investigators undertaking HLA disease 
association studies must be careful to take haplotype effects into account. 
Some haplotypes are more common in certain populations, an example in 
Caucasian populations being the most ancient “HLA-A1, C7, B8, DR3” haplotype, 
in which A*01 and B*08 sit in LD. It is suggested that in ages when infectious 
disease was the main determinant of individual survival such haplotypes may 
have carried some evolutionary advantage in dealing with common primitive 
pathogens, and have been maintained by positive selection. However, such 
haplotypes may be disadvantageous in modern times. For instance, the “HLA-A1, 
B8, C7, DR3” haplotype has been described as the “autoimmune haplotype” for 
its association with numerous autoimmune diseases including type I diabetes 
mellitus, Graves’ disease, SLE and many other conditions (Candore et al, 2002; 
Price et al, 1999).  
Such selective pressure has probably been instrumental in determining which 
alleles are present in a particular population. Allele frequencies vary in different 
populations around the world. The HLA-B*53:01 gene, which is associated with 
resistance to malaria, is more common in West African populations where it has 
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probably increased in frequency as a result of positive selection (Hill et al, 
1991). Similar ancient and interacting pressures are likely to have shaped the 
allele frequencies around the world. The geographical patterns of HLA diversity 
suggest significant evolution as man has spread around the globe (Abi-Rached et 
al, 2011), and, secondarily, may account for some of the ethnic differences seen 
in incidences of some viral-associated malignancies such as NPC and cHL. 
An international database has been devised to hold information on allele 
frequencies in different populations (Gonzalez-Galarza et al, 2011). This 
information tells us that, for example, the most common HLA-A allele in Scottish 
& UK populations is HLA-A*02 at 42-54% of the population. HLA-A*02 is in fact 
one of the commonest HLA-A alleles around the world suggesting that at some 
point the allele held a selective advantage. HLA-A*01:01 is a relatively common 
gene in those of Celtic heritage, present at 29-33% in the Scottish & UK 
population and up to 44% in Northern & Southern Irish populations vs. 11% in 
Chile and 2% in Hong Kong Chinese (all allele frequency data, accessed 
16/06/2013 (Gonzalez-Galarza et al, 2013)). 
1.7.1.3 HLA nomenclature 
HLA nomenclature, as defined by the WHO Nomenclature Committee for Factors 
of the HLA System (Marsh et al, 2010; Nunes et al, 2011) is used throughout this 
thesis. Briefly each HLA allele name has a unique number corresponding to up to 
four sets of digits separated by colons (Figure 1.16). All alleles receive at least a 
four digit name, which corresponds to the first two sets of digits; longer names 
are only assigned when necessary. The first two digits describe the type, which 
corresponds to the serological allotype. The next two digits define the subtypes, 
defined by different AA sequences. The next two digits define variants with 
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silent or non-coding differences in nucleotide sequence. The fourth set of digits 
defines variants in the untranslated regions of the gene (Figure 1.16). Letter 
suffixes may be used to define variants which are expression-based e.g. L for 
low-level of expression, N for null etc. Where HLA is discussed in the following 
text, the resolution of typing reflects that performed in the studies described.  
 
Figure 1-16  International HLA nomenclature 
As defined by WHO Nomenclature Committee for Factors of the HLA System (Marsh et al, 
2010). 
 
1.7.2 The Association between class I HLA and cHL 
The ethnic differences in incidence of cHL and the elevated risks seen in family 
members (particularly identical twins, Section 1.5), suggest that there is an 
inherited component to the risk of cHL. It is now apparent that there are strong 
associations between HLA class I genes and EBV+ve cHL.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
cHL was the first disease for which any HLA association was described in 1967 
(Amiel, 1967). Although earlier HLA-typing methods were limited by available 
technology, further studies (Dausset & Hors, 1975; Hors & Dausset, 1983; 
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Svejgaard et al, 1975; Falk & Osaba, 1974; Hansen et al, 1977) demonstrated 
that HLA-A*01 and HLA-B*08 were most closely associated with increased risk.  
This work was furthered by family segregation studies. The first of these, 
(Marshall et al, 1977), did not demonstrate any clear association with disease, 
although HLA-B*08 was seen more often in first-degree relatives of cases. It must 
be noted that the initial HLA-association studies were published in the era 
before the EBV-association of cHL was recognised and, as such, EBV status of 
disease is not reported. Further familial studies demonstrated excess of HLA-
B*35 and HLA-B*37 in cases within families (Greene et al, 1979). A greater than 
expected HLA identity between siblings with cHL was described and an 
association with HLA-A*01 reported (Hors et al, 1980). Similar haplotype 
concordance was observed between cHL-affected siblings in a study of 16 
families (Berberich et al, 1983). In addition, 8 of 16 families in this series had 
the A*01, B*08 haplotype.  
Population based studies (Hors & Dausset, 1983; Falk & Osaba, 1974; McDevitt & 
Bodmer, 1974; Harris et al, 1978; Bjorkholm et al, 1975) continued to 
demonstrate consistent associations with HLA-A*01, and to a lesser extent B*08, 
with A*03 and A*11 being less prevalent in cases as compared with controls.  
Interestingly, some of the earlier studies (Hornmark-Stenstam et al, 1978; Falk & 
Osoba, 1971; Hafez et al, 1985) also observed a survival advantage associated 
with particular HLA types; remarkably consistently these studies demonstrated 
that although HLA-*01 was associated with risk of disease, it was also associated 
with improved survival. Some of these were retrospective and may have been 
affected by survivor bias.  
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More recently, data analysed in the modern era with PCR-based HLA-typing 
better diagnostic accuracy and availability of EBV-status of disease, have 
confirmed the strong association between HLA genotype and EBV+ve cHL, 
suggesting that HLA-restricted CTL responses to EBV may play a key role in 
determining risk of developing disease. Genotyping studies across the HLA region 
have shown that microsatellite markers and SNPs in the HLA class I region are 
strongly associated with EBV+ve cHL (Diepstra et al, 2005; Niens et al, 2006). 
The markers associated with disease were shown to be in LD with HLA-A*01 
(associated with risk) and HLA-A*02 (protective) (Niens et al, 2007). 
Further evidence pointing to an association between class I HLA and EBV+ve cHL 
has been the study of HLA-associated genetic markers and risk of IM. As has been 
discussed, prior IM is associated with elevated risk of cHL. Studies have 
demonstrated that the SNPs and microsatellite markers in the class I HLA region 
associated with symptomatic IM are the same as in EBV+ve cHL (McAulay et al, 
2007). 
A recent large Scottish and Scandinavian case series analysed 934 patients with 
cHL for whom EBV status and class I HLA typing was available. In this study 
(Hjalgrim et al, 2010), HLA-typing was performed to 4-digit resolution, but the 
statistical analysis performed at 2-digit level. Increased risk of disease was 
associated with HLA-A*01 (OR per allele, 2.15; 95% CI, 1.60-2.88) and decreased 
risk with HLA-A*02 (OR per allele 0.70; 95% CI, 0.51-0.97). The effects were 
independent of each other, but dependent on allele copy number, resulting in an 
almost 10-fold greater odds of developing EBV+ve cHL in HLA-A*01 homozygotes 
when compared with HLA-A*02 homozygotes.  
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GWAS studies have corroborated the association with the HLA class I region with 
remarkably consistent ORs. In a recent GWAS study, the SNP rs2734986 in HLA-A 
was associated with EBV+ve cHL (OR, 2.45; 95% CI = 2.00 - 3.00, p = 1.2 × 10-15) 
but not with EBV-ve cHL (Urayama et al, 2012). 
The class I HLA link with EBV+ve cHL is biologically plausible. There is 
involvement of a pathogen (EBV) in the disease, to which the CTL immune 
response in known to be crucial. HLA class molecules, whilst known to be 
downregulated in EBV-ve cHL, presumably as a means of immune escape, are 
observed to be expressed at high levels on the surface of HRS cells in EBV+ve 
disease (Oudejans et al, 1996), thus suggesting that a CTL response to the 
malignant cell is still possible. 
Several groups have also observed associations between class II HLA and cHL, 
particularly EBV-ve cHL or NSHL. Such risk alleles include HLA-DPB*03:01 
(Bodmer et al, 1989; Taylor et al, 1999; Alexander et al, 2001), and class II 
associations have been verified in SNP studies (Moutsianas et al, 2011) and in 
GWAS studies (Cozen et al, 2011; Urayama et al, 2012). No association between 
Class II and EBV+ve cHL has been described and class II HLA is not discussed 
further. 
A criticism frequently levelled at HLA association studies is that the association 
observed may not be with the HLA allele in question, but may be with another 
gene in LD with the allele. This can only be answered by explaining the 
underlying mechanism of any association.  
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1.7.3 Exploring possible mechanisms for the association between 
class I HLA and EBV+ve cHL 
The association between HLA class I, most particularly HLA-A*01:01 and HLA-
A*02:01, and EBV+ve cHL suggests a critical role for the CTL response to EBV in 
determining risk of disease. 
EBV is an intensively studied virus. Over the last 20 years, a number of groups 
have interrogated the EBV-specific CTL responses. Generally, these studies were 
concerned with systematically mapping T cell epitopes and HLA-restrictions, and 
did not specifically seek or examine HLA-A*01:01 or HLA-A*02:01-restricted 
responses. 
That numerous immunodominant HLA-A*02:01-restricted peptides have been 
described is of interest given the protective effect of this allele. In contrast, in 
spite of intensive study, no confirmed HLA-A*01:01-restricted CTL responses to 
EBV latent or lytic proteins have been described (Hislop et al, 2007; Straathof et 
al, 2005b; Long et al, 2011b; Moss et al, 2001). HLA-A*01:01 is able to efficiently 
present peptides from viruses other than EBV. For instance, immunodominant 
peptides from CMV and Influenza virus raise very efficient CTL responses via this 
allele (Currier et al, 2002; DiBrino et al, 1993; Elkington et al, 2003; Wills et al, 
1996). Thus, there is no suggestion that HLA-A*01:01 is in any way deficient in 
terms of antigen presentation capability.  
This raises the possibility that absent or weak CTL responses specifically to EBV 
might lead to the elevated risk of disease. The stage in the disease process when 
the HLA-A*01:01 associated risk is exerting its effect is unknown. It may be that 
the CTL response to the proliferating tumour is critical, or, alternatively, it may 
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be that control either of initial infection or of viral persistence may be 
important. 
The HLA-A*01:01 associated risk is unexplained; individuals who carry HLA-
A*01:01 will also have potentially 4 or 5 other class I HLA alleles through which 
they may be able to raise an EBV-specific CTL response. It is not clear whether 
the increased risk associated with HLA-A*01:01 is simply because there are no 
EBV-specific responses restricted through this allele, or whether HLA-A*01:01 
exerts qualitative or inhibitory changes to the EBV-specific immune response.  
The interaction between HLA-A*01:01 and HLA-A*02:01, specifically the 
intermediate risk of disease seen in heterozygotes is also of interest. The reason 
for the elevated risk of disease in HLA-A*02:01/A*01:01 heterozygotes is unclear, 
since these individuals should be capable of mounting effective, even 
immunodominant, CTL responses to EBV. 
1.8  Summary  
The pathophysiology of EBV+ve cHL is gradually being elucidated; however many 
fundamental questions remain. EBV is ubiquitous, infecting much of the world’s 
population, but causing malignancy in only a small minority. The question of why 
some individuals in the face of a common and normally well-tolerated persistent 
infection develop EBV+ve cHL, whilst others do not, has not been answered.  
The cellular re-programming of the HRS cell is only part of the story; the central 
role of the tumour microenvironment in cHL tells us that this cancer, more than 
most lymphoid malignancies, manipulates the immune response. The recent 
findings of the associations of class I HLA allotype with risk of developing EBV+ve 
cHL only reinforce that immune response, particularly CTL response, is crucial in 
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disease pathogenesis. Such associations, however, do not explain the 
mechanisms at work. 
Clinically, the majority of patients with cHL do well, and are long-term survivors 
of their disease. Two main clinical challenges persist. First, as most patients 
survive their disease, focus moves to minimising the life-changing or life-
shortening late effects of therapy. Secondly, and more crucially, to say that cHL 
is a “done deal” in that the majority of patients survive does an injustice to the 
15-20% of patients who will succumb to their disease. Given the epidemiology of 
cHL, this means that every day young adults are dying of this disease. Current 
prognostication is not sufficiently accurate to target therapies, and there is no 
good evidence that such targeted approaches will improve outcome. New 
approaches are required both to identify and successfully treat such high-risk 
patients.  
1.9  Aims and Objectives 
This project aims to address a number of specific objectives regarding the role 
of class I HLA, specifically HLA-A*01:01 and HLA-A*02:01 in EBV+ve cHL, namely: 
Does the presence of an HLA-A*01:01 allele modify the magnitude of the CTL 
response to HLA-A*02:01-restricted epitopes? (Chapter 3) 
Can any HLA-A*01:01-restricted EBV-specific CTL responses be detected or are 
any inhibitory cytokine responses detected? (Chapter 4) 
Are HLA-A*01:01 and A*02:01 alleles a factor in determining clinical outcome in 
EBV+ve cHL? (Chapter 5) 
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2.1  Materials 
Materials used in the project are described in the relevant methods section.  
Suppliers and addresses are given in Appendix 1. Plastic ware is listed in Table 
2.1 and named in full at first use. Thereafter, for brevity, the shortened name 
listed in the table is used. 
Table 2-1 Plasticware 
Item Abbreviation used in text 
(where applicable) 
Supplier 
1.5 ml sterile screw-cap polypropylene 
microcentifuge tube 
1.5 ml screw-cap tube Elkay 
15 ml conical polypropylene tube   15 ml tube 
Falcon,  
BD Biosciences 
50 ml conical polypropylene tube   50 ml tube 
Falcon,  
BD Biosciences 
5 ml round-bottom polystyrene tube 
(Falcon #2054)  
5 ml tube BD Biosciences 
50 ml LeucoSep tube  Greiner Bio-One 
50 ml reagent reservoir - Costar™ reagent reservoir Corning Inc. 
48-well flat-bottom plate (Multiwell™) 48-well plate BD Biosciences 
96-well round-bottom sterile plate 
(Nunclon™ surface) 
96-well plate Sigma 
Corning 25 cm3 flask 25 cm3 flask SLS 
Corning 250 cm3 culture flask 250 cm3 culture flasks SLS 
NUNC™ 1.8 ml cryotube cryovial 
Fisher Scientific 
Inc. 
Pastette  
Fisher Scientific 
Inc. 
Pipettes  
Gilson Scientific 
Ltd. 
Pipette tip - 10 µl aerosol resistant tips 
(ART Reach™) 
 Sigma 
Pipette tip - 20 µl, 200 µl, 1000 µl  Rainin 
VACUETTE® tube  Greiner Bio-One 
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2.1.1 Culture media and solutions 
A list of the culture media, buffers and solutions used is given in Table 2.2. 
Table 2-2 Culture media, buffers and solutions 
Culture 
media, buffers 
and solutions 
Acronym 
used in 
text 
Purpose Recipe 
Complete 
culture 
medium 10% 
FBS† 
10% CCM 
General cell 
culture 
RPMI 1640 (Invitrogen) 500 ml 
FBS (Invitrogen) 50 ml 
Penicillin/Streptomycin (Invitrogen) 20 
ml 
L-glutamine (Invitrogen) 5 ml 
Total volume 575 ml 
Complete 
culture 
medium 20% 
FBS† 
20% CCM 
Culture of 
lymphoblastoid 
cell lines 
RPMI 1640 (Invitrogen) 500 ml 
FBS (Invitrogen) 100 ml 
Penicillin/Streptomycin (Invitrogen) 20 
ml 
L-glutamine (Invitrogen) 5 ml 
Total volume 625 ml 
Dulbecco's 
Phosphate 
buffered saline 
PBS Isotonic buffer 
Sterile water (Invitrogen) 100 ml 
10 x Dulbecco's phosphate buffered saline 
(Invitrogen) 11 ml 
Freezing 
medium 
FM 
Viable freezing of 
cells 
FBS (Invitrogen) 9.2 ml 
DMSO (Fisher) 0.8ml 
Mini-Macs 
(Modified 
magnetic 
activated cell 
separation) 
Buffer 
MMB 
For cell 
separation and 
cell counting 
10 x PBS (Invitrogen) 50 ml 
EDTA (supplier) 2 ml 
Bovine serum albumin (supplier) 2.5 g 
Fill to 500 ml with distilled water 
Filtered using a 500ml 0.45 µm Corning 
filter flask (Sigma) and dispensed into  
50 ml aliquots stored at 4oC. 
† By convention "10% CCM" is made by adding 50 ml FBS to 500 ml RPMI, and “20% CCM” by 
adding 100 ml FBS to 500 ml RPMI, which results in a slightly lower percentage serum. The 
medium is filtered using a 500 ml 0.45 µm Corning filter flask (Sigma) and dispensed into 50 
ml aliquots stored at 4oC. FBS, foetal bovine serum; PBS, phosphate buffered saline; DMSO, 
Dimethyl sulfoxide; EDTA, ethylendiamine tetra-acetic acid. 
 
2.1.2 Equipment 
Large items of equipment used in the project are detailed in Table 2.3 and 
mentioned in the text where relevant. 
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Table 2-3 Large items of equipment 
Item Supplier 
Heraeus Multifuge 3 S-R DJB Labcare Ltd. 
Jencons Sealpette vWR 
Pipetteboy-acu Integra Biosciences 
Allegra 6R Centrifuge Beckmann Coulter 
Incubator Thermo Scientific 
1500 series freezer -70oC MVE System 
Freezer -20oC Haier 
Vapour-phase nitrogen 
freezer 
New Brunswick Scientific 
FC500 Flow cytometer Beckmann Coulter 
AID (Autoimmun 
Diagnostika) Plate reader 
Oxford Biosystems/ Cadama 
Medical Ltd. 
 
2.2  Safety Measures 
All of the work carried out in this project was performed according to the 
required health and safety considerations, per University of Glasgow guidelines. 
Control of substances hazardous to health (COSHH) assessments were performed 
for all procedures. All work was performed in a Containment Level 2 laboratory; 
cell cultures, viruses and human samples were handled in a Class 2 
Microbiological Safety Cabinet (MSC). Gowns were worn over laboratory coats for 
all work undertaken in the MSCs. These gowns were autoclaved regularly, 
including after each occasion when virus or virus-infected cell lines were 
handled. All metal surfaces were sprayed with 70% alcohol (Fisher Scientific Inc.) 
before and after use. Liquids containing biological material were discarded into 
2% Virkon (Fisher Scientific Inc.) and other material coming into contact with 
biological substances was disinfected in 1% Virkon (Fisher Scientific Inc.). All 
waste material leaving the laboratory was autoclaved at 120oC and 100 kilo 
Pascal above atmospheric pressure for 20 minutes (min) prior to appropriate 
collection. All sharps waste was disposed of into standard sharps containers 
conforming to UN 3291 and BS 7320 standards. 
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2.3  Samples from Healthy Donors 
2.3.1 Subjects and Ethical Approval- The SHARE Study 
In order to study the HLA-restricted immune responses of healthy individuals, as 
discussed in the Introduction, a source of healthy human T and B lymphocytes 
was required. Healthy adult volunteers (age ≥ 18 years) were recruited to a 
study designated SHARE (Study of Healthy Adult Responses to EBV). Ethical 
approval for this study was obtained via the national Integrated Research 
Application System (IRAS), and granted via the West Glasgow Research Ethics 
Committee 2 (REC reference:  08/S0709/149). In addition, ethical approval was 
obtained from the University of Glasgow, Faculty of Veterinary Medicine Ethics 
and Welfare Committee, so that recruitment to the study could take place 
within the University of Glasgow. Ethical approval was also obtained from the 
clinical governance committee of the Scottish National Blood Transfusion Service 
(SNBTS) and various stakeholders within the SNBTS, for use of donors as detailed 
below. A questionnaire was administered to all recruits to the study, collecting 
basic demographic data, postcode, smoking status, and history of previous IM; 
this is included as Appendix 2. 
2.3.1.1 Recruitment  
The subjects were recruited in a number of ways. Firstly, healthy adults were 
invited to visit the Clinical Research Facility (CRF) at the Western Infirmary, 
Glasgow, where research nurses administered the questionnaire and collected 
blood samples. This recruitment mechanism was open to the public. Secondly, 
participants were recruited from within the University of Glasgow. Permission 
was granted by Dr. Graham Caie, University of Glasgow Clerk of Senate and Vice 
Principal, and the Heads of Faculties for recruitment e-mails to be sent to staff 
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and students. These were sent via distribution lists to all staff and students, with 
the exception of medical students. Volunteers recruited in this way were able to 
participate via the CRF, or approach me directly. Recruitment sessions were also 
held on the Garscube Estate (University of Glasgow). Thirdly, recruitment e-
mails were sent out to our collaborators and contacts within the local 
haematology community. Interested individuals requested a pack for further 
information. These individuals then arranged for local sampling, completed the 
questionnaire and returned the samples to the Leukaemia Research Fund (LRF) 
Virus Centre by pre-paid post in an appropriate biological transport container 
(Safebox™, Royal Mail). All participants recruited via these three routes 
completed the questionnaire and, as their HLA type was unknown, gave an initial 
blood sample (detailed below) for HLA typing and viral serology.  
Participants with HLA types of interest were then approached as detailed below 
for a further sample of 50 millilitres (ml) whole blood. 
Volunteers of known HLA type were also recruited from the SNBTS platelet- 
donor population. These donors are special in the donor community in that they 
altruistically donate apheresed platelets every few weeks. An advantage of this 
donor population was that their extended HLA type was known, thus enabling 
donors with specific HLA types to be targeted. A list of platelet donors with the 
HLA types relevant to the study was generated by John Tomkins, Senior 
Biomedical Scientist, Histocompatibility and Immunogenetics Service, SNBTS, 
Gartnavel General Hospital, Glasgow. Donor identities were pseudonymised and 
donors were identifiable to us only by their national donor (PROGESA) number. 
The donors with HLA types of interest were then approached by the clinical and 
nursing staff of the Old Athenaeum Donation Centre, Nelson Mandela Place, 
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Glasgow where platelet donations take place. As HLA type was already known, 
no initial sample was required. These donors were required only to complete the 
questionnaire, and donate a 50 ml whole blood sample. On some occasions, 
samples could not be transported to the LRF Virus Centre on the same day as 
they were collected, and so were kept overnight at room temperature (RT) at 
the Old Athenaeum Donation Centre prior to next day transportation. This 
information was recorded. SNBTS donors were not approached for further 
specimens. 
2.3.1.2 Consent, Pseudonymisation and Recall 
All subjects gave written, informed consent to participate in the study, and 
completed the questionnaire. Subjects without prior HLA-typing information 
were made aware that they may be approached for an additional blood sample. 
Consent forms and the top sheet of the questionnaire both contained patient-
identifiable data and were kept securely and separately by the laboratory 
clinical co-ordinator, Mrs. Shauna Crae. Participants were allocated a non-
sequential “SHARE number” at time of recruitment and staff processing the 
samples did not have access to the participant-identifiable data. On arrival of 
the initial sample at the laboratory, the participant was also allocated a 
sequential “LRF patient number”, a unique identifier which enabled data storage 
and unblinding by authorised personnel for recalls. All non-identifiable data 
were stored in a computer database held by the LRF Virus Centre (Section 
2.3.1.3). Access to the database is limited to authorised personnel.  Data were 
held in compliance with the Data Protection Act.  
Donors with HLA types relevant to downstream investigations were identified by 
me and decoding of donor numbers was performed by Mrs Crae or Prof. Jarrett. 
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Depending on the route of recruitment, donors were then contacted by CRF staff 
or by Prof. Jarrett. Donors were able to state a preference for mode of recall at 
time of initial recruitment, for example e-mail, telephone or letter. Donors were 
also offered the choice of donating their 50 ml blood sample at the CRF, and 
thus maintaining anonymity, or contacting me to arrange for a blood sample to 
be taken by me at a location convenient to the donor. Clinically suitable areas 
with appropriate facilities were used for all venepunctures.  
2.3.1.3 The LRF Virus Centre Database 
The LRF virus centre uses a computer database system to record details of all 
participants in studies (patients and healthy volunteers) and samples held. There 
are separate, linked databases for all participant information, events associated 
with any participant, diagnosis, samples and freezer location. This enables good 
research governance, and timeous and accurate retrieval of participant 
information and sample information. Participant names are not held on the 
database; instead each participant is allocated a unique “LRF patient number” 
which acts as an identifier on the system. All details described in the 
descriptions of the SHARE study and HLA & Outcome study (Chapter 5) were 
derived from records held on this database. 
2.3.1.4 Description of Cohort  
In total 172 individuals were recruited to the study. The recruitment target of 
200 subjects in an HLA-unscreened population was not necessary as, through the 
more targeted recruitment of the platelet donors, the study achieved its 
recruitment targets in terms of number of donors of required HLA type (Table 
2.4). 
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Table 2-4 Recruitment by HLA Class I genotype 
HLA type Target number to recruit Number recruited 
A*01:01/A*01:01 homozygotes 10 14 
A*01:01/A*02:01 heterozygotes 15 30 
A*02:01/A*02:01 homozygotes 15 18 
A*02:01/A*x heterozygotes†  15 26 
† (where x is any allele other than A*01:01 or A*02:01) 
 
 
Of the 172 subjects recruited to the study, 64% (n = 108) volunteers were female 
and 36% (n = 61) male. Information on sex was unavailable for three volunteers. 
The median age of the cohort was 39 years (range 18-68 years). Twenty six 
individuals (15.1%) reported a previous history of glandular fever and nineteen 
individuals (11.0%) stated in the questionnaire that this had been confirmed by a 
blood test. In these individuals, the episode of IM was a median of 18.5 years 
prior to entry into the study (range 1-39 years). The median age of individuals at 
time of IM was 19 years (range 5-30 years). Forty-four individuals (25.6%) had 
been smokers at some point, fifteen of whom (8.7% of total cohort) were current 
smokers.  
Deprivation category information, using the Carstairs 5–point score for 
deprivation, was available for 137 volunteers. First described by Carstairs and 
Morris in 1981 (Carstairs, 1981b; Carstairs, 1981a), Carstairs scores are a 
measure of access to societal resource, derived by combining selected variables 
taken from small area Census data, reflecting economic status of populations at 
a small geographical (postcode) level. The most recent update of the score, 
using 2001 census data (McLoone, 2004) was used. Four pieces of information 
(overcrowding, male unemployment, low social class and car ownership) were 
standardised and scored to define the Scottish postcodes into quintiles by 
deprivation (DEPCAT5). The proportion of individuals in each category, versus 
the expected Scotland-wide population proportion is given in Figure 2.1.  As can 
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be seen, there is a slightly higher proportion of individuals in Carstairs index 
category 1 (least deprived), as might be expected from a recruitment strategy 
targeting University and NHS employees.  
 
Figure 2-1 Carstairs deprivation index score of individuals in study  
Shown versus expected proportions. 
 
A number of possible biases as a result of the recruitment strategy were 
observed. Although not systematically recorded, we were aware of a small 
number of individuals who volunteered for this study because they had a relative 
with HL. As this study was selecting individuals by HLA type, and examining CTL 
response in healthy individuals, it was not felt that this would impact on the CTL 
responses assessed.  
Previous IM, confirmed by a blood test, was reported by 11.8% of recruits. Data 
on overall population prevalence of IM infection are not available, as it is not a 
notifiable disease. Previous studies have reported an annual incidence of 45-50 
cases per 100,000 population per year (Newell , 1957; Heath, Jr. et al, 1972) 
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and in a previous case-control study of IM and HL (Alexander et al, 2003) 4.7% of 
the healthy adult controls reported prior IM.  That almost 12% of subjects in our 
study population reported previous IM is higher than would be expected. This 
potential bias may be important as it is known that individuals who have 
suffered previous IM are at an elevated risk of cHL for a number of years and, as 
discussed in the Introduction, it is suggested that CTL response may be 
important in determining this risk. Since this information was recorded 
systematically for all cases, prior IM was included as a covariate in some 
analyses of CTL response.  
All adults recruited in to the study were healthy at time of recruitment. In 
addition, at time of recall for donation of the “large sample”, donors were again 
asked to verbally confirm that they were in good health. This was important as 
any illness e.g. viral infection may impact on the results of the analyses. One 
donor contacted us during the study period to inform us that since donating they 
had been diagnosed as suffering from multiple sclerosis (MS) and may have been 
symptomatic at time of donation. MS is an inflammatory disease of the central 
nervous system characterised by demyelination. It is increasingly being 
recognised that EBV, and immune response to EBV may be important in disease 
pathogenesis (Cepok et al, 2005; Habek et al, 2008; Jilek et al, 2012; Levin et 
al, 2010); for this reason, samples from this donor were excluded from the 
study. 
2.3.2 Peripheral Blood Sample Collection 
Samples were collected by venepuncture into VACUETTE® tubes (Greiner Bio-
One). For the initial “small” sample, whole blood samples were taken into a gel 
separation serum tube (5 ml) and into a tube containing ethylenediamine tetra-
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acetic acid (EDTA) as an anti-coagulant (5 ml). For the “large” specimen, 
approximately 50 ml of whole blood was collected into 9 ml tubes containing 
EDTA as an anti-coagulant.  
2.3.3 Sample Processing 
2.3.3.1 Processing of initial “small samples” 
Samples were allowed to equilibrate to RT. The time taken from sample 
collection to the beginning of sample processing was recorded. All blood 
centrifugation steps were performed using a Heraeus centrifuge, with brake on, 
unless stated otherwise. Serum was obtained by centrifuging the gel-separated 
sample at 1500 x gravity (g) for 15 min and 500 l aliquots were subsequently 
dispensed into 1.5 ml sterile screw-cap polypropylene microcentifuge tubes 
(Elkay). Aliquots were labelled with LRF patient number, sample number and 
date, and stored at -70oC. Samples were not heat inactivated. 
Plasma was obtained by centrifuging the anti-coagulated sample at 1500 g for 15 
min. Aliquots of 500 l plasma were dispensed, labelled and stored as above.   
The buffy coat, visible after centrifugation, was removed by Pastette (Fisher 
Scientific Inc.) into a 15 ml conical polypropylene tube (Falcon, B.D. 
Biosciences). DNA was extracted from the buffy coat, as described below.  
2.3.3.2 Processing of 50 ml “large” samples  
Peripheral blood mononuclear cells (PBMCs) were obtained by the separation of 
anti-coagulated whole blood using the LeucoSep centrifuge tube system (Greiner 
Bio-one). LeucoSep tubes were prepared by adding 15 ml of Lymphoprep density 
medium (Greiner Bio-one) at RT to each of four 50 ml LeucoSep tubes. These 
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were centrifuged at 1000 g for 30 seconds (s) to drive the medium through the 
membrane. Samples of approximately 50 ml anti-coagulated whole blood were 
allowed to equilibrate to RT. The blood was divided between 4 x 50 ml conical 
polypropylene tubes (Falcon, BD Biosciences) and the volume in each was made 
up to 30 ml with Hank's Balanced Salt Solution (HBSS) (Gibco, Invitrogen). These 
were then poured into each of the four prepared LeucoSep tubes which were 
then centrifuged at 800 g for 15 min with the brake off (0). The PBMC layer was 
removed using a Pastette (Fisher Scientific Inc.) and transferred to a 50 ml 
conical polypropylene tube (Falcon, BD Biosciences). The volume was made up 
to 20 ml with minimacs buffer (MMB) if required. Aliquots (2 x 100 l) were 
removed for flow cytometric analysis. The PBMCs were then used in downstream 
experiments, or taken through to B cell separation. 
2.3.4 Cell counting and analysis of cell viability 
Cells were counted at a 1 in 5 dilution (50 l Trypan blue 0.4% (Sigma), 30 l 
MMB and 20 l cells) using a haemocytometer (Neubauer 1/400 mm2, Hawksley) 
and a hand tally counter (ENM). Only viable cells, i.e. those not staining with 
Trypan blue, were counted. For all cell counts, 4 sets of 16 squares on the 
cytometer were counted, and the mean taken to give number of cells x 104 per 
ml. This was adjusted for the dilution factor. 
2.3.5 DNA extraction 
DNA extraction was performed using the Nucleon DNA extraction method (GE 
Healthcare). Cells were lysed by the addition of Reagent A to the buffy coat 
fraction at 4 x the volume of the buffy coat (approximately 4 ml). Tube contents 
were mixed on a rotary mixer (Beckman Coulter) for 5 min, and then centrifuged 
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at 1300 g for 5 min. The supernatant was removed carefully using a Pastette 
(Fisher Scientific Inc.), leaving a soft pellet. This pellet was re-suspended in 2 ml 
buffer B and briefly vortexed (HATi Rotamixer, HTZ), as per kit instructions. 
Sodium perchlorate (500 l, supplied as part of the Nucleon kit) was added and 
the contents of the tube mixed by inversion seven times, to facilitate protein 
removal. Chloroform (2 ml, Sigma) was added to this tube and the contents of 
the tube again mixed by inversion seven times. Resin beads (300 l, supplied as 
part of the Nucleon kit) were added and, without further mixing, tubes were 
centrifuged at 1300 g for 3 min. The supernatant was removed into 5 ml cold 
100% analar-grade ethanol (Fisher Scientific Inc.). The DNA was precipitated by 
gentle inversion, spooled out on the tip of a pipette tip and placed in a sterile 
screw cap tube. Excess ethanol was aspirated. The DNA pellet was left to air-dry 
for 10- 30 min, 100 l tris-EDTA (TE) (Microzone) was added and the sample left 
overnight to re-suspend, in a water bath (Grant) at 37oC. The DNA was then 
stored at 4oC before quantification and storage at -70oC. 
2.3.6 DNA quantification 
DNA was quantified using the fluorimetry-based Qubit system (Invitrogen) with 
the Quant-it dsDNA high-sensitivity assay kit for double-stranded DNA 
(Invitrogen). Following quantification as per kit instructions, DNA was diluted 
with TE (Microzone) to an appropriate concentration for storage at -70oC. DNA 
samples (1 µg) were sent to Dr. Little for HLA typing (detailed below). 
2.3.7 HLA Typing 
HLA typing was performed by Dr. Ann-Margaret Little, initially at The Anthony 
Nolan Trust Histocompatibility Laboratories (Fleet Road, Hampstead, London 
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NW3 2QG) and subsequently at NHS Greater Glasgow & Clyde (Tissue Typing and 
Immunology laboratory, Paul O’Gorman Building, Gartnavel Hospital). Molecular 
typing of class I HLA genes was performed to an intermediate resolution i.e. 
four-digit typing defining variations in AA sequence which may affect peptide 
binding affinity (Nunes et al, 2011) (See also Section 1.7.1.3). The method 
employs PCR using allele-specific primers (Gen-probe) and subsequent bead-
based sequence specific oligonucleotide (SSO) assay (Luminex). Assignment of 
the most likely allele from the allele strings generated was performed manually 
by Dr. Little using Quicktype for Lifematch software (Gen-probe).   
2.3.8 B cell Separation 
PBMCs were re-suspended in residual buffer and washed by filling the 50 ml tube 
with MMB and then centrifuging at 300 g for 10 min. The supernatant was 
removed by pouring off into a clean 50 ml tube, care being taken not to disrupt 
the cell pellet. The supernatant was further centrifuged at 500 g for 5 min and 
the supernatant removed as before. Cell pellets were re-suspended in residual 
buffer, diluted in 10 ml MMB and then combined in the first tube. The second 
tube was rinsed with 5 ml MMB, which was then added to the cell suspension 
(total volume 25 ml). An aliquot of 100 µl was removed for flow cytometry and a 
cell count performed as described. The cell suspension was divided between five 
or six 5 ml round-bottomed, polystyrene tubes (Falcon #2054, BD Biosciences) 
and centrifuged at 300 g for 10 min. Following removal of the supernatant, cells 
were re-suspended in MMB to a final concentration of 1 x 107 cells per 60 µl. 
Immunoglobulin constant region (FCR) blocking agent (Miltenyi Biotec) (20 l per 
1 x 107 cells) and CD20 microbeads (Miltenyi Biotec) (20 l per 1 x 107 cells) were 
added to the cell suspension. Following mixing, reactions were incubated at 4oC 
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for 15 min, with periodic re-mixing. After incubation, the cells were washed and 
the pellets re-suspended in 300 l MMB. One MS (medium capacity) cell-
separation column and one LS (large capacity) cell-separation column (Miltenyi 
Biotec) were prepared by placing in MiniMacs Separation Magnet Units (Miltenyi 
Biotec), inserting a 50 µm sterile cup Filcon filter (BD Biosciences) and flushing 
with 500 l (MS) or 3 ml (LS) MMB. The prepared cells were placed on the Filcon 
filter in the LS column, without introducing bubbles, and allowed to flow 
through. The column was washed three times with 3 ml MMB. The flow-through 
was collected and retained (“negative fraction 1”). The LS column was removed 
from the magnet; 5 ml MMB were added and plunged through to collect the 
CD20-positive fraction (“positive fraction 1”). Positive fraction 1 was pelleted at 
300 g for 7 min, re-suspended in 500 µl MMB and pipetted on to the prepared MS 
column. The column was washed three times with 500 l MMB and the flow-
through retained (“negative fraction 2”.) The MS column was removed from the 
magnet; 1 ml of MMB was added and plunged through to collect the CD20-
positive fraction (“positive fraction 2”).  
The “positive fraction 2” cells (CD20 positive B lymphocytes) were counted as 
described. An aliquot (20 l) was removed for flow cytometry and the remaining 
cells were then used in EBV-infected cell frequency experiments or frozen 
viably.  
The negative fractions 1 and 2 (B cell deplete PBMC (BD-PBMC) were combined 
and a cell count performed as described. An aliquot (100 µl) was removed for 
flow cytometry. The cells were then used fresh in ELISPOT assays (for 
optimisation experiments, see Section 2.8.3) or frozen viably for use at a later 
date.  
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2.4  Tissue Culture 
2.4.1 Viable Freezing of PBMCs 
PBMCs or BD-PBMCs obtained as above were frozen in aliquots of 1 or 2 x 107 
cells. Following counting as described in Section 2.3.4, the cell suspension was 
centrifuged at 300 g for 5 min, and re-suspended at 1 or 2 x 107 / ml in freezing 
medium. Cells were frozen in volumes of 1 ml in NUNC™ 1.8 ml cryotubes (Fisher 
Scientific Inc.), hereafter referred to as “cryovials”. Cells were taken to -70oC 
using the NALGENE™ (Fisher Scientific Inc.) system for controlled rate freezing. 
This commercial system employs a container, the base of which is filled with 
isopropyl alcohol (Fisher Scientific Inc.). The rate of freezing achieved is close to 
the ideal of -1°C / min, and allows the preservation of cell viability. The 
following day, cells were transferred to long-term storage in liquid nitrogen 
tanks at -200oC.   
2.4.2 Viable Freezing of Cell Lines 
All cell lines used or created in the study, detailed below and including LCLs, 
were frozen using the same method and conditions as for freezing of PBMC. 
2.4.3 Recovery of viably frozen cells 
The required aliquot of cells was identified using the LRF Virus Centre database – 
(Section 2.3.1.3). Using the usual safety procedures involved with liquid 
nitrogen, the cryovial was removed from the liquid nitrogen tank into a metal 
flask. The cryovial was defrosted slowly in water at 37oC. The defrosted vial was 
submerged briefly in 70% alcohol to sterilise the exterior surface before opening. 
The cells were then added drop wise to 10 ml 10% complete culture medium 
(CCM) at 37oC, washed by spinning at 300 g for 5 min and re-suspended in fresh 
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CCM, before counting as described. If required, cells were centrifuged again and 
re-suspended at the required concentration for use.  
2.4.4 Cell lines 
The human cell line 721.221 is an EBV-transformed LCL which does not express 
MHC Class I, i.e. it is negative for HLA-A, -B and –C. Professor John Trowsdale 
and Dr. Louise Boyle, Cambridge Institute for Medical Research, University of 
Cambridge, provided us with viably frozen 721.221 cells. In addition to the 
721.221 parental line, cells transduced to express only HLA-A*01:01 or HLA-
A*02:01 were provided. Transductions and checks on transduction efficiency 
were performed by Dr. Boyle. On receipt, cells were expanded and master 
stocks stored. Subsequent working stocks were derived from these cells. 
The B95-8 cell line is a primate lymphocyte cell line derived from the peripheral 
blood lymphocytes of a cotton-top tamarin. These cells release high titres of 
EBV, providing a source of infectious virus. The B95-8 cell line used in this work 
was gifted by Prof. Alan Rickinson of the School of Cancer Sciences, College of 
Medical and Dental Sciences, University of Birmingham. 
The P3HR1 cell line used in the production of slides for EBV VCA IgG serology was 
provided by Prof. Dorothy H. Crawford of the Centre for Infectious Diseases, 
University of Edinburgh.  
2.4.5 Generation of infectious EBV virus 
B95-8 cell cultures were used as a source of EBV for generation of LCLs.  EBV-
containing culture supernatant, rather than ultra-filtered pelleted virus, was 
used. The B95-8 cells described above were cultured in 10% CCM in Corning 250 
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cm3 culture flasks (SLS). The cultures were expanded by splitting 1:2 twice 
weekly. When the culture reached 6 flasks, each containing 220 ml, an equal 
volume of medium was added, and Parafilm M (Sigma-Aldrich Company Ltd.) 
applied to the flask lid to deprive the cells of gas, induce cellular stress and cell 
death. After 3-4 days, a visual check was performed to ensure that the cells 
were dead or dying. The culture was decanted into 50 ml tubes and centrifuged 
at 300 g for 5 min at 4oC. The supernatants were retained and filtered through a 
0.8 µm filter using a Costar filter bottle (Fisher Scientific Inc.) and vacuum pump 
(Millipore). Aliquots of 1 ml were frozen in 1.5 ml screw cap tubes. The EBV 
obtained was used only in the generation of LCLs and, as efficient 
transformation was achieved, titration of virus stocks was not performed.  To 
minimise risk of contamination, all EBV-infected cell cultures were handled in a 
MSC reserved for working with cell lines, and only after all other non-viral work 
was complete for the day. To avoid cross-contamination, a separate incubator 
was used for all viral work, and dedicated pipettes were used.  
2.4.6 Generation of donor LCLs 
Donor PBMCs were selected and defrosted as per Section 2.4.3. Each infection 
required 2 x 106 cells. Cells were pelleted at 400 g for 10 min in a 15 ml tube. 
The pellet was re-suspended in 500 µl B95-8 viral supernatant. T cell immune 
suppression was achieved by the addition of cyclosporin A (Sigma-Aldrich, UK). 
Master stocks of cyclosporin A (1mg/ml) in absolute alcohol (Fisher Scientific 
Inc.) were stored at -20oC; the working stock (100 µg/ml) was made by dilution 
in 20% CCM, and kept at 4oC. Ten microlitres of this were added to the cells, and 
the total volume was made up to 1 ml (final concentration 1 µg/ml cyclosporin 
A). The cell suspension was transferred to one well of a 48-well flat-bottom 
plate (Multiwell™, BD Biosciences). The plate was incubated at 37oC in 
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humidified 5% carbon dioxide (CO2). The cells were fed weekly by removal and 
addition of 300-500 µl 20% CCM and, when proliferating enlarging clumps were 
observed (usually at 2-4 weeks), cultures were split 1 in 2 with 20% CCM. 
Proliferating cells were fed twice weekly. Cells were transferred to a Corning 25 
cm3 culture flask (SLS) once cultures occupied 4-6 wells of the plate. When 
established, master stocks of each individual LCL were frozen viably, and 
working cultures continued for use in downstream experiments.  
2.5  Flow Cytometric Analysis 
All antibodies were purchased from Beckman Coulter. Cells (in volumes 
described in Section 2.3.3) were incubated with 10 µl antibody for 10 min (unless 
stated otherwise) at RT. CalLyse (100 µl, Invitrogen) was added to each tube, 
mixed well and incubated for a further 10 min at RT. Distilled water (2 – 3 ml) 
was added to each tube, and mixed well by vortexing (HATi Rotamixer, HTZ). 
The cells were centrifuged at 300 g for 5 min. The supernatant was removed and 
cells were resuspended in 500 µl of 1% paraformaldehyde (Sigma) to fix the cells. 
Samples were analysed using a Beckman FC500 flow cytometer. Five thousand 
events per sample were counted and analysed. Isotype controls were performed 
for every assay. 
2.5.1 Flow cytometry method for B cell depletion protocol 
The standard panel described below (Table 2.5) was used to analyse each 
“large” sample. An aliquot of 20 µl of cells was taken from the CD20 positive 
fraction into a 5 ml tube and 100 µl MMB added. Aliquots of 100 µl were taken 
from PBMC pre-fractionation and CD20 negative fractions respectively to 5 ml 
tubes, and 500 µl added to each. Cells were then aliquoted as per Table 2.5 (100 
µl cells per tube), and 10 µl of each antibody added. 
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Table 2-5 Flow cytometric analysis of B cell separations – standard antibody panel 
Cell Fraction Antibodies 
PBMC pre-fractionation 
CD3FITC/CD20PE  
CD3FITC/HLA-DR PE 
CD8FITC/CD4PE/CD3ECD 
CD20 negative fraction 
CD3FITC/CD20PE  
CD3FITC/HLA-DR PE 
CD8FITC/CD4PE/CD3ECD 
CD 20 positive fraction CD3FITC/CD20PE  
ECD, electron coupled dye; FITC, fluorescin isothiocyanate; PE, phycoerthyrin. 
2.5.2 Flow cytometry antibodies used in specific experiments  
In addition to the standard panel described above, additional antibodies were 
used in specific experiments. The antibodies are listed in Table 2.6 and the 
methods for these experiments described in Sections 3.2.5 and 4.2.4.5. 
Table 2-6 Flow cytometry antibodies used in specific experiments 
Cell Fraction Antibodies 
Optimisation of B-Deplete 
PBMC 
CD3FITC/HLA-DR PE 
CD3FITC/CD20PE  
CD8FITC/CD4PE/CD3ECD 
CD16FITC/56PE/3ECD 
CD15FITC/45PE/33ECD 
CTL Degranulation  CD107PE 
ECD, electron coupled dye; FITC, fluorescin isothiocyanate; PE, phycoerthyrin. 
2.6  Viral Serology 
2.6.1 Serology for EBV 
EBV serotyping (VCA IgG )was performed using an immunofluorescence method 
(Henle et al, 1974). Known positive and negative sera were used as controls.  
Briefly, 100-250 µl serum were heat inactivated at 56oC for 20 min. Sera samples 
at a 1:8 dilution in PBS (20 µl) were placed on prepared multi-well slides on 
which P3HR1 cells (Section 2.4.4) were fixed. Slides were incubated for 90 min 
at RT in a moist chamber then washed twice with PBS for 5 min in a slide holder 
and drained on a tissue. The fluorescin isothiocyanate (FITC)-conjugated, anti-
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human IgG secondary antibody (DAKO) was prepared as a 1:50 dilution in PBS, 
and 15 µl added to each spot on the slide. This was incubated for 45 min at RT in 
a moist chamber. Slides were washed as before and mounted with PBS:Glycerol 
(50:50) (Fisher) and a coverslip. Slides were read under a fluorescent microscope 
at x 25 objective; positive cells displayed a strong fluorescent green staining. 
For the purposes of this study, titres were not recorded, and results were 
recorded as either positive or negative. 
2.6.2 Serology for CMV 
CMV serotyping was performed at the West of Scotland Specialist Virology 
Laboratory, Gartnavel General Hospital (collaborators Dr. William F. Carman and 
Dr. Jane McOwan). Serotyping used the CMV IgG chemiluminescent microparticle 
immunoassay (Abbot Diagnostics) on the Abbot platform. Samples (100-250 µl 
serum) were prepared by heat inactivation at 56oC for 20 min, prior to analysis. 
The automated platform loaded samples and performed the immunoassay. Both 
low- and high-level positive controls and negative controls of CMV-specific IgG 
were provided with the assay. Results were recorded as either positive or 
negative.  
2.7  Peptides 
2.7.1 EBV peptides 
A list of peptides derived from EBV viral proteins and known to be presented by 
particular HLA specificities was synthesised from the published literature (see 
review (Hislop et al, 2007) and references in Table 2.7). The AA sequences of 
these peptides, their HLA-restriction, and the protein from which they are 
derived are listed in Table 2.7. The AA sequences of EBV proteins were taken 
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from the B95-8 reference sequence (Human herpesvirus 4) (National Center for 
Biotechnology Information (NCBI), 2008). The one-letter abbreviation for AA is 
per the International Union of Biochemistry and Molecular Biology  guidelines 
(IUPAC-IUB Joint Commission, 1984) (see Appendix 3.) 
2.7.2 CMV and Influenza peptides and the CEF pool 
Peptides derived from CMV and influenza virus proteins, known to be presented 
by particular HLA specificities, were used as controls in the experiments (Kern et 
al, 2000; Elkington et al, 2003; Collins et al, 1999; DiBrino et al, 1993; Suhrbier 
et al, 1993). The AA sequences of these peptides, their HLA-restriction, and the 
protein from which they are derived are listed in Table 2.8. Where pools of 
peptides were used, their compositions are detailed in the relevant results 
Chapters. 
The CEF (CMV, EBV, ‘flu) pool is a combination of 23 peptides derived from 
proteins expressed by CMV, influenza and EBV. These peptides are restricted 
through a range of HLA-specificities. This broad range of specificities covers the 
most common human HLA-types and three common viruses, and thus most 
individuals would be expected to raise a CTL response to at least one of the 
constituent peptides in this combination. The pool was first described by HIV 
vaccine researchers (Currier et al, 2002) and is now recognised by the 
international committee for the standardisation of ELISPOTS (Janetzki et al, 
2005) as a gold standard, positive control for quality control (QC) where 
ELISPOTs are used in clinical e.g. vaccine studies. The AA acid sequences of 
these peptides, their HLA-restriction, and the protein from which they are 
derived are listed in Table 2.9.  
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Table 2-7 EBV peptides used in the study 
AA sequence HLA restriction Protein Cycle Abbreviation Reference 
FMVFLQTHI A2 EBNA1 Latent FMV (Stuber et al, 1995) 
HPVGEADYFEY B3501 EBNA1 Latent HPV (Blake et al, 1997) 
RPQKRPSCI B7 EBNA1 Latent RPQK (Blake et al, 2000) 
IPQCRLTPL B7 EBNA1 Latent IPQ (Blake et al, 2000) 
DTPLIPLTIF A2/B51 EBNA2 Latent DTP (Schmidt et al, 1991) 
SVRDRLARL A2 EBNA3A Latent SVR (Burrows et al, 1994) 
RLRAEAQVK A3 EBNA3A Latent RLR (Hill et al, 1995) 
YPLHEQHGM B3501 EBNA3A Latent YPL (Burrows et al, 1994) 
RPPIFIRRL B7 EBNA3A Latent RPP (Hill et al, 1995) 
VPAPAGPIV B7 EBNA3A Latent VPA (Rickinson & Moss, 1997) 
QAKWRLQTL B8 EBNA3A Latent QAK (Burrows et al, 1994) 
FLRGRAYGL B8 EBNA3A Latent FLR (Burrows et al, 1990b) 
IVTDFSVIK A11 EBNA3B Latent IVT Gavioli (Gavioli et al, 1993) 
LLDFVRFMGV A2.01 EBNA3C Latent LLD (Kerr et al, 1996) 
RRIYDLIEL B27 EBNA3C Latent RRI (Brooks et al, 1993) 
EENLLDFVRF B44 EBNA3C Latent EEN (Burrows et al, 1990a) 
QPRAPIRPI B7 EBNA3C Latent QPR (Hill et al, 1995) 
SLREWLLRI A2 EBNA-LP Latent SLR (Lee et al, 2000) 
YLLEMLWRL A2 LMP1 Latent YLL (Khanna et al, 1998) 
YLQQNWWTL A2 LMP1 Latent YLQ (Khanna et al, 1998) 
TLLVDLLWL A2 LMP1 Latent TLL (Khanna et al, 1998) 
LLLIALWNL A2 LMP1 Latent LLL (Duraiswamy et al, 2003) 
LLVDLLWLL A2 LMP1 Latent LLVD (Duraiswamy et al, 2003) 
TVCGGIMFL A2 LMP2 Latent TVC (Straathof et al, 2005b) 
LIVDAVLQL A2 LMP2 Latent LIV (Straathof et al, 2005b) 
GLGTLGAAI A2 LMP2 Latent GLG (Meij et al, 2002) 
FLYALALLL A2 LMP2 Latent FLY (Lautscham et al, 2003) 
LLSAWILTA A2 LMP2 Latent LLS Lee (Lee et al, 2000) 
LTAGFLIFL A2 LMP2 Latent LTA (Lee et al, 1996) 
LLWTLVVLL A2.01 LMP2 Latent LLWT (Lee et al, 1996) 
CLGGLLTMV A2.01 LMP2 Latent CLG (Lee et al, 1993) 
FTASVSTVV A68 LMP2 Latent FTA (Straathof et al, 2005b) 
MGSLEMVPM B3501 LMP2 Latent MGS (Straathof et al, 2005b) 
LLWAARPRL A2 BARF0 Lytic LLWA (Kienzle et al, 1998) 
GLCTLVAML A2.01 BMLF1 Lytic GLC (Scotet et al, 1996) 
TLDYKPLSV A2.01 BMRF1 Lytic TLD (Hislop et al, 2002) 
RPQGGSRPEFVKL B7 BMRF1 Lytic RPQG (Pudney et al, 2005) 
LVSDYCNVLNKEFT B18 BRLF1 Lytic LVSD (Pepperl et al, 1998) 
ATIGTAMYK A11 BRLF1 Lytic ATI (Pepperl et al, 1998) 
RALIKTLPRASYSSH A2 BRLF1 Lytic RAL (Pepperl et al, 1998) 
YVLDHLIVV A2.01 BRLF1 Lytic YVL (Saulquin et al, 2000) 
DYCNVLNKEF A24 BRLF1 Lytic DYC (Pepperl et al, 1998) 
RVRAYTYSK A3 BRLF1 Lytic RVR (Pudney et al, 2005) 
EPLPQGQLTAY B3501 BZLF1 Lytic EPL (Pepperl et al, 1998) 
APENAYQAY B3501 BZLF1 Lytic APE (Redchenko & Rickinson, 1999) 
RAKFKQLL B8 BZLF1 Lytic RAK (Bogedain et al, 1995) 
ILIYNGWYA A2 GP110 Lytic ILI (Khanna & Burrows, 2000) 
VLTLLLLLV A2 GP350 Lytic VLT (Bharadwaj et al, 2001) 
VLQWASLAV A2 GP350 Lytic VLQ (Khanna et al, 1999b) 
QLTPHTKAV A2 GP350 Lytic QLT (Khanna et al, 1999b) 
LIPETVPYI A2 GP350 Lytic LIP (Khanna et al, 1999b) 
LMIIPLINV A2 GP85 Lytic LMI (Khanna et al, 1999b) 
TLFIGSHVV A2 GP85 Lytic TLF (Khanna et al, 1999b) 
SLVIVTTFV A2 GP85 Lytic SLV (Khanna et al, 1999b) 
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Table 2-8 CMV and influenza peptides used in the project 
Epitope AA sequence HLA restriction Protein Virus 
ECF 
pool 
Abbreviation 
CVETMCNEY A1 IE1 CMV 
 
CVE 
DEEEAIVAY A1 IE1 CMV 
 
DEE 
ELKRKMIYM B8 IE1 CMV 
 
ELK 
ELRRKMMYM B8 IE1 CMV 
 
ELRR 
QIKVRVDMV B8 IE1 CMV 
 
QIK 
VLEETSVML A2 IE1 CMV 
 
VLA 
IPSINVHHY B35 pp65 CMV 
 
IPS 
NLVPMVATV A2 pp65 CMV * NLV 
QEFFWDANDIYRIFA B44 pp65 CMV * QEF 
RKTPRVTGGGAMAGA B7 pp65 CMV * RKT 
YSEHPTFTSQY A0101 pp65 CMV 
 
YSE 
GILGFVFTL A2 Matrix 1 Influenza A * GIL 
CTELKLSDY A1 NP Influenza A * CTE 
ELRSRYWAI B8 NP Influenza A * ELRS 
ILRGSVAHK A3 NP Influenza A * ILR 
KTGGPIYKR A68 NP Influenza A * KTG 
SYRWAIRTR B27 NP Influenza A * SYR 
VSDGGPNLY A1 PB1 Influenza A * VSD 
 
Table 2-9 Composition of the CEF control peptide pool 
Epitope amino acid 
sequence 
HLA restriction Protein Virus Abbreviation 
NLVPMVATV A2 pp65 CMV NLV 
QEFFWDANDIYRIFA B44 pp65 CMV QEF 
RKTPRVTGGGAMAGA B7 pp65 CMV RKT 
CTELKLSDY A1 NP Influenza A CTE 
ELRSRYWAI B8 NP Influenza A ELRS 
GILGFVFTL A2 Matrix 1 Influenza A GIL 
ILRGSVAHK A3 NP Influenza A ILR 
KTGGPIYKR A68 NP Influenza A KTG 
SYRWAIRTR B27 NP Influenza A SYR 
VSDGGPNLY A1 PB1 Influenza A VSD 
EENLLDFVRF B44 EBNA3C EBV Latent EEN 
FLRGRAYGL B8 EBNA3A EBV Latent FLR 
IVTDFSVIK A11 EBNA3B EBV Latent IVT 
QAKWRLQTL B8 EBNA3A EBV Latent QAK 
RLRAEAQVK A3 EBNA3A EBV Latent RLR 
RPPIFIRRL B7 EBNA3A EBV Latent RPP 
RRIYDLIEL B27 EBNA3C EBV Latent RRI 
YPLHEQHGM B3501 EBNA3A EBV Latent YPL 
ATIGTAMYK A11 BRLF1 EBV Lytic ATI 
DYCNVLNKEF A24 BRLF1 EBV Lytic DYC 
GLCTLVAML A2.01 BMLF1 EBV Lytic GLC 
RAKFKQLL B8 BZLF1 EBV Lytic RAK 
RVRAYTYSK A3 BRLF1 EBV Lytic RVR 
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The individual peptides were synthesised as described in Section 2.7.3, and 
pooled at working stock concentration as described in Section 2.7.4. 
The prediction methods used to derive putative HLA-A*01:01-restricted EBV 
peptides, and the peptides sequences generated are described in Chapter 4. 
2.7.3 Source of synthetic peptides 
All peptides used in the study were synthetic peptides generated by Alta 
Bioscience (Birmingham, UK). Solid phase synthesis (EpiScan) was used to 
generate peptides of the specified sequences. Peptides were synthesised with C-
terminal free acids as this is the natural state of the peptide following digestion 
of the protein, prior to assembly with the HLA molecule.  Peptides were supplied 
as 2 mg dry product in individual tubes, with a specification sheet detailing 
purity and quantity. QC of purity was performed by high-performance liquid 
chromatography (HPLC), and these data were supplied with the peptides. 
2.7.4 Preparation of peptides  
Due to the relatively small numbers of AAs in the short peptides used in this 
study, the peptides varied in their polarity, i.e. some were hydrophobic, and 
some hydrophilic. In order to ensure uniform solubility of peptides, it is 
recommended that the initial reconstitution of all peptides is in dimethyl 
sulfoxide (DMSO). To ensure maximum purity of peptides was preserved, with 
minimal contamination, HPLC-grade DMSO (Fisher Scientific Inc.) was used 
throughout. Aseptic technique was used in reconstituting all peptides. The 
lyophilised peptides were dissolved in DMSO to a master concentration of 10 
mg/ml and stored at -20oC. Working stocks of peptide (100 µg/ml in 1 x PBS) 
were stored at -20oC. As peptides degrade with multiple freeze-thaws, aliquoted 
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volumes were those required for single experiments. For large sequences of 
experiments using the same peptides, the peptides were stored at working stock 
in 96-well sterile single-use round-bottom plates (Nunclon™, Sigma) with the 
peptides in the positions for their final use. These plates were sealed with PCR 
film (Thermo Scientific) to minimise evaporation.   
Peptides were used at a final concentration of 10 µg/ml (once cells in CCM were 
added) unless stated otherwise. Where pools of peptide were used, these were 
made from master stocks of peptide, diluted with 1 x PBS to a concentration for 
each individual peptide of 100 µg/ml. 
2.7.5 Optimisations with synthetic peptides 
2.7.5.1 Quantitation of peptides in solution  
Short-chain peptides vary in their solubility. Even when DMSO was used to 
reconstitute lyophilised peptides, differences were observed in the speed and 
ease of dissolving the solid peptides in solution. For this reason, and because 
responses between peptides were to be compared, efforts were made to 
measure the concentration of peptides in master stock solutions. The expected 
concentration of the peptides in master stock solutions was 10 mg/ml based on 2 
mg dry peptide reconstituted in 200 µl DMSO.  
Spectrophotometric absorption at 280 nm using a Nanodrop (ThermoFisher) was 
performed. The absorption curves at 280 nm were different for every peptide 
measured. The spectrophotometric absorption at 280 nm relies on the presence 
of aromatic AAs in proteins. Due to the short length of the peptides used, not 
every peptide contained aromatic AAs, and even small differences in the number 
of aromatic AAs made a large difference to the absorption and thus, the derived 
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concentration. The Nanodrop was therefore not a suitable technique for 
assessing peptide concentration in solution. 
Quant-iT™ technology (Invitrogen) is a fluorescent dye-based assay employing a 
detergent/dye based preparation which binds to the hydrophobic regions and 
the detergent coating on a protein. When actively bound, fluorescence is 
enhanced, and can be measured using the Q-bit™ fluorometer. As before, there 
was wide variability in peptide measurement, with strikingly low levels 
recorded. After discussion with the company’s technical service staff, it became 
apparent that the presence of hydrophobic pockets in the structure, and not 
merely hydrophobic AAs, are required to detect the protein. As the peptides are 
generally too short to form such pockets, and vary in their content of 
hydrophobic AAs, this was not a suitable technique for assessing peptide 
concentration in solution. 
Lastly, a Biuret assay was employed. This gold-standard assay of protein 
concentration detects the presence of peptide bonds, using a chemical 
technique whereby copper ions bind to the nitrogen of the peptide bonds in an 
alkaline solution. Results are compared against a standard curve generated from 
replicate dilutions of bovine serum albumin of known concentrations. This was 
felt to be a suitable technique due to the ubiquitous presence of peptide bonds, 
even in short-chain peptides. Where the assay was successful, concentration of 
the peptide was measured at 3.9-14 mg/ml. However, in more than half of the 
peptides tested (31 of 56), cloudiness was observed in the solution, rendering it 
unsuitable for analysis. The likely reason for this is that hydrophobic peptides 
can produce a cloudy solution when added to the biuret reagent, and this gives a 
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falsely high reading. The Biuret method was therefore not a suitable technique 
for assessing peptide concentration.  
In order to resolve this issue, advice from leaders in the peptide and T cell 
immunology fields was sought. Although most papers using peptides in ELISPOT 
techniques refer to protein concentration, little is mentioned of the methods 
used for assessing the quantification of peptides in solution. Advice was sought 
from Dr. John E. Fox, Director of Alta Bioscience (the company from which we 
purchased the peptides). The only reliable way of quantifying peptide is to 
accurately weigh the dry peptide at synthesis using matrix-assisted laser 
desorption and isolation (MALDI), and HPLC. Whilst this is done for single 
peptides in, for example, pharmaceutical use, it is too expensive and 
impractical to use for large panels of peptides as in this study. Experts in the 
ELISPOT field were consulted: Dr. Josephine Cox, Maryland, USA International 
AIDS vaccine Initiative & committee for the international standardisation of 
ELISPOTS; Dr. Graham Taylor, Birmingham, UK and lead author on a number of 
papers using ELISPOT to assess vaccine response, and Dr. Maher Gandhi, 
Queensland Institute of Medical Research and lead author on a number of papers 
using ELISPOT to assess EBV responses. All felt that peptides cannot be 
accurately quantified in solution using standard biochemical techniques. They 
agreed that for clinical trials work, quantification of dry peptide by the 
manufacturer as described is desirable, although still does not provide 
information on concentration in solution. However there was consensus that at 
the concentrations used in standard ELISPOT assays (1-10 µg/ml), peptides were 
in excess, and that accurate quantification of peptide concentration in solution 
was not required, and was not practiced by the majority of laboratories using 
ELISPOT outside the context of a clinical trial. A concentration of 10 mg peptide 
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per ml in master stock is assumed from this point, based on the assumption of 
full solubility of the supplied dry peptide in DMSO. 
2.7.5.2 Optimisation of peptide concentration for use in 
ELISPOTs 
To assess whether the peptides in solution were indeed at excess, a dose-
response experiment was performed, in which donors known to respond to 
particular peptides were exposed to these peptides at varying concentration. 
The results from three representative donors are shown in Figures 2.2, 2.3 and 
2.4.  
In these experiments, a consistent response was detected only at or above 5 
µg/ml. At this concentration, there was a clear discrimination between peptides 
driving a detectable response and those for which no response was detectable.  
In general, responses increased with increasing peptide concentration, 
suggesting that peptides present in the assay were not “in excess”. Some 
peptide responses (e.g. to the B*07:01-restricted CMV peptide RKT) in some 
donors were maximal at 10 µg/ml, whereas responses to other peptides 
increased at higher concentrations. However, it was apparent that the ELISPOT 
assay is exquisitely sensitive, and was capable of detecting responses to 
immunodominant peptides in some donors at peptide concentrations as low as 
0.625 µg/ml. As maximal sensitivity was important, in addition to the ability to 
compare responses, a concentration of 10 µg/ml was selected for use in 
subsequent assays. This was a good compromise between maximal response and 
minimal sensitivity. 
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Figure 2-2 Effect of varying peptide concentration, donor p4796  
PBMCs from donor p4796 (HLA-A*02:01 & B*07:01 heterozygote) exposed to three peptides: 
(HLA-B*07:01-restricted CMV peptide RKT, A*02:01-restricted EBV peptide GLC and A*02:01-
restricted CMV peptide NLV) at 0.3125 – 40 µg/ml. Results are expressed as the mean of 
duplicates in spot-forming cells (SFC) per 3 x 10
5
 cells; error bars demonstrate two standard 
deviations. The threshold of detection of a positive response (red line) is set at the mean of 
the highest negative control, plus two standard deviations. 
 
Figure 2-3 Effect of varying peptide concentration, donor p10036  
PBMCs from donor p10036 (B*07:01 heterozygote) exposed to a known reacting peptide 
(HLA-B*07:01-restricted CMV peptide RKT) at 0.3125 – 40 µg/ml. Results are expressed as 
the mean of duplicates in spot-forming cells (SFC) per 3 x 10
5
 cells; error bars demonstrate 
two standard deviations. The threshold of detection of a positive response (red line) is set 
at the mean of the highest negative control, plus two standard deviations.  
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Figure 2-4 Effect of varying peptide concentration, donor p10158  
PBMCs from donor p10158 (HLA-A*02:01/HLA-A*01:01 heterozygote, B*08:01 heterozygote) 
exposed to different peptides: A*01:01-restricted flu peptide CTE, A*02:01-restricted flu 
peptide GIL, A*02:01-restricted EBV peptide TLD, B*08:01-restricted EBV peptide QAK, 
B*08:01-restricted EBV peptide FLR and B*08:01-restricted EBV peptide RAK at 
concentrations of 2.5-20 µg/ml. Results are expressed as the mean of duplicates in spot-
forming cells (SFC) per 3 x 10
5
 cells; error bars demonstrate two standard deviations. The 
threshold of detection of a positive response (red line) is set at the mean of the highest 
negative control, plus two standard deviations. 
 
2.7.5.3 Optimisation of use of peptides in pools 
DMSO, the solvent used for peptide reconstitution is known to be toxic to cells 
when used at high concentration and for prolonged exposure times. One of the 
limitations on the number of peptides that can be used in a peptide pool is the 
final concentration of DMSO. At concentrations of > 2% for more than 2 hours, 
DMSO can be sufficiently toxic to PBMC to abolish detectable functional T cell 
responses (Kloverpris et al, 2010). It was crucial therefore that DMSO 
concentration be kept below this level, effectively limiting the pool size to 
fewer than 20 peptides. To ensure that responses were detectable in such pools, 
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single peptides eliciting known responses were combined with non-reactive 
peptides in pools of up to 25 peptides. Reliable responses were detected for 
these peptides in PBMCs from three donors. In this project, the maximal number 
of peptides in any pool was thirteen (see Table 3.2 in Chapter 3). There is some 
evidence that combining peptides into pools of greater than ten peptides can 
inhibit T cell proliferation assays, but not ELISPOT reactivities or cytokine 
secretion (Suneetha et al, 2009). To rule out the possibility of an effect in the 
HLA-A*01:01 experiments, described in Chapter 4, where maximal sensitivity was 
important, maximal pool size was restricted to five peptides.  
2.8  ELISPOT Assay 
The enzyme linked immunospot (ELISPOT) assay (Czerkinsky et al, 1988) was 
used for the detection of cells producing IFN-γ. This was performed using the 
IFN-γ ELISPOT kit (R&D Systems), which comprised the IFN-γ antibody-coated 
coated 96-well plate and the required reagents. Extensive optimisation was 
carried out as described in Sections 2.7.5 and 2.8.3.  
2.8.1 ELISPOT Assay Method 
2.8.1.1 Day 1 
Peptides used in ELISPOT experiments are described in more detail in the 
relevant Chapters.  The 10 µl aliquots of peptide previously prepared in sterile 
96-well round-bottom plates (Section 2.7.4) were defrosted at RT. Peptides were 
used at a final concentration of 10 µg/ml, unless stated otherwise. Aliquots (10 
µl) of appropriate positive and negative controls were added to the 
corresponding wells. All peptide stimulations or controls were performed in 
duplicate at a minimum.   
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Negative controls were a) CCM only and b) DMSO (Fisher Scientific Inc.) at a 1:50 
concentration in CCM, corresponding to the highest concentration of DMSO in the 
peptide preparations. The non-specific positive control was PHA 
(Phytohemagglutinin PHA-P lyophilised, Sigma Aldrich) reconstituted to a 
working concentration of 10 µg/ml in distilled water and kept at 4oC. Further 
specific positive controls included CMV and influenza peptides of known HLA 
restriction, and the internationally recognised standard positive control for 
ELISPOT assays, the CEF pool. The CEF pool is fully described in Section 2.7.2. As 
an example, a typical plate illustrating position of controls and test wells is 
given in Figure 2.5.  
PBMCs or BD-PBMCs had been prepared as described in Section 2.3.3 and 
suspended in 10% CCM to the desired concentration. Unless stated otherwise, a 
concentration of 3 x 106 cells / ml was used.  Cells in suspension (100 µl) as 
described, were added to pre-aliquoted peptides and controls. The cells were 
incubated with the peptide or control for approximately 30 min at RT.  
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Figure 2-5 Example of typical ELISPOT plate layout  
The positions of negative control wells (CCM alone, cells + CCM, cells + CCM + DMSO), 
positive control wells (IFN-γ alone, cells + PHA, cells + CEF pool) are shown. In this example, 
responses to 3 peptides, assayed in duplicate, are detected. 
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During this incubation step, the ELISPOT plate was prepared. All kit reagents, 
except detection antibody concentrate and dilution buffer 1, were brought to 
RT. The 96-well ELISPOT microplate (for brevity hereafter referred to as the 
ELISPOT plate) was prepared by filling all wells with 200 l sterile 10% CCM and 
incubating for approximately 30 min at RT. Care was taken at all steps not to 
damage the membrane at the base of the well with the pipette tip. The CCM was 
then discarded from the plate. The plate was placed, bottom down, on a piece 
of aluminium foil approximately 10 x 15 cm in size. This was tucked round the 
base of the plate and remained in-situ until after removal of the chromogen 
solution. The purpose of this was to reduce the recognised possibility of “edge-
effect”, whereby the external wells of the 96-well plate produce unreliable 
results (Kalyuzhny & Stark, 2001). The cells in suspension (100 µl) were 
transferred from the 96-well round-bottom plate where they were incubating to 
the ELISPOT plate using a multichannel pipette (vWR). 
The ELISPOT plate was covered with the lid, and the edges of the foil were then 
shaped round the plate. ELISPOT plates were incubated overnight (16 – 20 hours) 
at 37oC in 5% CO2. Care was taken not to disturb the plates during their 
incubation, to avoid “trails” made by moving cells producing IFN-γ, which might 
lead to aberrant cell counts.  
2.8.1.2 Day 2 
Cells were discarded into Virkon (Fisher Scientific Inc.) and the plates washed by  
manually filling each well completely with 250- 300 µl of the supplied wash 
buffer using a wash bottle, followed by complete removal of fluid at each step. 
This process was repeated a further three times to a total of four washes. After 
each step, plates were inverted and blotted against clean paper towels. The 
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final wash was left on the plate until the detection antibody was ready for use, 
to avoid the membrane becoming dry.  
Detection antibody was prepared as per kit instructions and 100 µl of diluted 
detection antibody, or appropriate negative control, were added to each well. 
PBS was used as a negative control for the detection antibody (wells e1 and e2). 
The plates were incubated overnight at 4oC.  
2.8.1.3 Day 3 
Streptavidin-AP was prepared as per kit instructions. The detection antibody was 
discarded and the plates were then washed 4 times as previously. Streptavidin-
AP (100 µl) was added to each well and the plate incubated for 2 hours at RT. 
The streptavidin conjugate was discarded and the plates were washed 4 times. 
The chromogen (a stabilised mixture of 5-bromo-4-chloro-3'indolylphosphate p-
toluidine salt (BCIP) and nitro blue tetrazolium chloride (NBT)) (100 µl) was then 
added to each well and the plate incubated for 1 hour at RT, in the dark. The 
chromogen was then discarded and the reaction stopped by rinsing the plate 
with deionised water. The plate was inverted and tapped against clean paper 
towels to remove excess water. The aluminium foil and flexible plastic under-
drain were removed. The bottom of the plate was wiped thoroughly with clean 
paper towels and the plate left to dry completely at RT for 60 – 90 min. The 
plates were then ready for the spots to be counted.  
2.8.2 Reading of ELISPOT plates 
Spots were counted using an automated ELISPOT plate reader (ViruSpot 4, AID 
Strasbourg Germany), courtesy of Prof. Brian Willett, Medical Research Council -
University of Glasgow Centre for Virus Research. The plate reader is supplied 
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with integral software. This was used to set parameters for optimal counting 
(specificity and sensitivity). Parameters were set for “intensity” (darkness of 
spots; minimum 20 – max 255, no units given), “spot size” (minimum 20 – 
maximum 5000, no units given) and “gradient” (the angle defined by a tangent 
from the maximum intensity to the background intensity; minimum 15o – 
maximum 90o). Uniform settings were used for all experiments to enable 
comparisons. An example of automated counting in a well is given in Figure 2.7 
(overleaf).  
Each well was manually reviewed to exclude the possibility of aberrant counting. 
Clear errors in counting were removed. Causes of such errors include plate 
movement during incubation or insufficient removal of cellular debris by washing 
(Figure 2.6). Absolute numbers of spots were counted. The results were 
exported to Excel (Microsoft corporation) for analysis. A visual record of each 
plate was recorded as a digital picture file.  
 
Figure 2-6 Examples of artefact in IFN-γ ELISPOT 
a. Artefact seen when a cell secreting IFN-γ moves during the incubation period. b. Small, 
light spots seen with insufficient removal of cellular debris by washing. c. An example of a 
“clean” well with low background and good discrimination of well-defined medium-sized 
spots. 
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Figure 2-7: Example of an automated counted well  
One well from a typical ELISPOT assay as read by the AID automated plate reader. The 
standard settings used for all assays are given to the right side of the image. The spots 
counted are seen as yellow “x”s. The tool bars to the top of the frame enable the user 
to manually review the spots counted, and to add or remove spots counted, or not 
counted, in error.  
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2.8.3 Optimisation of ELISPOT experimental conditions 
In order to ensure that the results obtained from the study were comparable 
with other published ELISPOT studies, a number of quality measures were 
assessed. A number of experiments were undertaken to establish the rationale 
and validity of the approaches taken in the experiments described in subsequent 
results Chapters. These results have a direct bearing on the work described in 
both Chapters 3 and 4. 
2.8.3.1 Demonstration of effect of B cell separation procedure 
on cell types present in PBMCs for ELISPOTs 
As the samples were undergoing a cell selection procedure involving the removal 
of CD20-positive B lymphocytes for use in another study, it was important to 
ensure that the BD-PBMCs were similar in characteristics to the PBMC prior to 
the separation. Flow cytometry was performed using CD3/ HLA-DR, CD3/CD20, 
CD3/CD4/CD8, CD16/56/3, CD15/45/33 antibody combinations in PBMC from 16 
donors. The CD16/56/3 antibody was primarily used to identify CD16/56 co-
marking NK cells. The CD15 marker identifies monocytes and contaminating 
neutrophils and eosinophils.  
Figure 2.8 demonstrates the pre & post B cell separation levels of CD20, CD3, 
CD3/ HLA-DR, CD4, CD8, CD16/ CD56 co-marking NK cells, and CD15 in PBMC 
large bleed samples. The only significant difference in pre & post separation was 
the expected depletion of CD20-positive B lymphocytes. An increase in the 
proportion of CD3 and CD4 lymphocytes present was seen, as would be expected 
given the number of CD20-positive B lymphocytes removed, and the fact that 
proportions are used in this analysis. No other significant differences between 
the populations were noted. Once the cellular composition of BD-PBMCs was 
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demonstrated, the antibody panel that was routinely used on every specimen 
pre & post B cell separation was limited to CD3/CD20, CD3/HLA-DR and 
CD4/8/3. 
 
Figure 2-8 Cellular composition of PBMC pre-& post-B cell separation.  
PRE, pre-separation sample (PBMC), NEG, CD20 negative fraction (BD-PBMC). Results from 
41 donors are presented. Note CD16/CD56 and CD15 staining were performed on only 16 of 
the 41 donors. Results are reported as percentage of ungated events. The values for pre-
separation samples and CD-20 negative fractions (BD-PBMC) were compared by unpaired t-
test and the p-values are shown to 3 decimal places. Error bars demonstrate the mean and 
the standard error of the mean.  
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2.8.3.2 Optimisation of cell number used in ELISPOTS 
The cell concentration or absolute number of cells per well used in ELISPOT 
assays varies in published series depending on the antigens and cell populations 
being tested, but is generally between 1 x 106 cells / ml and 1 x 107 cells / ml. 
Important features in determining this dose include having sufficient cells to 
detect a response (sensitivity), not having cells in excess, as this may result in 
non-specificity and, more pragmatically, the number of cells available for the 
experiment. In the case of this study, the cell number available for any one 
experiment was finite as cells were obtained from a single 50 ml blood sample. 
The volume of cell suspension used in every ELISPOT was 100 µl. Published 
studies suggest that a cell number of 1-4 x 105 cells per well (i.e. 1-4 x 106 cells/ 
ml) yields the highest ratio of spots to cells number (Hobeika et al, 2005; Britten 
et al, 2008). 
In order to determine the optimal cell number for the ELISPOT experiments in 
this study, a number of optimisation experiments were carried out. In the first 
experiment, an HLA-A*02:01 heterozygous donor (p4796) was exposed to three 
different peptides to which they were known to react. This was performed for 
cell concentrations of between 2 x106/ml and 5 x106/ml and the results are 
presented in Figure 2.9. As can be seen, responses were seen at all cell 
concentrations. Overall responses were lower when only 2 x 106 cells / ml were 
used, raising concerns regarding loss of sensitivity at this concentration. 
Sensitivity was higher using the higher cell concentrations.  
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Figure 2-9 Effect of varying cell number on ELISPOT response, donor p4796 
Donor p4796 (HLA-A*02:01 heterozygote) exposed to three peptides known to elicit 
responses in this donor (A*02:01-restricted EBV peptides DTP, SVR, LLD)  at 10 µg/ml. 
Results are expressed as SFC per 1 x 10
6
 cells to enable comparison of sensitivity of response 
by number of cells present. Mean of duplicates shown; error bars demonstrate standard 
deviation. 
 
Donor p4796 and a further donor who was heterozygous for HLA-A*02:01 
(p10158) were exposed to a number of different HLA-A*02:01-restricted 
peptides. In addition, as a negative control, they were also exposed to an EBV 
peptide restricted through HLA-B*35:01, which neither donor carried. Figure 
2.10 demonstrates the result of this experiment. In both donors, cell 
concentrations of 5 x 105 cells / ml and 1 x 106 cells / ml were insufficient to 
robustly detect a response. In contrast, when the highest cell concentration of  5 
x 106 cells / ml was used, most experiments showed a drop-off in sensitivity for 
the number of cells present and, in addition, non-specific responses to the 
negative control peptide were seen in one donor.  
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Figure 2-10 Effect of varying cell number on detection of responses 
A. Donor p10158.  B. Donor p4796. Representative results from two donors. ELISPOT with 
cells at concentrations between 5 x 10
5 
/ ml and 5 x 10
6
 / ml. Results are expressed as the 
mean of duplicates in spot-forming cells (SFC) per 1 x 10
6 
cells; error bars demonstrate 
standard deviation. Peptides used are the A*02:01-restricted flu peptide GIL, B*0801 
restricted EBV peptide QAK, B*08:01 restricted EBV peptide FLR, B*08:01 restricted EBV 
peptide RAK, HLA-B*07:01 restricted CMV peptide RKT, A*02:01-restricted EBV peptide GLC 
and A*02:01-restricted EBV peptide TLD. Note that neither donor has B*35:01; YPL is a 
B*35:01 restricted EBV peptide to which neither donor would be expected to respond, and is 
included as a negative control.  
 
A. 
B. 
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The highest sensitivity, with acceptable specificity was a cell concentration of 3 
x 106 cells / ml (3 x 105 cells per well). This concentration also ensured that 
there were sufficient cells from all donors to perform the planned experiments. 
For these reasons, a cell concentration of 3 x 106 cells / ml was used in all 
subsequent ELISPOT experiments. 
2.8.3.3 Comparison of fresh cells vs. viably-frozen cells 
It was important to be able to use the PBMCs at dates subsequent to collection, 
to maximise the use of the sample donated by subjects and to allow time for the 
establishment and growth of an LCL where necessary. The literature on use of 
ELISPOT to monitor CTL responses, e.g. following vaccination, suggests that 
viably frozen cells, stored at -70oC or in liquid nitrogen can be reliably used in 
ELISPOTs (Smith et al, 2007; Weinberg et al, 2009). A cell viability of > 75% 
following defrosting has been suggested as an “acceptance criterion” for use of 
cells in functional T cell assays. All cells used in the experiments in the project 
met this criterion. An additional measure of cell function following freezing and 
defrosting has been reported to include satisfactory response to PHA or other 
positive control. It has been demonstrated that, given such checks are in place, 
the frequency and magnitude of CD8 responses is unaffected by cryopreservation 
(Kreher et al, 2003). 
Cells taken fresh from donors were compared with cells from the same donors 
viably frozen and defrosted up to one year after their initial collection. Donor 
cells were exposed to a number of peptides and responses assessed by ELISPOT. 
Examples of results from 2 of 5 donors tested are shown in Figure 2.11. 
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Figure 2-11 Comparison of ELISPOT responses of fresh vs. viably frozen cells 
A. Donor p4796. B. Donor p10158.  PBMC obtained the same day were compared with PBMC 
viably frozen for up to one year. Results are expressed as the mean of duplicates in spot-
forming cells (SFC) per 3 x 10
5
 cells; error bars demonstrate standard deviation. Peptides 
used are the A*02:01-restricted EBV peptides SLR, YLQ, GLC and TLD, the B*08:01 restricted 
EBV peptides FLR, QAK and RAK, the A*02:01-restricted flu peptide GIL, and the HLA-B*07:01 
restricted CMV peptide RKT. Donors have relevant HLA allotype. Note that neither donor has 
B*35:01; YPL is a B*35:01 restricted EBV peptide to which neither donor would be expected 
to respond, and is included as a negative control. The unstimulated control was 10% CCM 
with DMSO at the same concentration as in the peptide solutions. 
 
A. 
B. 
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These results demonstrate that viably frozen cells give similar results in ELISPOT 
to fresh cells. However, some non-specific activation was noted in the viably 
frozen and defrosted cells, and this was more apparent in some donors. Non-
specific background reactivity of defrosted cells in ELISPOTs is a well-described 
phenomenon, and may occur as a result of cellular debris. It should not impair 
the ability to detect a response, provided the negative controls are dealt with 
appropriately. 
It has also been suggested that the use of foetal bovine serum (FBS) as a freezing 
medium may contribute to background reactivity (Prof. A. Rickinson and Dr. H. 
Long, oral communication). Some authors (Britten et al, 2008; Janetzki et al, 
2005; Janetzki et al, 2008) have described methods to reduce this non-specific 
background activation with frozen cells, by optimisation of the defrost and 
culture conditions for the ELISPOT. 
Firstly, it is recognised that resting the cells in CCM for a period of time from 1 – 
24 hours following the defrosting and wash steps can be beneficial (Britten et al, 
2008; Janetzki et al, 2008). For this reason, a comparison between unrested 
cells and cells rested for 1 hour was performed. In addition, some authors have 
reported that the addition of the exonuclease benzonase, which cleaves 
extracellular DNA, is helpful in reducing non-specific reactivity caused by cell 
clumping (Janetzki et al, 2005). Other authors have suggested that it is the 
presence of bovine serum in the CCM which causes non-specific reactivity in 
ELISPOTs, and that serum-free conditions may be preferable for ELISPOTs 
(Janetzki et al, 2009; Mander et al, 2010). Simply omitting the serum from the 
CCM can lead to poor cell viability. Addressing this, commercial companies have 
  Chapter 2: Materials and Methods 
160 
 
developed supplemented serum-free media specifically for T cell culture. One 
such agent, OpTmizer Serum-free medium (Invitrogen), was tested. 
The results of comparisons of the above conditions are shown in Figure 2.12. It 
was found that resting the cells was beneficial, with a reduction in non-specific 
background reactivity. When cells were rested, it was easier to differentiate 
between those peptide eliciting a response and those to which no response was 
detected. In contrast, unrested cells had higher reactivities to the “culture-
medium only” negative control and the “irrelevant” negative-control peptide. 
Again, differences between donors were noted. Donor p10158 demonstrated a 
reduction in responses when benzonase was added, and both donors 
demonstrated a reduction in responses with the serum-free media. Donor p4796 
demonstrated higher background reactivity with the serum-free media, with 
both the negative control and YPL negative-control peptide eliciting high 
responses. On the basis of these comparisons, a rest stage of at least 1 hour 
following cell defrost was added, but neither exonuclease nor T cell culture 
supplemented serum-free media were included in the protocol.  
Cut-off criteria for the exclusion of background reactivity have been 
recommended. The Society of Biologic Therapy recommend that the number of 
spot-forming cells (SFC) more than 2 standard deviations (SD) above the mean 
value of negative controls tested simultaneously (Keilholz et al, 2002) be used as 
a suitable measure for a responding antigen. This was verified experimentally 
(Hobeika et al, 2005), demonstrating that ELISPOT had a sensitivity of 85.7% and 
a specificity of 100% when this criterion was used. This criterion was used in this 
project for the ELISPOTS comparing HLA-A*02:01 responses. This is discussed 
further in Chapters 4 and 5.  
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Figure 2-12 ELISPOT responses with differing defrost and culture conditions 
A. Donor p4796. B. Donor p10158.  Results expressed as the mean of duplicates in spot-
forming cells (SFC) per 3 x 10
5
 cells; error bars demonstrate standard deviation. 
Comparisons are shown of viably frozen cells defrosted and used immediately, viably frozen 
cells defrosted and rested for a minimum of 1 hour in CCM, viably frozen cells defrosted and 
rested for a minimum of 1 hour in CCM containing benzonase and viably frozen cells 
defrosted and rested for a minimum of 1 hour in OpTmizer serum-free medium. CEF pool is 
the pool of 23 CMV, EBV and influenza peptides which is an internationally accepted positive 
control (see Chapter 2). Peptides used are the A*02:01-restricted EBV peptide GLC, the 
B*08:01 restricted EBV peptide RAK, the A*02:01-restricted flu peptide GIL, and the HLA-
B*07:01 restricted CMV peptide RKT. Note that neither donor has B*35:01; YPL is a B*35:01 
restricted EBV peptide to which neither donor would be expected to respond, and is 
included as a negative control.  
 
A. 
B. 
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2.8.4 Summary of ELISPOT optimisations 
Since the first description of IFN-γ ELISPOT to assess CTL responses (Czerkinsky 
et al, 1988; Czerkinsky et al, 1983), many published studies have described the 
optimal conditions for performing ELISPOTs, with the aim of generating 
meaningful, reproducible and comparable results. 
The results of the optimisation experiments described above were generally in 
line with published results, and remarkably consistent with the guidelines 
available from the international consensus bodies who advise on the optimal use 
of ELISPOT, such as the Cancer Vaccine Consortium of the Sabin Vaccine 
Institute (CVC/SVI) (Janetzki et al, 2008) and the International Committee for 
the Standardisation of ELISPOTS (Janetzki et al, 2005). Although peptide 
concentrations are routinely reported in the published literature, the accurate 
quantitation of peptides in solution is not possible without HPLC for every 
specimen. Such an approach is expensive and impractical unless small numbers 
of peptides are being employed. Consistent with the vast majority of published 
studies, peptide quantitation in this study assumed full solubility of the dry 
weight of peptide in DMSO. 
The optimisations support the use of cells at 3 x 106 cells / ml in the ELISPOTs (3 
x 105 per well) with a final peptide concentration of 10 µg/ml in each well. The 
use of viably frozen material was acceptable, provided that cells were allowed 
to rest in CCM for a minimum of one hour prior to use in the ELISPOT, and that 
appropriate criteria for exclusion of background reactivity were used.  
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2.9  Cytokine analysis 
Supernatants from incubations or stimulations of BD-PBMCs (100 µl) as detailed 
in Chapters 3 and 4 were aspirated and frozen in 96-well round-bottom plates at 
-70oC. Analysis of TNF-α, IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 and IL-17 was 
performed using the Human VersaMAP Multiplex Development System 9 Plex kit 
(R&D Systems) and read using the Bioplex system Luminex 100 plate reader (Bio-
Rad). Results are given in pg/ml of each cytokine. Details of the stimulation or 
controls used in any individual experiment are described in the relevant results 
Chapters.  
2.10  Statistical Analysis 
Statistical analyses were performed using SPSS Statistics, version 19 (IBM, UK) 
and Graphpad (Graphpad Software Inc., La Jolla, California, USA). Details of the 
statistical analyses performed are given in the relevant results Chapter. 
 
 
 
     
 
 
Chapter 3.  Does the presence of an HLA-A*01:01 
allele modify the magnitude of the CTL response to 
HLA-A*02:01-restricted epitopes?  
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3.1  Introduction  
Approximately one third of cHL is associated with the EBV. Class I HLA genes are 
associated with risk of developing EBV+ve cHL, as discussed in the Introduction.  
HLA-A*01:01 is associated with increased risk of EBV+ve cHL whereas HLA-
A*02:01 is associated with decreased risk, such that there is an almost 10-fold 
difference in odds of developing EBV+ve cHL between HLA-A*02:01 and HLA-
A*01:01 homozygotes with a gradation of risk in intermediate genotypes. This is 
demonstrated in Figure 3.1. 
 
Figure 3-1 Case-series Odds Ratios for EBV+ve cHL by selected combinations of HLA-
A*02 genotype. 
01, HLA-A*01:01; 02, HLA-A*02:01; x is any allele other than HLA-A*01 or HLA-A*02; CI, 
confidence interval. Data derived from (Hjalgrim et al, 2010).        
 
Class I HLA associations with EBV+ve cHL suggest that EBV-specific CTL responses 
may be critical in the pathogenesis of EBV+ve cHL.  Such responses could be 
important following initial infection, during persistent latent infection or during 
oncogenesis. Many EBV peptides are known to be presented by HLA-A*02:01 for 
recognition by the T cell immune system.  Indeed, many of the most 
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immunodominant EBV peptides presented through any class I allele are 
restricted through HLA-A*02:01 (Hislop et al, 2007). The reason for the elevated 
risk of disease in HLA-A*02:01/A*01:01 heterozygotes is therefore unclear, since 
these individuals should be capable of mounting an effective CTL response to 
EBV. 
There is no evidence to date that HLA-A*01:01 is capable of presenting any EBV 
peptide (examined further in Chapter 5). However, individuals who carry HLA-
A*01:01 will also have 4 or 5 additional class I HLA alleles through which they can 
raise a CTL response (i.e. both B alleles, both C alleles, and the additional HLA-A 
allele in the case of A*01:01 heterozygotes). EBV peptides can be presented via a 
wide range of human HLA types, and thus all individuals who are EBV 
seropositive would be expected to have a detectable EBV-directed CTL response. 
In particular, HLA-B*08:01, which presents a number of immunodominant EBV 
peptides resulting in a strong CTL response, is in LD with HLA A*01:01; thus, a 
large proportion of carriers of HLA A*01:01 should be able to effect an efficient 
anti-EBV CTL response via HLA-B*08:01. That HLA A*01:01 appears to increase 
risk of disease even in those individuals in whom you would expect to see a good 
EBV response raises the possibility that HLA-A*01:01 may be able to modify the 
magnitude of the EBV response restricted through HLA-A*02:01. 
This hypothesis led to the primary experimental question: Does the presence of 
an HLA-A*01:01 allele modify the magnitude of the CTL response to HLA-A*02:01-
restricted epitopes? In order to address this, I examined EBV-specific HLA-
A*02:01-restricted CTL responses in healthy individuals with the HLA-A 
genotypes: HLA-A*01:01/ HLA-A*02:01; HLA-A*02:01/ HLA-A*02:01; and HLA-
A*02:01/ HLA-A* x (where x is any allele other than A*01:01 or A*02:01).   
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3.2  Methods 
3.2.1 Recruitment  
Healthy individuals with the following HLA-A types were recruited (hereafter 
referred to as the “HLA-A*02 groups”): 
 HLA-A*01:01/ HLA-A*02:01 heterozygotes 
 HLA-A*02:01/ HLA-A* x heterozygotes (where x is any allele other than 
A*01:01 or A*02:01) 
 HLA-A*02:01/ HLA-A*02:01 homozygotes 
These groups with different HLA-A*02:01 genotypes were compared. Power 
calculations performed prospectively by Dr. Paul Johnson, Robertson Centre for 
Biostatistics, University of Glasgow determined that 15 individuals of each 
genotype were required to generate results which would demonstrate 
statistically significant differences in biological response. With n = 15 per group, 
any difference in CTL response of 4 percentage units between groups, allowing a 
within-group SD of 2 percentage units would give 100% power using a two-sample 
t-test. A difference of 2.81% would give 80% power. Any difference of < 4% 
between groups is unlikely to be clinically relevant, and therefore all potentially 
clinically important differences should be detected.  
Local population frequencies for class I HLA genotypes were available from the 
Scotland and Newcastle epidemiological study of Hodgkin's disease (SNEHD) 
study (Jarrett et al, 2003). These data suggested that 150 – 200 adults would 
need to be HLA-typed to identify ≥ 15 individuals in each of the target groups. 
The limiting factor in determining this number was the proportion of HLA-
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A*02:01 homozygotes in the general population. Supplementing the HLA-
unscreened general population with a HLA-targeted approach to donor 
recruitment via the SNBTS donor population meant that these targets were 
achieved (see Chapter 2). EBV-seropositive donors with the relevant HLA-type 
were recalled to provide a “large blood sample” as described in Chapter 2. 
Thirty-nine of seventy-four recalled donors provided a specimen and their 
characteristics are described in Table 3.1. They comprised: 
 15 HLA-A*01:01/HLA-A*02:01 heterozygotes (“A*02:01/A*01:01”) 
 12 HLA-A*02:01/ HLA-A*02:01 homozygotes (“A*02:01/A*02:01”) 
 12 HLA-A*02:01/HLA-A*x heterozygotes (“A*02:01/A*x”) 
All donors reported that they were well at time of donation of the large 
specimen. Samples were processed to BD-PBMCs as described in Section 2.3.3. 
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Table 3-1 Characteristics of individual HLA-A*02:01 donors  
LRF 
patient 
number 
Sex Age 
Self-
reported 
previous 
IM 
HLA-A 
allele 
1 
HLA-A 
allele 
2 
HLA-B 
allele 
1 
HLA-B 
allele 
2 
HLA-C 
allele 
1 
HLA-C 
allele 
2 
Site of donor 
recruitment 
Included in 
final 
ELISPOT 
analysis 
4,796 F 51 No 0201 0301 0702 4403 0401 0702 CRF No 
10,040 M 58 Yes 0201 0101 4402 4402 0501 0501 CRF  Yes 
10,097 F 57 No 0201 0101 0801 1501 0304 0701 CRF Yes 
10,098 M 44 No 0201 0301 0702 4402 0501 0702 CRF Yes 
10,100 F 24 No 0201 1101 1501 3701 0304 0602 CRF Yes 
10,115 F 28 Yes 0201 0201 4402 4402 0501 0501 CRF Yes 
10,117 F 41 Yes 0201 0201 1501 5101 0303 0401 CRF Yes 
10,121 F 37 No 0201 2902 0702 4403 0702 1601 CRF No 
10,134 F 28 No 0201 0101 1501 5702 0303 0701 CRF Yes 
10,151 F 49 No 0201 2501 1801 3701 0602 1203 CRF Yes 
10,157 M 47 No 0201 0101 0801 4402 0501 0701 CRF Yes 
10,158 M 38 No 0201 0101 0801 4001 0304 0701 CRF Yes 
10,169 F 25 No 0201 0101 0801 1501 0303 0701 CRF Yes 
10,170 M 45 No 0201 0201 1501 5701 0304 0602 CRF Yes 
10,171 F 43 No 0201 0301 0801 5501 0303 0701 CRF Yes 
10,172 F 28 No 0201 0201 1501 5701 0304 0602 CRF Yes 
10,237 F 49 No 0201 0101 0801 4001 0304 0701 CRF Yes 
10,239 F 28 No 0201 6801 1501 4403 0602 0701 CRF No 
10,277 F 43 No 0201 0101 0801 3501 0401 0701 CRF Yes 
10,279 F 24 No 0201 2902 1501 4001 0304 0304 CRF Yes 
10,282 F 53 No 0201 1101 0702 2705 0202 0702 CRF No 
10,284 F 40 No 0201 2301 0702 4403 0401 0702 CRF No 
10,287 F 23 No 0201 0301 1302 2705 0202 0602 CRF Yes 
10,353 F 43 No 0201 2902 4402 4403 0501 1601 CRF No 
10,485 M 50 No 0201 0201 NK NK NK NK SNBTS Yes 
10,486 M 53 No 0201 0101 NK NK NK NK SNBTS No 
10,488 NK 23 No 0201 0101 NK NK NK NK SNBTS Yes 
10,489 F 59 No 0201 0101 NK NK NK NK SNBTS Yes 
10,490 F 47 No 0201 0101 NK NK NK NK SNBTS Yes 
10,495 M 51 No 0201 0101 NK NK NK NK SNBTS Yes 
10,496 M 45 No 0201 0201 NK NK NK NK SNBTS Yes 
10,503 M 40 Yes 0201 0101 NK NK NK NK SNBTS Yes 
10,506 M 46 No 0201 0101 NK NK NK NK SNBTS Yes 
10,541 M 56 No 0201 0201 NK NK NK NK SNBTS Yes 
10,544 M 56 No 0201 0201 NK NK NK NK SNBTS Yes 
10,601 M 58 No 0201 0201 NK NK NK NK SNBTS Yes 
10,605 M 53 No 0201 0201 NK NK NK NK SNBTS Yes 
10,606 F 35 No 0201 0201 NK NK NK NK SNBTS No 
10,611 M 44 No 0201 0201 NK NK NK NK SNBTS Yes 
NK, not known; CRF, Donor recruited through either the CRF or the University of Glasgow; 
SNBTS, Scottish National Blood Transfusion Service; IM, infectious mononucleosis. Self-
reported IM in this case being those donors who stated that they had previous IM which had 
been confirmed with a blood-test.
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3.2.2 Flow cytometry 
Flow cytometry using antibodies to CD3, CD4, CD8 and HLA-DR was performed on 
the BD-PBMCs of all donors (as described in Section 2.5). The proportion of CD3-
positive cells that were positive for HLA-DR was measured to assess background 
T cell activation as this may lead to erroneously high responses in the ELISPOT 
assay. In addition the CD4/CD8 ratio was assessed in case differences between 
donors contributed to differences in IFN-γ CTL response measured by ELISPOT.  
3.2.3 ELISPOTs 
BD-PBMCs from the healthy individuals were subjected to ELISPOT analysis to 
examine the strength and depth of HLA-A*02:01-restricted EBV CTL responses. 
All HLA-A*02:01-restricted EBV peptides reported in the literature at time of 
study initiation (2008) were synthesised (n = 31) (Table 3.2). ELISPOT assays 
were performed as described in Section 2.8. Responses of 3 x 105 cells to single, 
un-pooled peptides at a concentration of 10 µg/ml were measured. Each peptide 
was assayed in duplicate. Positive controls (PHA and the CEF pool) and negative 
controls (CCM or CCM plus DMSO) were as described in Chapter 2. Plates were 
read as described in Section 2.8.2 using the same settings and thresholds on the 
plate reader for all plates. 
 
 
 
 
  Chapter 3: HLA-A*02:01-restricted responses 
171 
 
Table 3-2 HLA-A*02:01-restricted peptides used in the study 
Epitope AA sequence 
HLA 
restriction † 
Protein 
Virus or  
EBV Latent/ 
Lytic 
Three-letter 
abbreviation 
Peptide    
pool ‡ 
VLEETSVML A2 IE1 CMV VLA 1 
NLVPMVATV A2 pp65 CMV NLV 1 
GILGFVFTL A2 Matrix 1 Influenza A GIL 1 
FMVFLQTHI A2 EBNA1 Latent FMV 2 
DTPLIPLTIF A2/B51 EBNA2 Latent DTP 2 
SVRDRLARL A2 EBNA3A Latent SVR 2 
LLDFVRFMGV A2.01 EBNA3C Latent LLD 2 
SLREWLLRI A2 EBNA-LP Latent SLR 2 
LLLIALWNL A2 LMP1 Latent LLL 2 
LLVDLLWLL A2 LMP1 Latent LLVD 2 
TLLVDLLWL A2 LMP1 Latent TLL 2 
YLLEMLWRL A2 LMP1 Latent YLL 2 
YLQQNWWTL A2 LMP1 Latent YLQ 2 
FLYALALLL A2 LMP2 Latent FLY 3 
GLGTLGAAI A2 LMP2 Latent GLG 3 
LIVDAVLQL A2 LMP2 Latent LIV 3 
LLSAWILTA A2 LMP2 Latent LLS 3 
LTAGFLIFL A2 LMP2 Latent LTA 3 
TVCGGIMFL A2 LMP2 Latent TVC 3 
CLGGLLTMV A2.01 LMP2 Latent CLG 3 
LLWTLVVLL A2.01 LMP2 Latent LLWT 3 
LLWAARPRL A2 BHRF Lytic LLWA 4 
GLCTLVAML A2.01 BMLF1 Lytic GLC 4 
TLDYKPLSV A2.01 BMRF1 Lytic TLD 4 
RALIKTLPRASYSSH A2 BRLF1 Lytic RAL 4 
YVLDHLIVV A2.01 BRLF1 Lytic YVL 4 
ILIYNGWYA A2 GP110 Lytic ILI 4 
LIPETVPYI A2 GP350 Lytic LIP 4 
QLTPHTKAV A2 GP350 Lytic QLT 4 
VLQWASLAV A2 GP350 Lytic VLQ 4 
VLTLLLLLV A2 GP350 Lytic VLT 4 
LMIIPLINV A2 GP85 Lytic LMI 4 
SLVIVTTFV A2 GP85 Lytic SLV 4 
TLFIGSHVV A2 GP85 Lytic TLF 4 
† HLA-restriction reported is either at low resolution (“A2”) or medium resolution (“HLA-
A*02:01”) depending on the method of HLA-typing used in the reporting paper. 
‡Note peptides used individually in ELISPOT experiments and pooled only for CD107 
degranulation and cytokine secretion experiments. 
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3.2.3.1 Quality Control of ELISPOT experiments 
Plates were read and counted as described in Section 2.8.2. All individual wells 
were visually inspected at time of plate reading. All plates were reviewed by 
myself, and then by Prof. Ruth Jarrett and Dr. Karen McAulay. Donors were 
excluded if positive controls did not elicit a clear detectable CTL response. 
Plates where the SFC count for the positive controls did no exceed the mean of 
the highest negative control plus 2 SD were also removed from the analysis. 
Plates with excessive background reactivity, defined as a response detectable in 
either of the negative controls, were excluded.  
3.2.3.2 Scoring of ELISPOT results 
Results for each well were recorded as the number of SFC per 3 x 105 cells. The 
mean of each duplicate was calculated, and the SD obtained. The highest 
negative control plus 2 SD was taken as the cut-off for a “positive” response to 
any individual peptide (Figure 3.2). The recorded response to each individual 
peptide was taken as the mean value of the measured responses minus the value 
of the highest negative control plus 2 SD. 
For each donor the following values were recorded: 
1) The total number of HLA-A*02:01-restricted peptides to which a response was 
detected. 
2) The single highest (“maximal”) response detected to any peptide. 
3) The summative response i.e., the sum of all SFC counts for those peptides to 
which a response was detected. 
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The first of these measures gives an idea of breadth of the HLA-A*02:01-
restricted CTL response to EBV. The maximal and summative responses give 
measures of the depth of EBV response, and are probably the most 
physiologically relevant as they represent the highest overall (maximal) and 
cumulative (summative) strength of the CTL immune response to EBV restricted 
through HLA-A*02:01. 
The analyses performed looked at responses to (a) all known HLA-A*02:01-
restricted EBV peptides, (b) peptides derived from EBV latent proteins,  (c) 
peptides derived from EBV lytic proteins, and (d) peptides derived from those 
EBV proteins expressed by HRS cells (latency II). 
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Figure 3-2 Visual representation of ELISPOT scoring 
Responses to peptides or controls (x-axis) in spot-forming cells (SFC) per 3 x 10
5
 cells. 
Controls are coloured pale orange. Error bars represent 2 SD. The red-line represents the 
cut off for a “positive response” i.e. the highest negative control plus 2 SD. As can be seen 
in this analysis, one EBV peptide (LLWA) and one CMV peptide (NLV) gave positive results. 
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3.2.4 CTL degranulation by assessment of CD107 expression 
Assessment of cytotoxicity by degranulation was performed by flow cytometric 
analysis of CD107 expression after exposure to peptide pools. CD107 is expressed 
on the surface of CTLs when degranulation has occurred (Kannan et al, 1996) 
and it is possible to measure this using flow cytometry (Betts et al, 2003; Rubio 
et al, 2003).  
Cells from the same donors as used in the ELISPOTs (Table 3.1) were stimulated 
with peptide pools for 4 hours in the presence of anti-CD107a conjugated to PE. 
BD-PBMCs from donors were prepared as described and suspended in CCM at 3 x 
106 cells / ml in individual 5 ml tubes. Peptide pools (Table 3.2) were added to 
give a final concentration of each peptide of 10 µg/ml. PHA and the CEF peptide 
pool were used as positive controls. Cells in CCM plus DMSO at the same 
concentration as in the peptide pools were used as the negative control. Anti-
CD107a conjugated to phycoerythrin (PE) (BD BioSciences) (20 µl) was added to 
each tube and the cells incubated for 4 hours. One tube with cells plus CCM was 
used as an isotype control for each donor, incubated for 4 hours with the isotype 
control antibody instead of the anti-CD107a. Flow cytometry was performed 
using the Beckman FC500 flow cytometer. Five thousand events were counted. 
The percentage of CD107 positive events in the ungated population was recorded 
and the change in percentage expression (ΔCD107, the percentage CD107 in 
stimulated cells minus the percentage CD107 in unstimulated cells) used to 
assess CTL degranulation. 
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3.2.5 Cytokine analysis 
Cells from the same donors as used in the ELISPOTs (Table 3.1) were also used to 
assess cytokine secretion in response to EBV peptides. Peptide pools (10 µl at a 
final concentration of each peptide of 10 µg/ml) were added to 3 x 105 BD-
PBMCs in 100 µl CCM, prepared as described before. Due to limitations in 
available cell number, peptide pools 2 and 3 (latent peptides) were combined. 
Cells were incubated for 24 hours at 37oC in humidified 5% CO2, to replicate the 
conditions of the ELISPOTs. Supernatants (100 µl) were aspirated and frozen in 
96-well round-bottom plates at -70oC. Due to limitation of resource, stimulation 
controls (DSMO, PHA and CEF pool) were not used in this experiment, and 
baseline cytokine levels were not assessed. Analysis of TNF-α, IFN-γ, IL-2, IL-4, 
IL-5, IL-6, IL-10, IL-12 and IL-17 was performed using the Human VersaMAP 
Multiplex Development System 9 Plex kit (R&D Systems) and read using the 
Bioplex system Luminex 100 plate reader (Bio-Rad). Calibration controls were 
used to create the standard curve, and positive controls for beads and analytes 
were supplied with the kit. Results for each cytokine are given in pg/ml. 
3.2.6 Statistical Analysis 
3.2.6.1 ELISPOTS 
Data were analysed for the normality of distribution of results. The summary 
results obtained for each donor were grouped according to HLA-A*02 genotype; 
results from each group were then compared using a Kruskal-Wallis test for 
analysis of variance across groups or a Mann-Whitney test for comparison 
between pairs of groups (HLA-A*02:01/A*01:01 heterozygotes versus HLA*02:01/x 
heterozygotes, HLA-A*02:01/A*01:01 heterozygotes versus HLA-A*02:01 
homozygotes and HLA*02:01/x heterozygotes versus A*02:01 homozygotes).   
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The primary analysis was for response to all HLA-A*02:01-restricted EBV 
peptides. To correct for multiple testing in the primary analysis, a p-value of <     
0.025 is considered significant. This is based on the assumption that the 3 
measures of response (number of peptides, maximal response and summative 
response) are not independent.  
Further exploratory analysis was performed where responses were broken down 
by protein expression group (lytic, latent and latency II). In the exploratory 
analyses p-values of < 0.05 are reported.  
3.2.6.2 CTL Degranulation 
Data were analysed for the normality of distribution of results. The summary 
results obtained for each donor were grouped according to HLA-A*02 genotype; 
results from each group were then compared using Mann-Whitney test for 
comparison between pairs of groups (HLA-A*02:01/A*01:01 heterozygotes versus 
HLA*02:01/x heterozygotes, HLA-A*02:01/A*01:01 heterozygotes versus HLA-
A*02:01 homozygotes and HLA*02:01/x heterozygotes versus A*02:01 
homozygotes). As responses to the different pools of peptides are independent, 
to correct for multiple testing, a p-value of < 0.025 is considered significant.  
3.2.6.3 Cytokine analysis 
Median cytokine levels (pg/ml) were compared between groups. The primary 
question in this exploratory analysis was whether HLA-A*01:01 resulted in a 
change in cytokine profile, so the primary comparison was HLA-A*02:01/A*01:01 
heterozygotes versus the other HLA-A*02:01 groups considered together, using a 
Mann-Whitney test. In a secondary analysis, secretion was compared between all 
groups using a Kruskal-Wallis test for analysis of variance. Correction for 
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multiple testing was not performed in this exploratory analysis; p-values of < 
0.05 are reported. 
3.2.6.4 Analysis for confounding variables  
In order to identify variables that could potentially confound the above analyses, 
the distribution of selected demographic and laboratory variables was analysed. 
These included: age; sex; prior IM confirmed by blood test; whether the subject 
had ever smoked; time to processing of blood sample; percentage of CD3 cells 
positive for HLA-DR; and CD4/CD8 ratio. Analysis of confounders was performed 
using simple regression for continuous variables (age, HLA-DR level, time to 
processing and CD4/CD8 ratio) and by Pearson chi-square analysis for categorical 
variables (sex, previous IM, ever smoker). For the analyses of confounding, a p 
value of < 0.10 was considered significant.  
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3.3  Results 
3.3.1 Donor Characteristics  
Characteristics of the 39 donors included in the experiments are given in Table 
3.3. The three HLA-A genotype groups were well-matched for age, deprivation 
score, previous IM and smoking status. Females were significantly over-
represented in the HLA-A*02:01/x heterozygote group (Table 3.3, p = 0.01). In 
addition, due to the recruitment strategy, no HLA-A*02:01/x heterozygotes were 
recruited from SNBTS platelet donors. As the latter samples were more likely to 
have been processed the following day, this meant that “same-day processed” 
samples were over-represented in HLA-A*02:01/x heterozygotes (p = 0.006). 
Table 3-3 Summary of donor characteristics by HLA-A genotype 
 
HLA-A* 02:01 Group p-value for 
differences 
between 
groups 
HLA-A* 02:01 / 
A*01:01 
heterozygotes 
HLA-A*02:01 
homozygotes 
HLA-A*02:01 / 
other (x) 
heterozygotes 
Total Number  15 12 12 N/A 
Female, n (%) 7 (46.7) 4 (33.3) 11 (91.7) p = 0.01 ‡ 
Age (median, 
range) 
47 (23 -59) 45 (28-58) 41.5 (23-53) p = 0.45 † 
DEPCAT 5 
(median, range) 1 (1-5) 4 (1-5) 3 (1-4) p = 0.43 † 
Monospot-
confirmed 
previous IM §, n 
(%) 
2 (13.3) 2 (16.7) 0 (0) p = 0.36 ‡ 
Suspected 
previous IM §, n 
(%) 
2 (13.3) 2 (16.7) 1 (8.3) p = 0.79 ‡ 
Current 
smoker, n (%) 1 (6.7) 1 (8.3) 2 (16.7) p = 0.39 ‡ 
Ever smoked? n 
(%) 
3 (20.0) 5 (41.7) 3 (25.0) p = 0.67 ‡ 
Processed 
within 24 
hours, n (%) 
11 (73.3) 5 (41.7) 12 (100) p = 0.01 ‡ 
† regression (2-tailed t-test)  ‡ Pearson Chi-square analysis 
§ Note all IM is self-reported. As defined in this table, suspected previous IM is where an 
individual reported previous IM which was not confirmed by a blood test, and Monospot-
confirmed IM is where the individual told us that a doctor confirmed the IM diagnosis using a 
blood test. 
A p-value of < 0.05 is considered significant (highlighted in blue). 
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3.3.2 IFN-γ ELISPOT results by HLA-A*02:01 genotype 
Results presented are of IFN-γ ELISPOT experiments conducted using BD-PBMCs 
from healthy volunteers. In total, 8 of the 39 donors were excluded from the 
analysis as a result of the QC described in Section 3.2.3.1; one on the basis of 
lack of response to the positive controls and seven on the basis of high 
background reactivity in the negative controls. The excluded donors are 
indicated in Table 3.1. There was no common pattern in HLA-B or C alleles, or in 
the second HLA-A allele in HLA-A*02:01/x heterozygotes in the excluded donors 
(in case of systematic bias in cross-presentation causing background reactivity). 
The HLA type of the donor who failed to respond to the positive controls was 
HLA-A*02:01/HLA-A*03:01.  
Results from 31 donors were included in the analysis of ELISPOT results: 14 HLA-
A*01:01/ HLA-A*02:01 heterozygotes; 11 HLA-A*02:01/ HLA-A*02:01 
homozygotes; and 6 HLA-A*02:01/ A* x heterozygotes.  
Responses to EBV-derived peptides were observed in 30 of the 31 donors. One 
donor, an A*02:01 homozygote, demonstrated no detectable IFN-γ CTL response 
to any of the peptides tested. The median number of peptides recognised was 8 
(range 2 – 30 peptides). The mean maximal response to any peptide in all donors 
was 38 SFC / 3 x 105 cells (range 5-150 SFC / 3 x 105 cells). The mean summative 
response in all donors was 256 SFC / 3 x 105 cells (range 11 – 2059 SFC / 3 x 105 
cells).   
In the primary analysis of response (number of peptides, maximal response or 
summative response) to all EBV peptides tested, no significant differences were 
observed between the groups. No significant difference in response to A*02:01-
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restricted EBV peptides was observed between A*01:01/A*02:01 heterozygotes 
and A*02:01 homozygotes in any of the comparisons (number of peptides, 
maximal response or summative response).  
HLA-A*02:01/ A*x heterozygotes recognised more EBV peptides than either 
A*01:01/A*02:01 heterozygotes (p = 0.03) or A*02:01 homozygotes (p = 0.06), 
and this effect was greatest for lytic peptides (p = 0.01) (Figure 3.3). Where 
HLA-A*02:01/ A*x heterozygotes also demonstrated recognition of greater 
number of EBV lytic peptides than HLA-A*02:01 homozygotes (p = 0.01). No 
difference was observed in the number of HLA-A*02:01-restricted EBV peptides 
to which a response was detected between A*01:01/A*02:01 heterozygotes and 
A*02:01 homozygotes. 
Maximal responses to any EBV peptide (Figure 3.4) were highest in A*02:01/ A*x 
heterozygotes. Differences reached significance when responses to lytic peptide 
were compared between HLA-A*02:01/ A*x heterozygotes and HLA-
A*02:01/A*01:01 heterozygotes (p = 0.02) and when responses to latent peptide 
(p = 0.05) or latency II peptides (p = 0.04) were compared between A*02:01/x 
heterozygotes and HLA-A*02:01 homozygotes. No difference in single maximal 
response to A*02:01-restricted EBV peptides was observed between 
A*01:01/A*02:01 heterozygotes and A*02:01 homozygotes.  
The summative response to all HLA-A*02:01-restricted EBV peptides tested was 
higher in A*02:01/ A*x heterozygotes compared with HLA-A*02:01/A*01:01 
heterozygotes (p = 0.05). For lytic peptides, significant differences were 
observed between A*02:01/ A*x heterozygotes and HLA-A*02:01/A*01:01 
heterozygotes (p = 0.02) and between A*02:01/ A*x heterozygotes and HLA-
A*02:01 homozygotes (p = 0.01).  
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Figure 3-3 Number of HLA-A*02:01-restricted EBV peptides eliciting responses 
Results are presented by a) total number of peptides recognised, b) number of lytic peptides 
recognised, c) number of latent peptides recognised and d) number of latency II peptides 
recognised, all by HLA-A genotype. Error bars demonstrate the mean and the standard error 
of the mean. Lytic peptides, peptides derived from proteins expressed during lytic cycle 
replication; Latent peptides, peptides derived from proteins expressed during viral latency; 
Latency II peptides, peptides derived from peptides derived from those EBV proteins 
expressed in the latency II expression programme, as in HRS cells. For the primary analysis 
(all peptides), p values of < 0.025 are considered significant. For the exploratory analyses of 
lytic, latent and latency II peptides, p-values of < 0.05 are considered significant, and are 
shown in red. 
  
a) 
B. 
b) 
c) d) 
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Figure 3-4 Single maximal response to HLA-A*02:01-restricted EBV peptides 
Results are presented by a) maximal response to any HLA-A*02:01-restricted EBV peptide, b) 
maximal response to any HLA-A*02:01-restricted EBV lytic peptide, c) maximal response to 
any HLA-A*02:01-restricted EBV latent peptide and d) maximal response to any HLA-A*02:01-
restricted EBV latency II peptide, all by HLA-A genotype. Error bars demonstrate the mean 
and the standard error of the mean. Latent peptides, peptides derived from proteins 
expressed during viral latency; Latency II peptides, peptides derived from peptides derived 
from those EBV proteins expressed in the latency II expression programme, as in HRS cells. 
For the primary analysis (all peptides), p values of < 0.025 are considered significant. For 
the exploratory analyses of lytic, latent and latency II peptides, p-values of < 0.05 are 
considered significant, and are shown in red. 
 
a) b) 
c) d) 
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Figure 3-5 Summative (total) responses to HLA-A*02:01-restricted EBV peptides 
Results are presented by a) summative response to any HLA-A*02:01-restricted EBV peptide, 
b) summative response to any HLA-A*02:01-restricted EBV lytic peptide, c) summative 
response to any HLA-A*02:01-restricted EBV latent peptide and d) summative response to 
any HLA-A*02:01-restricted EBV latency II peptide, all by HLA-A genotype. Error bars 
demonstrate the mean and the standard error of the mean. Latent peptides, peptides 
derived from proteins expressed during viral latency; Latency II peptides, peptides derived 
from peptides derived from those EBV proteins expressed in the latency II expression, as in 
HRS cells. For the primary analysis (all peptides), p values of < 0.025 are considered 
significant. For the exploratory analyses of lytic, latent and latency II peptides, p-values of 
< 0.05 are considered significant, and are shown in red. 
 
 
a) b) 
c) d) 
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3.3.3 Confounding variables in ELISPOT analysis  
Given the surprising finding that the responses measured in the ELISPOT analysis 
were of greater breadth and depth in HLA-A*02:01/ A*x heterozygotes, 
compared to either HLA-A*02:01 homozygotes or A*02:01/A*01:01 heterozygotes, 
the data were examined to look for potential confounding variables. 
First, in order to exclude cross-presentation by another allele as cause of the 
results, particularly in the high responders, the other class I alleles present in 
donors were examined manually for any trends. There was no systematic 
difference between higher and lower responders in terms of the other class I 
alleles present. The high-responding outlying donors in the responses were 
different for number of peptides recognised (donors 10170, 10237, 10279 and 
10287), maximal response (donors 10170, 10237, 10279 and 10503) and 
summative responses (donors 10151, 10171 and 10279.) 
Second, the data were analysed for potential confounding variables. The 
variables analysed included time to processing of specimen, sex, donor self-
reported blood test-confirmed IM, if ever-smoked, percentage of CD3 cells 
positive for HLA-DR and CD4/CD8 ratio.  
Potential confounding variables were first compared by genotype group. Given 
that 7 of the 8 donors excluded from the analysis were female and 6 of the 8 
processed the same day, the comparison of donors described in Section 3.3.1 
was repeated for those donors included in the final ELISPOT analysis (n = 31, 
Table 3.1). A summary of the characteristics of these 31 donors and the 
potentially confounding variables is given in Table 3.4.  
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Significant differences between the groups are noted in regard to sex, time to 
processing and the percentage of CD3 cells positive for HLA-DR. There were 
significantly more female donors and samples that were processed on the same 
day in the HLA-A*02:01/ A*x heterozygote group compared to the other groups. 
Fewer CD3 cells were HLA-DR-positive in the HLA-A*02:01/ A*x heterozygote 
group compared to the other groups, although all were within the expected 
normal range of < 20% (source; personal communication, Gartnavel General 
Hospital Haematology Laboratory, Glasgow).  
Where differences between the groups were noted, analysis for potential 
confounding was performed. A summary of the analysis of potentially 
confounding variables by HLA-group is shown in Table 3.5.  
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Table 3-4 Characteristics of the 31 donors included in the ELISPOT analysis 
 HLA-A* 02:01 Group 
p-value for 
differences 
between 
groups 
HLA-A* 02:01 / 
A*01:01 
heterozygotes 
n (%) 
HLA-A*02:01 
homozygotes 
 
n (%) 
HLA-A*02:01 / 
other (x) 
heterozygotes 
n (%) 
Total Number  14 11 6 N/A 
Female  7 (53.8) 3 (27.3) 5 (83.3) p = 0.08  ‡ 
Age * 47 (23 -59) 45 (28-58) 41.5 (23-53) p = 0.21 † 
DEPCAT 5 * 2.23(1-5) 3.37 (1-5) 3 (1-4) p = 0.10 † 
Monospot-
confirmed 
previous IM § 
2 (14.3) 2 (18.2) 0 (0) p = 0.55 ‡ 
Suspected 
previous IM § 
2 (14.3) 2 (18.2) 1 (16.7) p = 0.68 ‡ 
Current smoker 1 (7.1) 2 (18.2) 1 (16.7) p = 0.68 ‡ 
Ever smoked? 1 (7.1) 1 (9.1) 1 (16.7) p = 0.80 ‡ 
Processed 
within 24 hours 
11 (78.6) 5 (45.5) 6 (100) p = 0.04 † 
% of CD3 cells 
positive for 
HLA-DR * 
5.5 (2.1-10.8) 7.10 (4.4-16.1) 3.95 (1.5-5.5) p = 0.030 † 
CD4/CD8 ratio * 2.29 (1.42-5.00) 2.53 (1.43-4.80) 1.80 (0.93-3.20) p = 0.277 ‡ 
* Age, DEPCAT 5, CD3/HLA-DR and CD4/CD8 ratio are presented as median and range. 
† regression (2-tailed t-test) 
‡ Pearson Chi-square analysis 
§ Note all IM is self-reported. As defined in this table, suspected previous IM is where an 
individual reported previous IM which was not confirmed by a blood test, and Monospot-
confirmed IM is where the individual has told us that a doctor confirmed their IM using a 
blood test.  
Results presented by HLA-group. A p-value of < 0.05 is considered significant (highlighted in 
blue). 
 
Table 3-5 Confounding by ELISPOT responses 
Measure of 
ELISPOT response 
p-value for associations with confounders † 
Time to processing Sex % of CD3 cells 
positive for HLA-DR 
Total number of 
peptides 
0.198 0.519 0.158 
Maximum of all 
peptides 
0.015 0.033 0.230 
Sum of all peptides 0.030 0.008 0.170 
† Equal variances not assumed, data assumed to be not normally distributed Mann Whitney 
analysis performed for categorical variables and Kruskal-Wallis analysis performed for 
continuous variables. A p-value of < 0.10 is considered significant (highlighted in blue). 
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In the analysis of potential confounding variables by ELISPOT response, only sex 
and time to processing were associated with significant differences in response.  
Female donors demonstrated higher maximal (p = 0.001) and summative 
responses (p = 0.03) (Figure 3.6). Samples processed on the same day as 
collection also demonstrated significantly higher maximal (p = 0.02) and 
summative (p = 0.03) responses (Figure 3.7). 
Separating the effects of sex and time to processing on the ELISPOT outcome 
measures is difficult, as there was tight association between the two variables; 
14 of 15 female donor specimens were processed the same day, and 8 of 9 
samples processed after more than 24 hours came from male donors (Table 3.6). 
 
Table 3-6 Association of time to processing with sex of the donor 
 
Time to sample processing 
(number of donors) 
Same Day Next Day 
Sex  (number of 
donors) 
Male 7 8 
Female 14 1 
Chi square analysis p = 0.014. 
In this table, n = 30; datum on sex was missing for 1 donor.  
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Figure 3-6 Effect of sex on ELISPOT responses to HLA-A*02:01-restricted peptides  
a) Number of peptides recognised, b) maximal response to any peptide and c) summative 
response to any peptide by sex. Maximal and summative responses to HLA-A*02:01-restricted 
EBV peptides, although not number of peptides recognised, are significantly higher in the 
CTLs from female donors. p-values of < 0.05 are considered significant, and are shown in 
red. 
 
a) 
b) c) 
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Figure 3-7 Effect of time-to-processing on ELISPOT responses to HLA-A*02:01-
restricted peptides  
 a) Number of peptides recognised, b) maximal response to any peptide and c) summative 
response to any peptide time to processing. Maximal and summative responses to HLA-
A*02:01-restricted EBV peptides, although not number of peptides recognised, are 
significantly higher in samples processed on the same day as collection, versus those 
samples processed the next day. p-values of < 0.05 are considered significant, and are 
shown in red. 
 
 
 
 
 
a) 
b) c) 
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3.3.3.1 Sub-group analyses to assess effect of confounding 
variables 
On the basis of the differences observed in CTL response by sex and time-to-
processing, these variables were studied in further detail, to assess if 
differences by HLA group would continue to be observed. Sub-group analyses of 
CTL response by HLA genotype were performed including samples only from 
female donors (n = 15, Figure 3.8), or with only samples processed the same day 
(n = 22, Figure 3.9). In the analysis of female donors only, significant differences 
were no longer observed when the number of peptides eliciting a response and 
the single maximal response were compared between A*02:01/x heterozygotes 
and the other two groups. HLA-A*02:01/x heterozygotes were still observed to 
have higher summative responses than either HLA-A*02:01 homozygotes or HLA-
A*02:01/A*01:01 heterozygotes (p = 0.01). In the analysis of samples processed 
on the same day, significant differences in number of peptides eliciting a 
response and the single maximal response by HLA-A*02:01 genotype were no 
longer observed. Higher summative responses continued to be observed in HLA-
A*02:01/x heterozygotes compared with HLA-A*02:01/A*01:01 heterozygotes, 
and this approached significance (p = 0.08). 
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Figure 3-8 Sub-group analysis of responses in female donors only 
Responses to all peptides in samples from female donors by HLA-A genotype group. Results 
are presented by a) number of HLA-A*02:01-restricted EBV peptides recognised, b) maximal 
response to any HLA-A*02:01-restricted EBV peptide, c) summative response to any HLA-
A*02:01-restricted EBV peptide. Error bars demonstrate the mean and the standard error of 
the mean. p-values of < 0.05 are considered significant, and are shown in red. 
 
a) 
b) c) 
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Figure 3-9 Sub-group analysis in samples processed on the same day as collection 
Responses to all peptides in samples processed on the same day as collection by HLA-A 
genotype group. Results are presented by a) number of HLA-A*02:01-restricted EBV peptides 
recognised, b) maximal response to any HLA-A*02:01-restricted EBV peptide, c) summative 
response to any HLA-A*02:01-restricted EBV peptide. Error bars demonstrate the mean and 
the standard error of the mean. p-values of < 0.05 are considered significant, and are shown 
in red. 
 
 
 
a) 
b) c) 
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3.3.3.2 Analysis of difference between HLA-A*02:01/A*01:01 
heterozygotes and HLA-A*02:01 homozygotes if HLA-
A*02:01/A*x heterozygotes are excluded 
It was apparent from the analyses of confounding variables that sex and time to 
sample processing were associated both with HLA genotype and ELISPOT 
response. It was also apparent that the HLA-A*02:01/x heterozygotes were the 
group with most excluded donors (7 of the 8 excluded donors), the highest 
proportion of females (5/6), and in which all of the samples were processed on 
the same day. It is probably not valid, therefore, to draw any conclusions for 
ELISPOT responses in this group.  
The other two groups (HLA-A*02:01/A*02:01 homozygotes and HLA-
A*02:01/A*01:01 heterozygotes) were well matched (Table 3.7), and therefore 
any differences in ELISPOT responses observed between these groups would be 
likely to be real. As mentioned above, no significant difference in any measure 
of ELISPOT response was noted between these two groups. 
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Table 3-7 Comparison of donor characteristics between HLA-A*02:01 homozygotes 
and HLA-A*02:01/A*01:01 heterozygotes only 
 HLA-A* 02:01 Group p-value for 
differences 
between groups 
HLA-A* 02:01 / 
A*01:01 heterozygotes 
HLA-A*02:01 
homozygotes 
Total Number  14 11 N/A 
Female, n (%) 7 (53.8) 3 (27.3) p = 0.24 ‡ 
Age (median, range) 47 (23 -59) 45 (28-58) p = 0.63 † 
DEPCAT 5 (mean, 
range) 
2.23 (1-5) 3.37 (1-5) p = 0.10 † 
Monospot-confirmed 
previous IM §, n (%) 
2 (14.3) 2 (18.2) p = 1.00 ‡ 
Suspected previous 
IM §, n (%) 
2 (14.3) 2 (18.2) p = 1.00 ‡ 
Current smoker, n 
(%) 
1 (7.1) 2 (18.2) p = 0.57 ‡ 
Ever smoked? n (%) 1 (7.1) 1 (9.1) p = 1.00 ‡ 
Processed within 24 
hours, n (%) 
11 (78.6) 5 (45.5) p =0.12 ‡ 
† Regression (2-tailed t-test) 
‡ Fisher’s exact test 
§ Note all IM is self-reported. As defined in this table, suspected previous IM is where an 
individual reported previous IM which was not confirmed by a blood test, and Monospot-
confirmed IM is where the individual has told us that a doctor confirmed their IM using a 
blood test. A p-value of < 0.05 is considered significant. 
 
Linear logistic regression modelling, to adjust for the effects of confounding 
variables, was not performed as a) ELISPOT response results were not normally 
distributed, b) donor numbers were small, and c) the inclusion of only one male 
donor in the HLA-A*02:01/x group precluded adjustment for the effect of sex. 
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3.3.4 CTL Degranulation by donor HLA-A*02:01 genotype 
Assessment of T cell cytotoxicity by measuring cellular degranulation was 
performed by flow cytometric analysis of CD107 expression after exposure to 
peptide pools. PBMCs from the same 39 donors described in Section 3.3.1 were 
exposed to the pools of EBV peptides described in Section 2.7.1 (two pools of 
latent peptides and one pool of lytic peptides). Two cases were excluded, one 
because of unacceptably high levels of staining in the isotype negative control 
(LRF patient number 10495) and the other for high baseline and negative control 
CD107 levels rendering the result uninterpretable (LRF patient number 10485). 
Results are presented in Figure 3.10  
Four individual donors (three HLA-A*02:01/A*x heterozygotes and one A*02:01 
homozygote, Figure 3.10) demonstrated higher levels of CD107 expression 
following exposure to the EBV peptide pools (latent and lytic). These donors, 
p10098, p10100, p10115 and p10279, were not the same donors in whom 
particularly high ELISPOT responses were observed. HLA-A*02:01/x 
heterozygotes demonstrated greater cytotoxicity assessed by CD107 expression 
than either A*01:01/A*02:01 heterozygotes or A*02:01 homozygotes. No 
difference was observed between HLA-A*02:01 homozygotes and HLA-
A*02:01/A*01:01 heterozygotes, thus echoing the pattern in the IFN-γ ELISPOTS. 
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Figure 3-10 CTL degranulation, by HLA-A*02:01 genotype 
As assessed by CD107 expression following stimulation. ΔCD107, Difference in CD107 
expression from baseline (in percent) genotype group. Responses shown are to a) Pool 2 (a 
pool of HLA-A*02:01-restricted EBV latent peptides), b) Pool 3 (a pool of HLA-A*02:01-
restricted EBV latent peptides), and c) Pool 4 (the pool of HLA-A*02:01-restricted EBV lytic 
peptides). Error bars demonstrate the mean and the standard error of the mean. p-values of 
< 0.025 are considered significant, and are shown in red. 
a) 
b) 
c) 
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Analysis of potential confounding variables was performed (Table 3.8). Unlike in 
the ELISPOT analyses, sex of the donor had no effect on the level of CD107 
expression following stimulation by EBV peptide pools. However, same day 
processing was associated with higher ΔCD107 values; thus, as with the ELISPOT 
responses, any differences observed in the HLA-A*02:01/A*x heterozygote group 
cannot be considered valid. 
Table 3-8 Potential confounding variables and CD107 responses 
ΔCD107 
response 
p-value for associations with confounders (2-tailed t test) 
Time to 
process 
sample 
Sex 
Donor 
reported 
blood test 
confirme
d IM 
Ever 
smoked 
% of CD3 
cells 
positive 
for HLA-
DR 
CD4/CD8 
ratio 
Pool 2 0.03 0.71 0.09 0.18 0.16 0.54 
Pool 3 0.05 0.17 0.17 0.64 0.23 0.99 
Pool 4 0.07 0.53 0.55 0.97 0.17 0.89 
† Equal variances not assumed, data not normally distributed, Mann Whitney analysis 
performed for categorical variables and Kruskal-Wallis analysis performed for continuous 
variables. p-values of < 0.10 are considered significant (highlighted in blue). 
 
3.3.5 Cytokine production following stimulation of BD-PBMCs 
with EBV peptides by donor HLA-A*02:01 genotype 
Cells from the same 39 donors used for the CD107 flow cytometry experiments 
were also used to assess cytokine secretion by HLA-A*02:01 genotype in response 
to EBV peptide. The same pools of peptides derived from EBV proteins expressed 
during latent infection (“latent peptides”) and EBV proteins expressed during 
the lytic replication phase (“lytic peptides”) as described in Section 2.7.1 were 
used in an overnight stimulation (described in Section 3.2.5).  
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Results are given as level of a given cytokine in pg/ml following the stimulation. 
Results of responses to lytic peptides are given in Figure 3.11, and those in 
response to latent peptides in Figure 3.12.  
The mean level of each cytokine as secreted in response to overnight stimulation 
with lytic peptides is given in Table 3.9 and to latent peptides in Table 3.10. The 
statistical analyses of the cytokine secretion levels are presented in Table 3.11.  
In response to lytic peptides, HLA-A*02:01/A*01:01 heterozygotes produced 
significantly higher levels of IL-10 (mean 1427 vs. 155 pg/ml p = 0.03), IL-17 (84 
vs. 70 pg/ml p = 0.02) and IL-5 (35 vs. 29 pg/ml p = 0.04) compared to both 
other HLA-A groups. In response to latent peptides, IFN- secretion was higher in 
A*02:01 /x heterozygotes compared to other groups (2552 vs. 552 pg/ml, p = 
0.007).  
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Figure 3-11 Cytokine secretion in response to EBV lytic peptides, by HLA group  
a) TNF-α, b) IFN-γ, c) IL-2, d) IL-4, e) IL-5, f) IL-6, g) IL-10, h) IL-12 and i) IL-17. Figure over 
two pages (this page and overleaf). Concentrations are in pg/ml. Note different scales on y-
axis used due to differences in levels of cytokines secreted. Bars represent mean and 
standard deviation. For statistical analysis of these data see Table 3.11. 
 
  
a) b) 
c) d) 
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Figure 3-11 (Continued) Cytokine secretion in response to EBV lytic peptides, 
by HLA group  
e) f) 
g) h) 
i) 
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Figure 3-12 Cytokine secretion in response to EBV latent peptides, by HLA group  
a) TNF-α, b) IFN-γ, c) IL-2, d) IL-4, e) IL-5, f) IL-6, g) IL-10, h) IL-12 and i) IL-17. Figure over 
two pages (this page and overleaf). Concentrations are in pg/ml. Note different scales on y-
axis used due to differences in levels of cytokines secreted. Bars represent mean and 
standard deviation. For statistical analysis of these data see Table 3.11. 
  
a) b) 
c) d) 
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Figure 3-12 (Continued) Cytokine secretion in response to EBV latent peptides, by 
HLA group  
 
 
 
e) f) 
g) h) 
i) 
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Table 3-9 Cytokine secretion in response to lytic HLA-A*02:01-restricted EBV 
peptides 
 
Cytokine 
HLA Group 
HLA-A*02:01/ A*01:01 
heterozygotes 
HLA-A*02:01 / A*02:01 
homozygotes 
HLA-A*02:01 / other 
heterozygotes 
Mean (pg/ml) SD Mean (pg/ml) SD Mean (pg/ml) SD 
IL-10 1427.33 3161.29 42.14 38.28 279.50 498.61 
IL-4 192.89 25.82 184.00 16.02 193.80 29.63 
IL-2 203.11 39.94 197.59 54.89 192.50 49.72 
IL-12 p70 67.22 15.11 57.86 23.01 59.70 16.50 
IFN-γ 192.06 174.68 2552.27 6816.35 876.90 2272.62 
IL-17 83.94 15.96 71.09 7.64 68.95 11.93 
IL-5 35.39 13.22 30.45 2.65 28.15 1.87 
TNF-α 22164.05 6182.87 14135.09 9903.47 19914.20 7939.74 
IL-6 21183.33 5447.03 18637.00 8773.70 19240.60 6548.13 
Lytic EBV peptides, peptides derived from proteins expressed during EBV replicative cycle. 
Raw data shown as mean (pg/ml) and standard deviation. Results presented by HLA group. 
 
Table 3-10 Cytokine secretion in response to HLA-A*02:01-restricted latent EBV 
peptides  
  
 Cytokine 
HLA Group 
HLA-A*02:01/ A*01:01 
heterozygotes 
HLA-A*02:01 / A*02:01 
homozygotes 
HLA-A*02:01 / other 
heterozygotes 
Mean (pg/ml) SD Mean (pg/ml) SD Mean (pg/ml) SD 
IL-10 1282.50 2539.99 50.45 44.93 2377.18 5837.97 
IL-4 200.89 30.80 207.45 37.36 180.50 26.11 
IL-2 197.50 52.15 179.00 26.09 177.82 34.28 
IL-12 p70 76.28 31.41 58.95 15.91 65.55 17.91 
IFN-γ 531.17 1235.08 104.50 30.39 7430.50 9509.47 
IL-17 81.72 20.48 72.50 10.98 71.73 13.43 
IL-5 37.56 17.29 29.80 3.04 29.77 3.57 
TNF-α 20816.55 6862.47 16528.00 8486.19 19157.91 8931.80 
IL-6 22355.89 4898.52 19060.85 7831.87 20721.96 6564.74 
Latent EBV peptides, peptides derived from proteins expressed in EBV latent phase. Raw 
data shown as mean (pg/ml) and standard deviation (SD). Results presented by HLA group. 
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Table 3-11 Statistical analysis of cytokine secretion in response to EBV peptides  
  
Response to Lytic Peptides Response to Latent Peptides  
Primary analysis 
HLA -
A*02:01/A*01:01 
vs. other groups 
Secondary 
analysis - 
between all 
three groups 
Primary analysis 
HLA -
A*02:01/A*01:01 
vs. other groups 
Secondary 
analysis - 
between all 
three groups 
Cytokine 
Mann-Whitney  
(p-value) 
Kruskal-Wallis 
(p-value) 
Mann-Whitney 
(p-value) 
Kruskal-Wallis 
(p-value) 
IL-10 0.03 0.04 0.06 0.10 
IL-4 0.46 0.63 0.51 0.15 
IL-2 0.21 0.44 0.37 0.64 
IL12 p70 0.10 0.22 0.20 0.32 
IFN-γ 0.98 0.31 0.59 < 0.01 
IL-17 0.03 0.08 0.25 0.51 
IL-5 0.09 0.04 0.17 0.39 
TNF-α 0.17 0.15 0.57 0.65 
IL-6 0.60 0.81 0.51 0.76 
Latent EBV peptides, peptides derived from proteins expressed in EBV latent phase; lytic 
EBV peptides, peptides derived from proteins expressed during EBV replicative cycle. P-
values are given to 2 decimal places. A p-value of < 0.05 is considered significant 
(highlighted in blue). Results presented by HLA group. 
 
3.3.5.1 Analysis of cytokine secretion for potential 
confounding variables 
As confounding had been detected in the analysis of ELISPOT and CD107 results, 
analysis for confounding on the cytokine secretion results was performed. As can 
be seen, the distribution of levels of some cytokines was different by time to 
processing, sex, smoking status and CD4/CD8 ratio; however smoking status and 
CD4/CD8 ratio were not significantly different in the three HLA groups and 
therefore would not have affected the results. Echoing the result of the ELISPOT 
experiments, secretion of  cytokines could plausibly be confounded by time to 
processing and sex, and therefore any differences in cytokine secretion observed 
in A*02:01 /x heterozygotes in response to EBV peptides cannot be regarded as 
valid. 
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Table 3-12 Cytokine secretion by potentially confounding variables  
Peptide 
pool 
Cytokine 
p-value for associations with confounders 
Time to 
process 
sample 
Sex 
Donor 
reported 
blood 
test 
confirm
ed IM 
Ever 
smoked 
% of CD3 
cells 
positive 
for HLA-
DR 
CD4/CD8 
ratio 
Latent 
TNF-α 0.23 0.82 0.80 0.18 0.24 0.32 
IL-10 0.05 0.53 0.33 0.79 0.11 0.29 
IL-4 0.06 0.00 0.70 0.81 0.12 0.38 
IL-2 0.82 0.46 0.18 0.25 0.13 0.37 
IL-12 0.35 0.59 0.77 0.53 0.17 0.35 
IL-6 0.03 0.53 0.90 0.50 0.73 0.48 
IFN-γ 0.08 0.16 0.73 0.54 0.86 0.20 
IL-17 0.31 0.02 0.26 0.37 0.28 0.32 
IL-5 0.15 0.88 0.76 0.38 0.88 0.02 
Lytic 
TNF-α 0.26 0.05 0.61 0.18 0.35 0.28 
IL-10 0.81 0.19 0.42 0.97 0.13 0.37 
IL-4 0.12 0.05 0.82 0.05 0.79 0.13 
IL-2 0.30 0.65 0.92 0.40 0.84 0.44 
IL-12 0.30 0.07 0.72 0.12 0.09 0.33 
IL-6 0.24 0.86 0.38 0.16 0.69 0.65 
IFN-γ 0.00 0.10 0.42 0.01 0.27 0.42 
IL-17 0.47 0.43 0.68 0.99 0.97 0.47 
IL-5 0.25 0.50 0.32 0.04 0.25 0.16 
† Equal variances not assumed, data assumed to be not normally distributed, Mann Whitney 
analysis performed for categorical variables and Kruskal-Wallis analysis performed for 
continuous variables. A p-value of < 0.10 is considered significant (highlighted in bold). 
 
As in the ELISPOT experiments, further analysis for confounding was performed 
if the most confounded group, the HLA-A*02:01/A*x heterozygotes, were 
removed. This analysis is given in Table 3.12. Of those cytokines where 
significant differences in secretion by HLA group were noted (IL-10, IL-17 and IL-
5) no confounding was found, and, as discussed, HLA-A*02:01 homozygotes and 
HLA-A*02:01/A*01:01 heterozygotes were well matched such that any 
comparisons between these two groups remain valid. 
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3.3.6 Summary of Results  
HLA-A*02:01-restricted EBV-specific CTL responses in healthy individuals were 
examined to assess if the presence of an HLA-A*01:01 allele would modify the 
magnitude of the CTL response elicited. 
Significant differences by HLA-A*02:01 genotype in CTL responses to HLA-
A*02:01-restricted EBV peptides as assessed by IFN-γ ELISPOT were observed. In 
these experiments, HLA-A*02:01/x heterozygotes demonstrated responses of 
greater magnitude (summative and maximum) and greater breadth (number of 
peptides recognised), as compared with both HLA-A*02:01 homozygotes and HLA-
A*01:01/A*01:01 heterozygotes. This effect was observed for lytic and latent 
peptides. These data therefore disproved the null hypothesis that responses 
should be the same in all HLA-A*02:01 genotype groups; however there were no 
differences between HLA-A*02:01 homozygotes and HLA-A*02:01/A*01:01 
heterozygotes and therefore the magnitude of responses did not reflect the risk 
of developing EBV+ve cHL. 
The results were unexpected and analysis of potentially confounding variables 
shed some light on the possible reasons for this, demonstrating higher ELISPOT 
responses in females and in samples collected and processed on the same day. 
The HLA-A*02:01/A*x heterozygote group was found to be highly confounded by 
these variables, with 100% of specimens being processed on the same day and 5 
of the 6 donors being female. The effect of the confounding variables also 
affected the CTL degranulation experiments, and probably also accounted for 
the elevated secretion of IFN-γ observed HLA-A*02:01/A*x heterozygote group in 
the cytokine analysis. Thus, whilst this group did demonstrate greater CTL 
toxicity assessed by several outcome measures used, this cannot be concluded to 
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be due to HLA phenotype. As discussed in Section 3.2.6, linear regression 
modelling with adjustment for these confounding variables was not possible due 
to non-normally distributed data, small numbers and the inclusion of one male 
subject in the HLA-A*02:01/A*x group.  
Only 31 ELISPOTs passed the QC criteria, falling short of the 45 required by the 
power calculation, and with the majority of excluded donors falling in to the 
HLA-A*02:01/A*x heterozygote group. Recruitment to the study reached required 
targets, but incomplete recall and exclusion of results on the basis of QC criteria 
led to incomplete attainment of the numbers of required donors. Further studies 
are being carried out in the laboratory at present to increase numbers in the 
different HLA groups.  
The power calculation was performed prospectively based on assumptions of the 
nature of the ELISPOT responses which would be seen. However, in retrospect, 
the data generated could not justify the type of analysis used in the power 
calculation, as data were not normally distributed and the variability seen was 
greater than expected.  
In response to lytic peptides, HLA-A*02:01/A*01:01 heterozygotes produced 
significantly higher levels of IL-10 (mean 1427 vs. 155 pg/ml p = 0.03), IL-17 (84 
vs. 70 pg/ml p = 0.02) and IL-5 (35 vs. 29 pg/ml p = 0.04) compared to the other 
HLA-A*02 groups. As all lytic peptides were in the same pool, it was not possible 
to determine if this effect was principally due to differences in responses to 
particular group of lytic peptides i.e. those derived from IE vs. late proteins. 
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3.4  Discussion 
That female sex and time-to-processing led to greater IFN-γ CTL responses is 
perhaps not surprising, although has not previously been reported with regard to 
EBV responses. Greater magnitude of immune responses in females is a well-
recognised phenomenon (Klein, 2012) and is thought, in part, to account for the 
higher prevalence of autoimmune disease in women. More specifically, the CTL 
immune response has been shown to be of greater magnitude in women 
(Hewagama et al, 2009), an effect which may be seen in stronger responses to 
viruses and vaccines (Peacock et al, 2004; Villacres et al, 2004). It is possible 
that the higher EBV-specific CTL responses from females observed in this study 
may go some way to explaining the higher prevalence of EBV-associated 
malignancies such as cHL (Shenoy et al, 2011; Glaser et al, 1997), Burkitt’s 
lymphomas (Boerma et al, 2004) and NPC (Yu & Yuan, 2002) in men as compared 
with women.  
Samples processed on the same day as donation gave higher responses in the 
ELISPOTs, again perhaps not surprising, as instinctively one would feel that T 
cells freshly removed from the body would be capable of greater responses. This 
was not addressed in the optimisation stage, as ELISPOTS have been 
demonstrated to be possible and reliable in samples processed up to 30 hours 
from venesection (Matijevic & Urban, 2005) and in samples shipped at RT e.g. in 
studies of CTL responses to vaccines (Schultes & Whiteside, 2003; Ferrari et al, 
1997). The magnitude of difference this made to the results was therefore 
surprising. In studies where qualitative responses are analysed, in situations 
where all samples are processed after the same delay or in situations where 
comparisons are between groups that are well matched this may not matter. 
However, because of the recruitment strategies adopted in this study, most HLA-
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A*02:01/A*x heterozygotes (as the commonest group) were recruited via the CRF 
(University and NHS staff). The majority of these donors were female and their 
samples were processed on the same day, principally because of the timing and 
location of collection. In contrast, HLA-A*02:01/A*01:01 heterozygotes and HLA-
A*02:01 homozygotes were more evenly distributed between the CRF donors and 
the SNBTS donors; SNBTS donors having a more equal sex distribution and more 
likely to have samples processed the following day.  
If this study were to be repeated or extended, groups would have to be matched 
for sex, or restricted to one sex, and to include only samples processed on the 
same day as collection.  
Delays in processing resulting from the B cell selection (Section 2.3.3) should 
also be avoided, given these results. Pragmatically adopted to maximise the use 
of a donation from a given donor, the separation step did not lead to any 
difference in ELISPOT responses, but all comparisons were performed on samples 
processed the same day as collection. 
Analysis of a panel of inflammatory cytokines measured in response to 
stimulation of PBMC by EBV peptides demonstrated significant differences 
between the HLA-phenotype groups. The elevated secretion of IFN-γ by HLA-
A*02:01/A*x heterozygotes in response to EBV peptides is likely to be 
confounded by the same factors discussed above, and cannot be accepted as 
valid.  
However, this analysis did demonstrate a possible effect of HLA-A*01:01 in HLA-
A*02:01/A*01:01 heterozygotes, as this group demonstrated significantly higher 
secretion of IL-10 (with a nearly 10-fold difference), IL-17 and IL-5 in response to 
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stimulation with EBV peptides. Analysis of potential confounders suggests not 
only that comparisons of these cytokines were not affected by confounding, but 
also that comparisons between HLA-A*02:01/A*01:01 heterozygotes and HLA-
A*02:01 homozygotes are valid. Whilst a criticism of any multiplexed approach is 
detection of significant differences through multiple analysis (Bonferroni 
correction was not performed due to sample size), the magnitude of the 
difference observed for IL-10 is provocative and should be investigated further. 
The null hypothesis of this study, that all HLA-A*02:01 carriers should have the 
same response to HLA-A*02:01-restricted EBV peptides was not disproved. 
Responses in the HLA A*02:01 / A*x heterozygote group were greater than in the 
other groups but had to be disregarded for reasons of confounding, and adjusted 
analysis was not possible. 
Comparisons of CTL responses in HLA-A*02:01/A*01:01 heterozygotes and HLA-
A*02:01 homozygotes were valid, but differences by ELISPOT, CTL degranulation 
as assessed by CD107 expression and by IFN-γ secretion were not demonstrated.  
I did not find evidence that HLA-A*01:01 specifically inhibited CTL responses to 
A*02:01-restricted EBV peptides.  
The primary experimental question “Does the presence of an HLA-A*01:01 allele 
modify the magnitude of the CTL response to HLA-A*02:01-restricted epitopes?” 
was partly answered. Exploratory analysis of cytokine levels in response to 
stimulation with EBV peptides did demonstrate differences in HLA-
A*02:01/A*01:01 heterozygotes, compared to other groups. In response to EBV 
lytic peptides, A*02:01/*01:01 heterozygotes demonstrated significantly higher 
levels of cytokines associated with a T-helper (Th) cell response.  A Th response 
is typically generated by CD4 cells via a HLA class II (not class I) restricted 
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response. A number of possibilities may explain this; first the existence of the Ts 
population, a population of inhibitory, regulatory CD8+ve, CD28-ve T cells (Chess 
& Jiang, 2004; Cortesini et al, 2001), which initiate a secondary immune 
response which includes secretion of cytokines associated with suppression of a 
CTL response. Second, as discussed in the Introduction, the class I HLA genes sit 
in a large cluster of genes on chromosome 6, the function of many of which are 
immune in nature. This includes many genes directly or indirectly involved in 
cytokine expression. There are high levels of LD in this area of the chromosome, 
therefore the level of secretion of any given cytokine may not be directly causal, 
but instead could be as a result of association with a class I HLA gene. 
Therefore, it is biologically plausible that different levels of “Th2” cytokines 
may be seen in response to viral stimuli by class I HLA genotype. 
IL-5 is produced by Th2 cells and is important in the antibody mediated immune 
response and in recruitment of eosinophils.  IL-5 has also been shown to be 
important as an autocrine growth factor in EBV-transformed LCLs (Baumann & 
Paul, 1992). In addition, a Th2 profile which includes IL-5 as part of the process 
driving eosinophilia, is known to be implicated in the pathogenesis of cHL (Di 
Biagio et al, 1996). 
IL-17 is a pro-inflammatory cytokine and is the archetypal cytokine of a group of 
cytokines which conventionally determine the response of the subset of CD4+ Th 
cells known as Th17 cells. Physiologically, the IL-17 response is thought to be 
important in mucosal immunity. IL-17 producing T-cell subsets have been 
implicated in the pathogenesis of autoimmune diseases such as MS and type 1 
diabetes mellitus (Mills, 2008), and also chronic active EBV infection (Ohta et al, 
2013) where seemingly immune competent individuals can succumb to severe, 
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potentially fatal illness in the face of EBV infection. In addition, in recent years, 
it has been recognised that IL-17 can also be produced by novel CD8+, CD161+ T 
lymphocytes, the so-called Tc17 cells (Tajima et al, 2011; Sundrud & Trivigno, 
2013). Such Tc17 cells have been observed in solid tumours such as gastric 
cancer where they influence the tumour microenvironment by promoting 
migration of myeloid derived suppressor cells and suppressing CD8+ CTL function 
(Zhuang et al, 2012). Tumour associated macrophages are known to be 
important in cHL where they are associated with poor outcome (see Section 
1.3.7) and it is notable that these can stimulate differentiation of Tc17 cells 
(Zhuang et al, 2012). It is possible that the differential IL-17 secretion is 
observed by class I HLA type in this study may be due to antigen specific Tc17 
responses. Whilst not assessed in this study, this hypothesis could be evaluated, 
e.g. by flow cytometry, in future studies of HLA-A*01:01 restricted responses to 
EBV. 
IL-10 was originally thought to be produced only by Th2 cells. It is now known 
that IL-10–secreting CD8 T cells represent a phenotypically distinct Ts cell 
lineage (Noble, Blood, 2006) and that the IL-10 produced by effector Th1 cells 
normally help to limit the collateral damage caused by exaggerated 
inflammation (Trinchieri, JEM, 2007). There is strong evidence that IL-10 may 
play an important role in the pathogenesis of cHL. In addition to the described 
immune suppressive roles, there is also some evidence that IL-10 can enhance B 
cell proliferation (Guedez et al, 2001). Levels of IL-10 have been found to be 
elevated in adults with cHL, where they are associated with poor prognosis 
(Sarris et al, 1999; Rautert et al, 2008). IL-10 has been particularly implicated in 
the pathogenesis of EBV+ve cHL (Ohshima et al, 1995), and in a recent study, a 
particular IL-10 gene polymorphism (rs 1800890) was associated with lower risk 
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of HL in adults over 40, whose disease is more commonly EBV-associated (Yri et 
al, 2012). Differential secretion of IL-10 by HLA-A*02:01 genotype in response 
rubella vaccination has been reported (Ovsyannikova et al, 2007), although has 
not yet been described in response to EBV. 
These data suggest that overall HLA-A phenotype does not significantly affect 
the EBV-specific CTL response restricted through HLA-A*02:01. However, the 
cytokine profiles observed following stimulation with EBV peptides might begin 
to explain some of the HLA-associated differences in risk of developing EBV+ve 
cHL, and merit further exploration. 
           
 
 
Chapter 4.  Can HLA-A*01:01-restricted responses 
to EBV be detected? 
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4.1  Introduction 
Class I HLA genes determine CTL responses, keeping viral infection under tight 
control in healthy hosts. As discussed in the Introduction and in Chapter 3, HLA-
A*01:01 is associated with increased risk of EBV+ve cHL whereas HLA-A*02:01 is 
associated with decreased risk (Hjalgrim et al, 2010). In the model described in 
this paper, the OR for EBV-related cHL conveyed by each additional HLA-A*01 
allele was 2.15 (95% CI, 1.60–2.88).  
The association between HLA-A*01:01 and EBV+ve cHL suggests that such EBV-
specific immune responses might be important in the pathogenesis of this 
disease. Many immunodominant EBV peptides are known to be presented by class 
I alleles other than HLA-A*01:01. To date, no HLA-A*01:01-restricted response to 
any EBV-derived peptide has been described.  However, individuals who carry 
HLA-A*01:01 will also have other class I HLA alleles through which they may be 
able to raise an EBV-specific CTL response. It is not clear whether the increased 
risk associated with HLA-A*01:01 is simply because there are no EBV-specific 
responses restricted through this allele, or whether HLA-A*01:01 exerts 
qualitative or inhibitory changes to the EBV-specific immune response. 
EBV is an intensively studied virus. Over the last 20 years, a number of groups 
have interrogated the EBV-specific CTL responses. Generally, these studies were 
concerned with mapping T cell epitopes and HLA-restrictions, and did not 
specifically seek or examine the HLA-A*01:01-restricted response. It is notable, 
however, that in spite of intensive study, no EBV peptide epitopes have been 
described that present through HLA-A*01:01 (Hislop et al, 2007; Long et al, 
2011b; Moss et al, 2001). HLA-A*01:01 is able to efficiently present peptides 
from viruses other than EBV. For instance, immunodominant peptides from CMV 
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and Influenza raise very efficient CTL responses via this allele (Currier et al, 
2002; DiBrino et al, 1993; Elkington et al, 2003; Wills et al, 1996). Thus, there is 
no suggestion that HLA-A*01:01 is in any way deficient in terms of antigen 
presentation capability.  
The only study to specifically examine the HLA-A*0:01 response (Brennan & 
Burrows, 2008) used a strategy of stimulating responses with A*01:01 expressing 
721.221 LCLs, assessing responses with intracellular cytokine staining for IFN-γ. 
Negligible responses were detected; however, good EBV-specific responses were 
noted to 721.221 LCLs transduced with other class I alleles, and to HLA-A*01:01-
restricted peptides from other viruses e.g. CMV. Potential weaknesses of this 
study are that weak responses might represent allogeneic responses to minor 
histocompatibility antigens presented by the 721.221 cells, and that intra-
cellular cytokine staining assay is less sensitive than other techniques, such as 
ELISPOT, for detecting CTL responses. However, in general, this study supported 
the hypothesis that there are no HLA-A*01:01-restricted CTL responses to EBV.  
In the present study we sought to determine whether HLA-A*01:01-restricted 
EBV-specific CTL responses could be detected. In addressing this question, a 
sensitive methodology (ELISPOT) was adopted, and a strategy of using 
synthesised EBV-sequence derived peptides to avoid erroneous detection of 
allogeneic responses to minor histocompatibility antigens. A stimulation step 
using EBV-infected LCLs was employed to boost any low-level memory-CD8 CTL 
responses present. As a secondary exploratory question, I examined whether any 
inhibitory cytokine responses could be detected following stimulation of PBMCs 
with LCLs expressing HLA-A*01:01.  
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4.2  Methods 
4.2.1 Power calculation 
To determine whether HLA-A*01:01-restricted EBV-specific CTL responses can be 
detected by ELISPOT analysis, healthy individuals homozygous for HLA-A*01:01 
were studied.  
The sample size was determined prospectively using power calculations 
performed by Dr. Paul Johnson, Robertson Centre for Biostatistics, University of 
Glasgow. It was determined that 10 individuals homozygous for HLA-A*01:01 
were required to detect statistically significant EBV-specific CTL responses. With 
n = 10, assuming a background negative control SFC of 3% as compared to the 
positive controls, a SD of 2 percentage units and a cut-off for a positive response 
of  5% of the positive control, n = 10 will give 85% power to detect any response 
using a paired t-test. As most published ELISPOT studies report positive 
responses at a level of at least 8% of the positive control, I should be able to 
detect any HLA-A*01:01-restricted EBV-specific CTL responses should they exist.   
Local population frequencies for class I HLA genotypes were available from the 
in-house SNEHD study controls (Jarrett et al, 2003). HLA-A*01:01 homozygotes 
are relatively uncommon in the population (approximately 5%) and thus, these 
data suggested that approximately 200 adults would need to be HLA-typed to 
identify 10 individuals homozygous for HLA-A*01:01. Supplementing the HLA-
unscreened general population with a HLA-targeted approach to donor 
recruitment via the SNBTS donor population meant that these targets were 
achieved (see Chapter 2). EBV-seropositive individuals homozygous for HLA-
A*01:01 (n = 11) were selected from a pool of healthy adults who agreed to take 
part in this study. The donors used are listed in Table 4.1. None of these HLA-
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A*01:01 homozygous donors reported previous IM or were smokers. Additional 
donors heterozygous for HLA-A*01:01 and HLA-A*02:01 (n = 2) were used in 
comparisons – these were donors p10158 and p10134 as detailed in Table 3.1 
(Chapter 3). Donors were recalled to provide a “large blood sample” (Section 
2.3.2). All donors reported that they were well at time collection of this 
specimen. Samples were processed to BD-PBMCs (Section 2.3.3). Autologous LCLs 
were established from donors as described in Section 2.4.6. 
4.2.2 Peptide prediction  
As discussed above, HLA-A*01:01-restricted responses to EBV have never been 
described and therefore sequences of HLA-A*01:01-restricted peptides are not 
available in the published literature. In order to predict those peptides derived 
from EBV proteins which might be suitable for presentation in the binding groove 
of HLA-A*01:01, peptide prediction software was used. Prediction strategies 
have been successfully used previously to identify such epitopes, e.g. in the case 
of CMV (Elkington et al, 2003). 
A number of different software packages are freely available on-line. In order to 
determine the optimal prediction package, at time of study initiation in 2008, 
four of the leading packages (described in the Introduction) were compared. 
They were tested on their ability to identify previously characterised epitopes of 
known HLA-specificity from two viral proteins, namely HLA-A*01:01-restricted 
CMV IE-1 and HLA-A*02:01-restricted EBV LMP2 epitopes. The proportion of 
previously characterised peptides identified by the software was recorded. The 
software packages require the full AA sequence of the protein to be entered, 
and a HLA restriction selected. The reference sequence of these  
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 Table 4-1 HLA-A*01:01 homozygous donors  
LRF Patient 
Reference 
Number 
Sex Age 
Carstairs 5-
point 
deprivation 
score † 
HLA-A 
Allele 1 
HLA-A 
Allele 2 
HLA-B 
Allele 1 
HLA-B 
Allele 2 
HLA-C 
Allele 1 
HLA-C 
Allele 2 
Site of donor 
recruitment 
Used in 
ELISPOTs with 
no prior 
stimulation 
Used in 
stimulated 
ELISPOTs 
Used in 
cytokine 
analysis 
10,116 F 68 NK 0101 0101 0801 0801 0701 0701 CRF Yes Yes Yes 
10,288 M 25 5 0101 0101 0801 4402 0501 0701 CRF No Yes Yes 
10,494 M 51 0 0101 0101 NK NK NK NK SNBTS Yes No Yes 
10,498 M 41 3 0101 0101 NK NK NK NK SNBTS Yes No Yes 
10,504 F 48 4 0101 0101 NK NK NK NK SNBTS Yes No No 
10,534 M 52 0 0101 0101 NK NK NK NK SNBTS Yes Yes Yes 
10,553 F 65 1 0101 0101 NK NK NK NK SNBTS Yes No Yes 
10,568 F 38 5 0101 0101 NK NK NK NK SNBTS Yes No Yes 
10,569 M 46 2 0101 0101 NK NK NK NK SNBTS Yes No Yes 
10,613 M 40 1 0101 0101 NK NK NK NK SNBTS Yes No Yes 
10,616 M 49 1 0101 0101 NK NK NK NK SNBTS Yes No Yes 
 † Carstairs deprivation scores described in Section 2.3.1.4. 
 NK, not known; for SNBTS donors, only HLA-A* genotype information was available; CRF, Donor recruited through either the CRF or the  University 
 of Glasgow; SNBTS, Scottish National Blood Transfusion Service. 
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proteins was derived from UniProt KB (Uniprot Consortium, 2008), 
(http://www.uniprot.org/, accessed 18/11/08). As shown in Table 4.2, 
SYFPEITHI predicted the highest proportion of actual epitopes, with the other 
three packages performing poorly. On the basis of the above comparisons, 
SYFPEITHI was used to predict EBV- derived epitopes restricted through HLA-
A*01:01.  
Table 4-2 Comparison of peptide prediction programmes 
Software 
Proportion of HLA-A*02:01-
restricted EBV LMP2 epitopes 
correctly predicted (%) 
Number of HLA-A*01:01-
restricted CMV IE-1 epitopes 
correctly predicted (%) 
SYFPEITHI 7/8 (87.5%) 2/2 (100%) 
RANKPEP 0/8 (0%) 
1/2 (50%) – but not predicted to 
bind with sufficient strength to 
stimulate immune response 
ProPred 1/8 (12.5%) 1/2 (50%) 
BIMAS (NIH) 2/8 (25%) 
2/2 (100%) – but only 1 predicted 
to bind with sufficient strength 
 
4.2.3 HLA-A*01:01 predicted peptides 
The AA sequences of the following EBV proteins were obtained from UniProt 
(Uniprot Consortium, 2008), (http://www.uniprot.org/, accessed 18/11/08): the 
latency II proteins EBNA1, LMP1, LMP2A, LMP2B; additional proteins expressed in 
the latency III pattern namely EBNA-LP, EBNA2, EBNA3A, EBNA3B, EBNA3C; and 
lastly, proteins expressed in the early lytic phase including BZLF1, BRLF1, 
BMLF1, BMRF1 (EA protein D), BALF2 (major DNA binding protein) and BALF5 
(DNA polymerase).  
Peptides with a score of > 23% (which would usually predict binding sufficient to 
elicit a T cell response) were selected for synthesis. If no peptides from an 
individual protein met this criteria, the top five candidate epitopes per protein 
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were selected, unless a binding strength of < 16% was predicted, in which case 
fewer than five peptides were synthesised. The total number of peptides 
synthesised was 61. Nonamers (epitopes of 9 AAs length) were selected as this is 
the optimal binding length for the class I HLA molecule. 
The AA sequences of these peptides and the protein from which they are derived 
are listed in Table 4.4 (overleaf). Peptides were synthesised and reconstituted as 
described in Sections 2.7.3 and 2.7.4. Pools of no greater than 6 peptides were 
used (Table 4.4) and each peptide was used at a final concentration of 10 µg/ml.  
4.2.3.1 HLA-A*01:01 Control peptides 
HLA-A*01:01-restricted peptides derived from either CMV or influenza A (n = 5) 
were used as controls (Table 4.3). Used in combination in the HLA-A*01:01 
experiments, they are referred to as “peptide pool 1”. 
Table 4-3 HLA-A*01:01-restricted CMV and Influenza A derived peptides used as 
positive controls 
Epitope AA 
sequence 
HLA 
restriction 
Protein Virus  
Three-letter 
abbreviation 
Peptide 
pool 
YSEHPTFTSQY A0101 pp65 CMV YSE 1 
CTELKLSDY A1 NP Influenza A CTE 1 
CVETMCNEY A1 IE1 CMV CVE 1 
DEEEAIVAY A1 IE1 CMV DEE 1 
VSDGGPNLY A1 PB1 Influenza A VSD 1 
 
 
 
 
 Chapter 4: HLA-A*01:01-restricted responses to EBV 
223 
 
Table 4-4 Peptides predicted to be presented through HLA-A*01:01 and used in the 
study 
AA sequence HLA restriction Protein Latent/ Lytic Abbreviation Peptide pool 
ATSYHRDIY A1 PRED BALF2 LY ATS 2 
PDDEPRYTY A1 PRED BALF2 LY PDD 2 
PPEWLKGHY A1 PRED BALF2 LY PPE 2 
QSQPGPCGY A1 PRED BALF2 LY QSQ 2 
YKDLVKSCY A1 PRED BALF2 LY YKD 2 
ILDRARHIY A1 PRED BALF5 LY ILD 3 
REDSSWPSY A1 PRED BALF5 LY RED 3 
STGEEAGRY A1 PRED BALF5 LY STG 3 
VIDILNQAY A1 PRED BALF5 LY VID 3 
VYDILETVY A1 PRED BALF5 LY VYD 3 
CTDESYGKR A1 PRED BMLF1 LY CTD 4 
KEETGNSSY A1 PRED BMLF1 LY KEE 4 
STDGEISSS A1 PRED BMLF1 LY STD 4 
VVETLSSSY A1 PRED BMLF1 LY VVE 4 
YNFVKQLFY A1 PRED BMLF1 LY YNF 4 
YNFVKQLFY A1 PRED BMLF2 LY YNF 4 
ALAVLSKCY A1 PRED BMRF1 LY ALA 5 
AVSFRNLAY A1 PRED BMRF1 LY AVS 5 
GEACLTLDY A1 PRED BMRF1 LY GEA 5 
NPDLYVTTY A1 PRED BMRF1 LY NPD 5 
VSVPILRFY A1 PRED BMRF1 LY VSV 5 
HSRVRAYTY A1 PRED BRLF1 LY HSR 6 
QLGSLVSDY A1 PRED BRLF1 LY QLG 6 
SSHAGQRSY A1 PRED BRLF1 LY SSH 6 
SVEITLRSY A1 PRED BRLF1 LY SVE 6 
VTDRFFIQA A1 PRED BRLF1 LY VTDR 6 
AFDQATRVY A1 PRED BZLF1 LY AFD 7 
APENAYQAY A1 PRED BZLF1 LY APE 7 
DSELEIKRY A1 PRED BZLF1 LY DSE 7 
LPQGQLTAY A1 PRED BZLF1 LY LPQ 7 
SSENDRLRL A1 PRED BZLF1 LY SSE 7 
TTDEGTWVA A1 PRED EBNA1 LA TTD 8 
TWVAGVFVY A1 PRED EBNA1 LA TWV 8 
VGEADYFEY A1 PRED EBNA1 LA VGE 8 
YGGSKTSLY A1 PRED EBNA1 LA YGG 8 
DTDSLGNPS A1 PRED EBNA2 LA DTD 9 
ESPSSDEDY A1 PRED EBNA2 LA ESP 9 
LALHGGQTY A1 PRED EBNA2 LA LAL 9 
LSVIPSNPY A1 PRED EBNA2 LA LSV 9 
PLDRDPLGY A1 PRED EBNA2 LA PLD 9 
ATEVLDLSI A1 PRED EBNA3A LA ATE 10 
FLQRTDLSY A1 PRED EBNA3A LA FLQ 10 
RSEGPGPTR A1 PRED EBNA-LP LA RSE 10 
VTTQRQSVY A1 PRED EBNA-LP LA VTT 10 
AVTQAPTEY A1 PRED EBNA3B LA AVT 11 
KNIPQTLPY A1 PRED EBNA3B LA KNI 11 
LVSSGNTLY A1 PRED EBNA3B LA LVSS 11 
TNEEIDLAY A1 PRED EBNA3B LA TNE 11 
VTDFSVIKA A1 PRED EBNA3B LA VTDF 11 
ESSDDELPY A1 PRED EBNA3C LA ESS 12 
ISHEEQPRY A1 PRED EBNA3C LA ISH 12 
KTIGNFKPY A1 PRED EBNA3C LA KTI 12 
PKDAKQTDY A1 PRED EBNA3C LA PKD 12 
PSMPFASDY A1 PRED EBNA3C LA PSM 12 
ATDDSGHES A1 PRED LMP1 LA ATD 13 
LLALLFWLY A1 PRED LMP1 LA LLAL 13 
LLVLGIWIY A1 PRED LMP1 LA LLVL 13 
PHGPVQLSY A1 PRED LMP1 LA PHG 13 
CLPVIVAPY A1 PRED LMP2 LA CLP 14 
LLAAVASSY A1 PRED LMP2 LA LLAA 14 
MLVLLILAY A1 PRED LMP2 LA MLV 14 
SEERPPTPY A1 PRED LMP2 LA SEE 14 
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4.2.4 ELISPOTs 
EBV-specific CTL response were investigated in BD-PBMCs with and without 
stimulation with LCLs using IFN-γ ELISPOT analysis (Figure 4.1). 
 
Figure 4-1 Flowchart of experiments performed in Chapter 4 
CTL responses in HLA-A*01:01 homozygotes and HLA-A*01:01/A*02:01 heterozygotes, either 
with prior stimulation by LCLs or with no prior stimulation; full details given in text.  
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In the first set of experiments, donor BD-PBMCs, prepared as in Section 2.3.3.2, 
were exposed to either test peptides (in pools) or positive and negative controls. 
BD-PBMCs (100 µl at 3 x 106 cells / ml) were exposed to peptides at a final 
concentration in the well of 10 µg/ml. All assays were performed in duplicate. 
ELISPOTS were performed as described in Section 2.8; in these experiments, 
overnight exposure to peptide or control was the only stimulation.  
Plates were read and counted as described (Section 2.8.2). All individual wells 
were visually inspected at time of plate reading. All plates were reviewed by 
myself, and then by Prof. Ruth Jarrett and Dr. Karen McAulay. Any donor where 
the positive controls did not elicit a clear detectable CTL response was 
excluded. Plates where the SFC for the positive controls did not exceed the 
mean of the highest negative control plus one SD were also removed from the 
analysis. Plates with excessive background reactivity, defined as a response 
detectable in either of the negative controls, were excluded. ELISPOTs satisfying 
these QC criteria were included in the analysis. To maximise sensitivity in 
detecting any response, the highest mean negative control plus 1 SD was taken 
as the cut-off for a “positive” response. 
In the second set of experiments, responses were examined following 
stimulation of donor BD-PBMCs with irradiated autologous LCLs at day 0 and 
irradiated 721.221 cells, a HLA class I-deficient LCL transduced to express only a 
single class I HLA allele (courtesy Prof Trowsdale, University of Cambridge, 
Section 2.4.4), at day 10. In the case of HLA-A*01:01 homozygotes, day 10 
stimulation was with HLA-A*01:01 expressing 721.221 cells and, in the case of 
HLA-A*02:01/A*01:01 heterozygotes, the culture was split at day 10 and 
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stimulated with either HLA-A*01:01 expressing or A*02:01 expressing 721.221 
cells. At day 16, the stimulated BD-PBMCs were subjected to ELISPOT analysis. 
4.2.4.1 PBMC Stimulation - Day 0  
Autologous LCLs (Section 2.4.6) were counted, washed and re-suspended in 20% 
CCM at a concentration of 1 x 106 cells / ml. These were placed in a 25 cm3 
flask, and the lid was replaced and sealed with Parafilm. 
The cell in these flasks were irradiated at 4000 rad (40Gy) using the RS225 high-
voltage irradiator (Xstrahl Ltd, UK), courtesy of Prof. Anthony Chalmers, Beatson 
Institute of Cancer Research, Glasgow. 
BD-PBMCs (1 – 2 x 107 cells) were thawed as described in Section 2.4.3. Viable 
cells were counted (Section 2.3.4), washed and re-suspended in 20% CCM at a 
density of  4 x 106 cells / ml. Aliquots of 2 x 106 cells (500 µl) were dispensed 
into each well of a 48-well plate. Irradiated LCLs (5 x 104 cells in 50 µl) were 
added to each well giving an effector: stimulator ratio of 40:1.  The cells were 
incubated at 37oC in 5% CO2 for 10 days.  
4.2.4.2 PBMC Stimulation - Day 10  
721.221 cells expressing HLA-A*01:01 or HLA-A*02:01 were prepared as described 
in Section 2.4.4. Cells were counted, washed and re-suspended in 20% CCM at a 
concentration of 1 x 106 cells / ml in 25 cm3 flasks. The cells in these flasks were 
irradiated at 4000 rad (40Gy) as above. 
Supernatant (50 µl) was removed from each of the wells of the 48-well plate 
described in Section 2.9. These were frozen at -70oC in screw-cap tubes for later 
use. The stimulated cultures from the wells in the 48-well plate were pooled and 
 Chapter 4: HLA-A*01:01-restricted responses to EBV 
227 
 
counted. A volume containing at least 1 x 105 cells was removed for flow 
cytometry. The remainder was re-suspended and combined with the irradiated 
721.221 LCLs expressing HLA-A*01:01 or HLA-A*02:01 at a ratio of 4:1 (e.g. 4 x 
106 cells from the stimulated cultures: 1 x 106 irradiated 721.221 A01 cells).  IL-2 
(Gibco, Invitrogen Ltd., UK) was then added to a final concentration of 20 IU/ 
ml. The combined cell suspension was aliquoted into wells of a 48-well plate 
(500 µl per well, number of wells determined by number of cells retrieved from 
the stimulated cultures) and incubated at 37oC in 5% CO2 for a further 6 days.  
4.2.4.3 Day 16: Cell harvest 
Supernatant (50 µl) was removed from each of the wells of the 48-well plate. 
These were frozen in screw-cap tubes at -70oC for later use. The cell cultures in 
the wells were pooled and a viable cell count performed. A volume containing at 
least 1 x 105 cells was removed for flow cytometry. The cells were washed and 
re-suspended in CCM at a concentration of 1.5 x 106 cells / ml for use in 
ELISPOTs. 
4.2.4.4 ELISPOTS using stimulated BD-PBMCs 
ELISPOTs were set up as in Section 2.8. In addition to the pools of A*01:01 
predicted peptides and the appropriate positive and negative controls, wells 
were set up with either HLA-A*01:01 or HLA-A*02:01 expressing 721.221 cells at 
a ratio of 8:1 (PBMC:LCL), and with autologous LCLs at ratio of 8:1 (PBMC:LCL). 
The LCLs did not require to be irradiated for this short incubation. The ELISPOTs 
were then performed as previously described in Section 2.8.1, with the 
difference that due to limitation in available cell number, PBMCs were plated at 
1.5 x 105 cells / well. At the end of the 24 hour incubation (prior to development 
 Chapter 4: HLA-A*01:01-restricted responses to EBV 
228 
 
of the ELISPOT), supernatants (50 µl) were collected from each well and stored 
at -70oC for later use. QC of the ELISPOTS was as described. 
4.2.4.5 Flow cytometry on Day 10 and Day 16 stimulated cell 
cultures 
In order to determine the characteristics of the stimulated cell cultures, flow 
cytometry (Section 2.5) for CD3/CD20, CD16/CD56/CD3, CD3/HLA-DR and 
CD4/CD8/CD3 was performed on the samples from the day 10 and day 16 
stimulated cell cultures.  
4.2.5 Cytokine analysis 
In exploratory analyses, supernatants from the cultures were sampled at day 10 
and day 16 to assess cytokine secretion in response to stimulation with EBV-
infected LCLs. Analysis of TNF-α, IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 and IL-
17 was performed using a multiplex assay as described in Chapter 3 using the 
Human VersaMAP Multiplex Development System 9 Plex kit (R&D Systems) and 
read using the Bioplex system Luminex 100 plate reader (Bio-Rad). Calibration 
controls used to create the standard curve, and positive controls for beads and 
analytes were supplied with the kit. Cytokine levels are given in pg/ml. 
TGF-β cannot be measured in the multiplex assay as the cytokine requires ex-
vivo acid activation before it can be measured. TGF-β was assayed using an 
enzyme-linked immune assay (ELISA) kit (E-bioscience, UK). The supernatants 
from the same donors and stimulations as used in the multiplex assay were 
analysed. Samples were diluted 1:10 with the provided assay buffer as per kit 
instructions (180 μl assay buffer (1x) and 20 μl sample). Samples were then acid 
activated by the addition of 20 μl 1N hydrochloric acid (HCl) to the 200 μl of 
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diluted sample, and incubated for 1 hour at RT. Neutralisation was achieved by 
the addition of 20 μl 1N NaOH (sodium hydroxide). The result of the dilution and 
acid-activation steps was a 1:12 dilution of the samples. Samples were then 
added in duplicate to the microwell plate and the ELISA performed as per kit 
instructions. The plates were read on a colourimetric plate reader at 450 nm. 
Standards for creation of a standard curve were included with the kit.   
4.2.5.1 Statistical Analysis 
Cytokine levels were compared using an independent samples 2-tailed t-test 
analysis; Mann-Whitney analysis was not possible due to the presence of < 3 
samples in some of the groups. Equal variances were not assumed. A p-value of < 
0.05 is taken as significant. Correction for multiple testing was not performed. 
Cytokine levels in the following samples were compared: 
 Day 10 culture supernatants from HLA-A*02:01/A*01:01 heterozygotes and 
HLA-A*01:01 homozygotes 
 Day 16 culture supernatants from HLA-A*01:01 homozygotes stimulated 
with A*01:01 expressing 721.221 LCLs and HLA-A*01:01/A*02:01 
heterozygotes stimulated with A*01:01 expressing 721.221 LCLs 
 Day 16 culture supernatants from HLA-A*01:01 homozygotes stimulated 
with A*01:01 expressing 721.221 LCLs and HLA-A*01:01/A*02:01 
heterozygotes stimulated with A*02:01 expressing 721.221 LCLs 
 Day 16 culture supernatants from all those stimulations performed with 
A*01:01 expressing 721.221 LCLs and those performed with A*02:01 
expressing 721.221 LCLs (remembering that all donors used in this 
experiment carried at least 1 copy of HLA-A*01:01). 
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4.3  Results 
4.3.1 Flow Cytometry 
The characteristics of the cells present in the stimulated cell cultures at day 10 
and day 16 were analysed by flow cytometry.  CD16 and CD56 expression was 
analysed to assess presence of NK cells. Events positive for CD16 and CD56 were 
counted and given as a percentage of forward scatter/side scatter-gated events. 
The gate was set to include viable cells and exclude the cellular debris seen 
following stimulation which renders interpretation of ungated events difficult. 
The gate was the same for all analyses performed. In all donors, a CD16/CD56 
co-marking population was present at day 10 (median 2.05%, range 0.9% - 16.5%) 
and at day 16 (median 6.35%, range 1.9% - 12.5%). 
T cell activation, as demonstrated by the proportion of CD3-positive cells also 
positive for HLA-DR, increased following stimulation with LCLs from a median of 
4.8% at day 0 to a median of 65.3% at day 16. This is demonstrated in Figure 4.2. 
There was an increase in the proportion of CD8 T cells present in the cultures 
following stimulation. This is demonstrated in Figure 4.3.  
In all cases, the stimulated cell cultures contained populations of cells 
associated with antigen presentation (e.g. NK cells, monocytes) and cell-
mediated immune response (CD4 and CD8 T cells) (data not shown). 
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Figure 4-2 Activation of CD3 positive T cells following stimulation. 
Activation demonstrated percentage of CD3-positive events also positive for HLA-DR. Events 
in the forward-scatter/side-scatter gate defined in Section 4.3.1 were counted. Error bars 
demonstrate mean and S.E.M. 
 
Figure 4-3 Proportion of CD8-positive T cells following stimulation. 
The percentage of CD8-positive events is given. Events in the lymphocyte gate counted only. 
Error bars demonstrate mean and S.E.M. 
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4.3.2 ELISPOTS with no prior stimulation 
In the ELISPOTs using unstimulated PBMC, plates from 10 donors passed QC 
criteria, as detailed in Table 4.1. The ELISPOT from donor p10288 was rejected 
on the basis of high background counts in the negative control wells.   
Responses to positive controls or HLA-A*01:01-restricted CMV and influenza 
peptides were present in all of the donors. No response to any of the predicted 
HLA-A*01:01-restricted EBV peptides was detected in any of the 10 donors. 
4.3.3 Stimulated ELISPOTS 
ELISPOTs using stimulated cells were analysable for 3 of 11 HLA-A*01:01 
homozygous donors (p10534, p10116 and p10288). Two ELISPOTS were excluded 
on the basis of lack of response in the positive control wells (p10494 and p10498) 
and five because of high background counts in the negative control wells 
(p10553, p10568, p10569, p10613 and p10616). For one donor (p10504), an LCL 
could not be raised, and thus it was not possible to perform stimulation.  
ELISPOTs from five donors were included in the analysis. In the three analysable 
ELISPOTS from homozygous donors, responses to positive controls or HLA-
A*01:01-restricted CMV and influenza peptides were detected. No response to 
any of the HLA-A*01:01-restricted EBV peptides was detected. The two ELISPOTS 
from HLA-A*01:01/ A*02:01 heterozygotes demonstrated positive responses to 
positive controls or HLA-A*01:01-restricted CMV and influenza peptides. In the 
heterozygotes, responses to HLA-A*02:01-restricted EBV peptides, but not HLA-
A*01:01-restricted EBV peptides, were detected.  
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The three homozygous donors mounted strong responses to their autologous EBV-
infected LCL. This is a well-recognised phenomenon. Only one of the three 
donors generated a response to the A*01:01-restricted 721.221 cell line. The lack 
of a response in two of the three donors suggests lack of EBV antigen 
presentation via HLA-A*01:01. The response seen in the third donor could be an 
HLA-A*01:01-restricted EBV response, or an allogeneic response to minor 
histocompatibility antigens on the 721.221 cells. The strong responses to the 
autologous LCL but weaker responses to the HLA-A*01:01 expressing 722.221 
LCLs support the hypothesis that class I HLA alleles other than HLA-A*01:01 are 
driving the EBV-specific CTL response. 
The HLA-A*02:01/A*01:01 heterozygotes demonstrated strong ELISPOT responses 
to their autologous EBV-infected LCL and to the HLA-A*02:01 expressing 721.221 
LCL, but only weak responses to the HLA-A*01:01 expressing 722.221 LCLs. 
4.3.4 Cytokine responses   
As described in Section 4.2.5, in an exploratory analysis, supernatants from the 
stimulations were collected at day 10 and day 16, and analysis of TNF-α, IFN-γ, 
IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 and IL-17 performed using a multiplex assay.  
Results of the stimulations at day 10 are presented in Figure 4.4 and Table 4.5. 
Results of the stimulations at day 16 are presented in Figure 4.5 and Tables 4.6 
and 4.7.  
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Figure 4-4 Levels of cytokine at day 10 of stimulation  
a) TNF-α, b) IFN-γ, c) IL-2, d) IL-4, e) IL-5, f) IL-6, g) IL-10 and h) IL17. Concentrations are in 
pg/ml. Bars represent the mean. Statistical analyses of these data are presented in Table 
4.5. Note IL-12 is omitted as this cytokine was not detected in any sample. 
 
 
a) b) 
c) d) 
e) f) 
g) h) 
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Table 4-5 Levels of cytokine at day 10 of stimulation 
  
  
Cytokine 
HLA Group p-value of 
comparison 
between 
groups * 
HLA-A*01:01/ A*01:01 
homozygotes 
HLA-A*02:01/ A*01:01 
heterozygotes 
Mean (pg/ml) SD Mean (pg/ml) SD 
TNF-α 384.48 270.04 191.66 174.36 0.320 
IFN-γ 277.38 342.07 136.78 139.83 0.390 
IL-2 143.59 52.70 109.23 34.41 0.359 
IL-4 † 14.67 16.11 5.22 NA* NR 
IL-5 13.99 27.80 27.84 4.55 0.170 
IL-6 3519.88 1747.82 395.01 368.83 0.001 
IL-10 2.65 1.14 1.22 0.20 0.004 
IL-17 ‡ 17.64 32.11 16.11 16.90 0.737 
IL-12 p70 § ND ND ND ND ND 
Mean cytokine levels are shown along with SD  
NR, not detectable 
† IL-4 7/12 samples had levels below the dynamic range of the assay 
‡ IL-17 3/12 samples had levels below the dynamic range of the assay  
§ IL-12 12/12 samples had levels below the dynamic range of the assay 
* Independent samples t-test, equal variances not assumed, comparisons not performed for 
IL-4 and IL-12 as invalid given missing results. p-values given to 3 decimal places, a p-value 
of < 0.05 is considered significant (highlighted in blue) 
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Figure 4-5 Levels of cytokine at day 16 of stimulation 
a) TNF-α, b) IFN-γ, c) IL-2, d) IL-5, e) IL-6, f) IL-10 and g) IL-17.  Groups are I) HLA-A*01:01 
homozygotes vs. A*01:01 expressing 721.221 LCLs, II) HLA-A*01:01/A*02:01 heterozygotes vs. 
A*01:01 expressing 721.221 LCLs and III) HLA-A*01:01/A*02:01 heterozygotes vs. A*02:01 
expressing 721.221 LCLs. Concentrations are in pg/ml. Bars represent the mean. Statistical 
analyses of these data are presented in Table 4.7. Note IL-4 and IL-12 are omitted due to 
levels below the dynamic range of the assay. 
 
a) b) 
c) d) 
e) f) 
g) 
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Table 4-6 Levels of cytokine at day 16 of stimulation 
  
  
Cytokine 
HLA Group 
HLA-A*01:01/ A*01:01 
homozygotes 
HLA-A*02:01/ A*01:01 
heterozygotes, A*01:01 
stimulation  
HLA-A*02:01/ A*01:01 
heterozygotes, A*02:01 
stimulation 
Mean 
(pg/ml) SD 
Mean 
(pg/ml) SD 
Mean 
(pg/ml) 
SD 
TNF-α 28.46 16.43 198.21 225.77 136.98 114.13 
IFN-γ 180.49 191.30 110.84 23.30 116.68 108.38 
IL-2 2266.05 1496.52 502.88 137.12 206.18 7.89 
IL-5 14.64 26.52 75.38 18.99 90.03 1.74 
IL-6 636.95 830.52 286.98 324.95 62.17 17.78 
IL-10 1.78 2.33 1.20 0.34 0.86 0.05 
IL-17† 8.42 10.38 1.25 ND ND ND 
IL-4‡ 23.86 10.99 ND ND ND ND 
IL-12 p70§ ND ND ND ND ND ND 
Mean cytokine levels are shown along with SD  
ND, not detectable 
† IL-17 9/14 samples had levels below the dynamic range of the assay 
‡ IL-4 5/10 HLA-*01:01 homozygote and 4/4 HLA-A*02:01/A*01:01 heterozygote samples had 
levels below the dynamic range of the assay 
§ IL-12 14/14 samples had levels below the dynamic range of the assay 
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Table 4-7 Statistical analysis of cytokine levels at day 16 of stimulation  
Cytokine 
HLA-A*01:01/ A*01:01 
homozygotes vs. HLA-
A*02:01/ A*01:01 
heterozygotes 
stimulated with A*01 
expressing 721.221 
LCLs 
HLA-A*01:01/ A*01:01 
homozygotes vs. HLA-
A*02:01/ A*01:01 
heterozygotes 
stimulated with A*02 
expressing 721.221 
LCLs 
All stimulations with 
A*01 expressing 
721.221 LCLs vs. All 
stimulations with A*02 
expressing 721.221 
LCLs 
p-value  p-value p-value 
IL-10 0.472 0.241 0.204 
IL-2 0.367 0.056 0.040 
IFN-γ 0.284 0.184 0.165 
IL-5 0.002 0.005 0.009 
TNF-α 0.480 0.406 0.493 
IL-6 0.293 0.568 0.626 
* Independent samples t-test, equal variances not assumed, comparisons not performed for 
IL-4, IL-12 or IL-17 as invalid given missing results. P-values given to 3 decimal places, a p-
value of < 0.05 is considered significant (highlighted in blue). 
 
4.3.4.1 Summary of cytokine responses to stimulation 
At day 10, HLA A*01:01 homozygotes produced almost 10-fold higher levels of IL-
6 than HLA-A*01:01/A*02:01 heterozygotes (mean 3519 vs. 395 pg/ml p = 0.001). 
Levels of IL-10 were marginally higher in HLA A*01:01 homozygotes; however, 
the levels in both groups were extremely low (< 5pg/ml), and the higher mean in 
the A*01:01 homozygotes was most likely due to two outliers (see Figure 4.4). 
The IL-10 results are therefore not regarded as biologically significant. There 
were no significant differences in any of the other cytokines examined. At day 
16, although IL-6 levels had fallen from the day 10 levels, higher levels 
continued to be observed in the HLA-A*01:01 homozygotes, although differences 
were no longer statistically significant. 
At day 16, HLA-A*01:01 homozygotes demonstrated lower levels of secretion of 
IL-5 as compared with HLA-A*01:01/A*02:01 heterozygotes stimulated with 
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either A*01 expressing 721.221 LCLs (14.64 pg/ml vs. 75.38 pg/ml, p = 0.002) or 
A*02 expressing 721.221 LCLs (14.64 pg/ml vs. 90.03 pg/ml, p = 0.005). In 
addition, levels of IL-5 were lower in all stimulations of HLA-A*01 carriers 
performed with A*01 expressing 721.221 LCLs vs. those performed with A*02 
expressing 721.221 LCLs (24.76 pg/ml vs. 90.03 pg/ml, p = 0.009).  
Higher levels of IL-2 were seen at day 16 compared with day 10, as would be 
expected given that IL-2 was added to the cultures. However, higher levels were 
seen in the stimulations of all HLA-A*01 carriers performed with A*01 expressing 
721.221 LCLs vs. those performed with A*02 expressing 721.221 LCLs (1972.19 
pg/ml vs. 206.18 pg/ml, p = 0.040) even although the same amount of IL-2 was 
added to all cultures. 
ELISA for TGF-β was performed as described in Section 4.2.5. TGF-β levels were 
below the dynamic range of the assay in 35 of the 36 samples tested, and 
comparisons between groups were not possible. This most probably resulted 
from the sample dilution, which was required to negate the presence of TGF-β in 
FBS in CCM. 
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4.4  Discussion 
In the present study we sought to determine whether HLA-A*01:01-restricted 
EBV-specific CTL responses could be detected. Using sensitive methodologies and 
a peptide prediction strategy, no HLA-A*01:01-restricted CTL responses to EBV 
were detected in this study. This lack of response was observed in unstimulated 
BD-PBMCs and also following stimulation using EBV-infected LCLs to boost low-
level memory-CD8 CTL responses.  
The lack of demonstrable HLA-A*01:01-restricted EBV-specific CTL response may 
in part explain the elevated risk of EBV+ve cHL associated with HLA-A*01:01.  
The increased disease risk associated with lack of an allele is perhaps surprising 
given that HLA-A*01:01-positive individuals should be able to present EBV 
peptides through 4 or 5 other class I alleles. However, this argument may be 
overly simplistic. The critical CTL response to EBV, which is reflected in disease 
risk, may be important at any stage from primary EBV infection to establishment 
of EBV+ve cHL. Although responses to EBV peptides restricted through at least 35 
other class I alleles, including 13 HLA-A, 19 HLA-B and 3 HLA-C alleles, have 
been reported, one could hypothesise that the response to those peptides 
presented in the latent infection in general, or the latency II programme in 
particular, are most important in the context of EBV+ve cHL; there, therefore, 
may not be the redundancy in response traditionally assumed. Responses to the 
latency II peptides are much more restricted in the range of HLA-types through 
which a response can be generated; to date, responses to these proteins have 
been reported only for 8 B-alleles, 7 A-alleles and no HLA-C alleles (Hislop et al, 
2007). In this context, lack of response through a single common allele (HLA-
A*01:01) may become more important.  
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One of the mysteries of the class I HLA-associated risks of EBV+ve cHL has been a 
consistent reporting of association with HLA-B*08 (as discussed in the 
Introduction), an allele that elicits immunodominant EBV responses. As HLA-
A*01:01 is in LD with HLA-B*08:01 (~50% of healthy HLA-A*01:01 carriers are 
B*08:01-positive, in-house data, unpublished), it has been intriguing that the 
strong responses expected through B*08:01 do not abrogate the risk associated 
with HLA-A*01:01. However, one of the most immunodominant CTL responses 
restricted through HLA-B*08:01, and to EBV in general, is to “RAKFKQLL”, a 
peptide from the EBV lytic cycle protein BZLF1. It may be significant that 
B*08:01 has been shown to present only one latency II peptide for recognition by 
the CTL immune response; an epitope derived from EBNA1 which is reported to 
have a high level of sequence polymorphism adversely affecting presentation for 
CTL recognition (Bell et al, 2008) . This supports the hypothesis that CTL 
immune response to the latency II peptides at time of EBV+ve cHL disease 
development may be biologically relevant. 
In a secondary analysis, cytokine excretion in response to stimulation with EBV 
was examined. This study is small and exploratory but the finding of different 
levels of cytokine secretion in response to stimulation with EBV-infected LCLs in 
HLA-A*01:01 homozygotes and HLA-A*01:01/A*02:01 heterozygotes is interesting  
HLA-A*01:01 homozygotes generated much higher levels of IL-6 than HLA-
A*01:01/A*02:01 heterozygotes following stimulation with autologous LCLs. IL-6 
is a cytokine with potent antiviral activity, and would therefore be hypothesised 
to be associated with better responses and lower risk of disease. However, as 
discussed in Chapter 1, IL-6 has been implicated in the pathogenesis of cHL and 
other B cell neoplasms. Elevated levels of IL-6 were described in identical twins 
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of cases of cHL compared with matched healthy controls (Cozen et al, 2004), 
and in pre-diagnosis samples from cases of cHL compared with healthy 
individuals (Gaiolla et al, 2011). Both IL-6 and the IL-6 receptor have been 
shown to be expressed in cHL cell lines and by HRS cells in primary tissue where 
it is thought to act as an autocrine growth factor (Jucker et al, 1991). Should 
HLA-A*01:01 stimulate IL-6 in response to EBV peptides, particularly the latency 
II expression profile expressed by the HRS cell, it is biologically plausible that 
this could lead to elevated risk of EBV+ve cHL. 
It should be pointed out that LCLs, particularly early-passage LCLs, are known to 
secrete IL-6 in response to EBV lytic peptides (Jones et al, 2007). The levels 
found in our study are in the range previously reported to be secreted by LCLs 
(Wroblewski et al, 2002). The LCLs used in our study were irradiated and 
therefore would be considered non-functional, and were washed before re-
suspension, such that any differences noted would be unlikely to be due to LCL 
activity. It is possible, however, that the higher levels observed may be due to 
differential cell kill of LCLs in the stimulations. This was not directly assessed 
and this caveat should be borne in mind in interpreting these results. 
Higher levels of IL-2 were also seen after 16 days of stimulation in A*01:01 
homozygotes. Previously known as T cell growth factor, IL-2 is a cytokine 
secreted by CD4 and CD8 T cells. IL-2 helps drive a Th1 cytokine antiviral 
response, including activating CTLs; in particular, IL-2 is crucial for recall 
responses by CD8 memory T cells. However, it has become clear in recent years 
that one of the main functions of IL-2 is to drive a CD25+ve Treg response, which 
may help limit autoimmunity (Malek, 2008). Treg cells have been implicated in 
the pathogenesis of EBV+ve cHL (Assis et al, 2010). In addition, STAT5 
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phosphorylation is one of the main downstream events following IL-2 signalling 
and phosphorylated STAT5 has been shown to be present at high levels in the 
nuclei of HRS cells (Hinz et al, 2002). IL-2 levels have been shown to be higher in 
cHL patients versus controls (Viviani et al, 1998). In a study of cytokine 
responses to viruses (Makedonas et al, 2010), some individuals were shown to 
secrete IL-2, rather than IFN-γ from CTLs in response to EBV peptides. The HLA 
type of the individuals concerned was not given, but it is interesting to speculate 
that this could be associated with class I HLA type. Given the drive towards a 
Treg response induced by IL-2, one might wonder that the higher levels of IL-2 
seen in HLA-A*01:01 homozygotes in response to EBV in this study might mean 
reduced EBV-specific immunity at time of initial infection, or at time of EBV+ve 
cHL cancer development.   
Lower levels of secretion of IL-5 were also seen in HLA-A*01:01 homozygotes in 
comparison to A*01:01/A*02:01 heterozygotes. IL-5 is one of the cytokines 
upstream in the JAK-STAT pathway (Murray, 2007), and is implicated in the 
proliferation and apoptosis resistance of HRS cells (Farrell & Jarrett, 2011). IL-5 
is also secreted by HRS cells (Teruya-Feldstein et al, 2000) and is important in 
driving the eosinophilia associated with the disease. Thus, the finding of lower 
levels in the group more at risk of developing EBV+ve cHL is more difficult to 
reconcile. This finding in the context of the cytokine responses seen in HLA-
A*02:01 carriers and in disease outcome is discussed further in Chapter 6. 
Differential cytokine secretion in response to viruses in individuals associated 
with class I HLA phenotypes has previously been described. The TNF-α, IL-6 and 
IL-1β responses to smallpox vaccination showed an associated with HLA-B 
phenotype (Ovsyannikova et al, 2011). In a study of responses to the measles 
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vaccine, HLA-A*01:01 was associated with lower levels of IFN-γ secretion 
(Ovsyannikova et al, 2005). The authors of these studies suggest that levels of 
cytokine secretion in response to stimulation by viruses may be controlled by 
HLA genes or genes in close LD to these alleles. Although HLA class I phenotype 
is associated primarily with CTL response, it may be that some of the inter-
individual variability seen with cytokines, many of which are implicated in 
autoimmune and malignant disease, is due to class I HLA phenotype. 
Whilst this study is too small to offer conclusive findings, it generates interesting 
hypotheses for testing in future research. The absence of a detectable IFN-γ CTL 
response to EBV restricted through HLA-A*01:01 may be important. The 
understanding of the stage in cHL oncogenesis at which class-I HLA-associated 
risk is operating is not clear, and these findings favour the idea that the critical 
response may be to latency II antigens.  
It is also possible to speculate that similar mechanisms may be operating in 
other EBV-associated malignancies, particularly those with HLA-class I 
associations. The most notable of these, NPC, is particularly associated with 
HLA-A*02:07 (Li et al, 2009b). In GWAS studies the association localises to the 
peptide binding groove of the HLA-A molecule (Tang et al, 2010) suggesting a 
critical role for the variable region and antigen presentation.  The mechanisms 
behind this association, the tissue tropism of this malignancy and why the HLA 
allele associated with risk should be different to EBV+ve cHL are currently 
unexplained. It is possible that lack of CTL response to critical stage-specific 
antigens or differential cytokine secretion may also underlie the HLA-associated 
risks of NPC, and this might merit further study. 
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Further studies into the risks associated with the different class I allotypes are 
merited, as are studies elucidating the immune response to the latency II 
programme of EBV. The cytokine profiles observed in response to stimulation 
with EBV are exploratory, but intriguing. Further studies are required to clarify 
these findings and to study the mechanisms involved.
   
 
 
Chapter 5.  Does class-I HLA phenotype influence 
outcome in Hodgkin lymphoma? 
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5.1  Introduction 
A high proportion of patients with cHL are cured with standard treatment; > 90% 
in early-stage disease and > 75% in advanced stage disease (Connors, 2005; 
Townsend & Linch, 2012). The ability to predict outcome is important so that 
those patients who will not be cured by standard first-line treatment approaches 
can be targeted for alternative management, and to avoid over-treatment (and 
the attendant toxicities) in those patients with good outcomes. Established 
prognostication tools (Lister et al, 1989; Hasenclever & Diehl, 1998) employ 
clinical features of the disease at presentation to predict outcome and whilst 
useful, have limitations. The IPS (Hasenclever & Diehl, 1998) was designed to 
predict outcome in advanced stage disease. It is not currently used to 
treatment-stratify in the UK as it is insufficient to accurately predict those 
extremely poor outcome patients who may require a different front-line 
approach. 
As a result, international efforts are focusing on finding and validating additional 
tools to refine and enhance current approaches to prognostication. Reinforcing 
the critical role of the immune system in the pathogenesis of cHL, discussed in 
the Introduction, it is note-worthy that the majority of the biologically-based 
prognostic approaches (“biomarkers”) use features which characterise the 
immune response to the disease. Such approaches include prognostication based 
on the tumour microenvironment including tumour-associated macrophages 
(Steidl et al, 2010a; Sanchez-Espiridion et al, 2012), CTLs and Tregs (Oudejans et 
al, 1997; Alvaro et al, 2005) and also the peripheral blood lymphocyte/ 
monocyte ratio (Porrata et al, 2011). Additional studies have examined the 
prognostic importance of cytokines including: TARC (Weihrauch et al, 2005); IL-
10 (Rautert et al, 2008) and combined cytokine profiles (Casasnovas et al, 2007).   
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EBV+ve cHL, in contrast to EBV-ve cHL, retains the ability to express class I HLA 
(Oudejans et al, 1996). As it is known that the risk of developing EBV+ve cHL is 
associated with class I HLA genotype, specifically the numbers of HLA-A*01:01 
and HLA-A*02:01 alleles (as discussed in Chapters 1, 3 and 4) and that class I HLA 
is involved in the presentation of EBV peptides for recognition by the cellular 
immune response, it follows that HLA may be important in determining the 
immune response to the disease and therefore affect clinical outcome.  
Previous studies, antedating modern HLA-typing techniques and treatment 
approaches identified certain HLA alleles as associated with clinical outcome in 
HL, as well as in NHL (Lu et al, 2011). In HL, the class II HLA allele DPB1*09:01 
was associated with significantly shorter duration of remission (Oza et al, 1994). 
Patients with the HLA-A1 antigen (now A*01) were identified as having greater 
chance of cure and reduced chance of death from HL (Hafez et al, 1985). 
Indeed, “survivor bias”, the inadvertent selection of survivors in early 
retrospective disease-association studies, identified both HLA-A 1 (now A*01) 
and B8 (now B*08) as particularly prevalent in long-term survivors of HL (Falk & 
Osoba, 1971).  
Given these associations, a pilot study was performed to examine the association 
of HLA-A*01:01 and A*02:01 with clinical outcome in a large cohort of patients 
with cHL. 
5.1.1 Aims & Objectives 
This study aimed to determine if HLA-A*01:01 and A*02:01 alleles are a factor in 
determining clinical outcome in EBV+ve cHL.   
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5.2  Methods 
5.2.1 Patient cohort 
Patients with cHL were collated from two previous studies: the Scotland and 
Newcastle Epidemiological Study of Hodgkin’s disease (SNEHD) (Jarrett et. al, 
Blood, 2005) and the “Investigation of the cause of Hodgkin lymphoma” (ITCH 
Study), an on-going study of patients principally from the West of Scotland. Both 
studies have ethical approval.  
Cases were selected on the basis of availability of tumour EBV status, a suitable 
sample for HLA typing and clinical follow-up data and included 269 cases from 
the SNEHD study and 155 from the IPHL (total n = 424).  
Clinical treatment decisions were made by individual physicians. HLA genotyping 
was performed as described in the Introduction to an intermediate resolution 
using allele-specific PCR (Gen-probe) and subsequent bead-based sequence 
specific oligonucleotide (SSO) assay (Luminex). Allele assignment was performed 
using Quicktype for Lifematch software (Gen-probe).   
Clinical follow-up data were obtained through clinical records, liaison with 
treating physicians, and the Scotland and Newcastle Lymphoma Group (SNLG) 
database. Where the patients resided in Scotland, additional follow-up data 
regarding vital status, date of death and cause of death were available from the 
Information Services Division (ISD), NHS National Services Scotland, Edinburgh, 
UK. This was requested for 131 cases where follow-up was less than 96 months 
or where cause of death was unknown. These data are derived from death 
certificate information and from the Community Health Index (a register of all 
patients in NHS Scotland). Data regarding relapse and progression were not 
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systematically recorded at the LRF Virus Centre and the current cancer registry 
systems in Scotland do not systematically collect data on relapse or progression. 
As a result, EFS was not included in the analysis. 
5.2.2 Statistical Analysis 
The outcome of main interest was survival in EBV+ve cases. EBV-ve cases and all 
cases together were analysed for comparison and DSS were analysed by number 
of HLA-A*01:01 alleles, number of HLA-A*02:01 alleles, and by the presence or 
absence of HLA-A*01:01 or HLA-A*02:01. Certain other factors e.g. age, sex, 
disease stage at presentation were analysed to enable comparison with other 
data sets and to exclude confounding. Statistical analyses used Kaplan-Meier 
estimates of survival; survival curves were compared using the log-rank test. A 
p-value of < 0.05 is considered as demonstrating significant survival differences.  
A Cox proportional hazard regression model was generated for analyses of OS 
and DSS with the association of the presence or absence of HLA-A*01:01 or HLA-
A*02:01, the number of HLA-A*01:01 alleles and the number of HLA-A*02:01 
alleles, following adjustment for histological subtype, clinical stage, age and 
sex. All analyses of histological subtype were restricted to NS and MC subtype. 
Hazard ratios are not reported due to the non-categorical nature of some of the 
variables. Two-sided p-values are reported. A p-value of < 0.05 is considered 
significant. All analyses were implemented using SPSS v.19. 
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5.3  Results 
5.3.1 Description of Cohort 
The analysis included 424 cases diagnosed between 1993 and 2008. The 
demographic make-up of the cases is summarised in Table 5.1. 137 cases (32.3%) 
had EBV+ve cHL. Median follow up was 92 months (range 1-226 months). As 
internationally defined (Section 1.4.1), 57.9% of patients had advanced stage 
disease. Histological subtype of disease was available for all 424 patients. 
Table 5-1 Characteristics of cases included in the analysis of clinical outcome 
 Cases (n = 424) Missing (n) 
Female, n (%) 191 (45.0) 0 
Age (median, range) 34 (15 -78) 1 
Age group, n (%) 
≤ 34 years 215 (50.8) See above 
35-49 years 92 (21.7) See above 
≥ 50 years 116 (27.4) See above 
Follow up in months (median, range) 92.0 (1-226) 0 
DEPCAT 5 (mean, range)† 3.35 (1-5) 129 
EBV+ve cHL, n (%) 137 (32.3%) 0 
 
Clinical Stage, n (%) 
I 55 (17.4) 
108 
II 135 (42.7) 
III 73 (23.1) 
IV 53 (16.8) 
B-symptoms, n (%) 138 (43.8) 109 
Advanced stage disease, n (%) 183 (57.9) 108 
Histological Sub-type, 
n (%) 
Nodular sclerosis 302 (71.2) 
0 
Mixed cellularity 95 (22.4) 
Lymphocyte rich 13 (3.1) 
Lymphocyte-depleted 2 (0.5) 
cHL, not otherwise 
specified 
12 (2.8) 
† DEPCAT (Carstairs deprivation category, defined in Section 2.3.1.4) 
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5.3.2 Survival Analysis 
5.3.2.1 Analysis of all cases – OS 
In the analysis of all cases, OS was worse with increasing age (p < 0.001) (Figure 
5.1) and with male sex (p = 0.039, Figure 5.2). Accepted prognostic criteria such 
as advanced clinical stage were predictive of poor survival in all cases (advanced 
stage vs. early stage disease, p = 0.033, Figure 5.3). In contrast, histological 
subtype (NS vs. MC cases) was not found to be predictive of OS (p = 0.469, Figure 
5.4). In unadjusted Kaplan-Meier analysis, EBV status of the cHL was predictive 
of OS with EBV+ve cHL being associated with poorer survival than EBV-ve disease 
(p = 0.016, Figure 5.5), although more EBV+ve disease was seen in the older 
adult group (50.9% of cases > 50 years having EBV+ve disease as compared to 
only 22.3% of those aged 34 years or less). There were no significant differences 
in OS by number or presence of HLA-A*02:01 and A*01:01 alleles (summarised in 
Table 5.2). 
Cox proportional hazard regression analysis of OS identified age (p < 0.001) and 
clinical stage (p = 0.005) independently associated with OS in all cases.  
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Figure 5-1 Overall survival in all cases by age group 
OS, overall survival. Cases are stratified by age group: ≤ 34 years old; 35-49 years old; and ≥ 
50 years old. 
 
Figure 5-2 Overall survival in all cases by sex 
OS, overall survival; F, female; M, male 
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Figure 5-3 Overall survival in all cases by clinical stage of disease 
OS, overall survival. Early vs. advanced stage disease shown. 
 
 
Figure 5-4 Overall survival in all cases by histological subtype of cHL 
OS, overall survival. Analysis restricted to mixed cellularity and nodular sclerosis subtypes. 
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Figure 5-5 Overall survival in all cases by EBV status of the cHL 
OS, overall survival 
Table 5-2 Unadjusted log-rank comparisons of overall and disease-specific Kaplan-
Meier estimates of survival in all cases by HLA-A*01:01 and HLA*02:01 genotype.     
Factor 
Overall survival 
Disease-specific 
survival 
p-value p-value 
Presence of an HLA-A*01:01 allele 0.556 0.071 
Number of HLA-A*01:01 alleles 0.792 0.158 
Presence of an HLA-A*02:01 allele 0.307 0.996 
Number of HLA-A*02:01 alleles 0.480 0.992 
P-values are from the log-rank comparisons of overall and disease-specific Kaplan-Meier 
estimates of survival by a single variable as stated. A p-value of < 0.05 is considered 
significant.  
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5.3.2.2 Analysis of all cases – disease-specific survival 
DSS was analysable for 358 of the 424 cases. Unadjusted log-rank comparison of 
Kaplan-Meier estimates of survival demonstrated that only advanced stage 
disease was associated with statistically significant poorer DSS (p = 0.001, Figure 
5.6), with the majority of deaths due to cHL occurring before 5 years. DSS was 
not associated with EBV status of the disease (p = 0.634, Figure 5.7). Histological 
subtype was not predictive of DSS (p = 0.967, data not shown). In the analysis of 
all cases, neither number nor presence of HLA-A*02:01 alleles was associated 
with DSS. In the analysis of all cases, improved DSS was seen in carriers of an 
HLA-A*01:01 allele, approaching statistical significance (p = 0.071) (Figure 5.8). 
Cox proportional hazard regression analysis of DSS in all cases identified only 
clinical stage (p = 0.006) as independently prognostic of outcome. 
 
Figure 5-6 Disease-specific survival in all cases by clinical stage 
DSS, disease-specific survival. Early vs. advanced stage disease shown. 
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Figure 5-7 Disease-specific survival in all cases by EBV status of the cHL 
DDS, disease-specific survival. 
 
 
Figure 5-8 Disease-specific survival in all cases by the presence or absence of an 
HLA-A*01:01 allele 
DSS, disease-specific survival. 
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5.3.2.3 Analysis of EBV-negative cases- OS  
Unadjusted log-rank comparison of Kaplan-Meier estimates of survival 
demonstrated that only increasing age group (p < 0.0001) and male sex (p = 
0.003) were associated with inferior OS in EBV-negative cases. Neither advanced 
stage (p = 0.32) nor histological subtype (p = 0.61) were associated with poorer 
OS in this group. Neither HLA-A*02:01 nor HLA-A*01:01 demonstrated any 
significant association with OS or DSS in EBV-negative cases (see Table 5.3.) 
Patients with EBV-ve cHL who had an HLA-A*02:01 allele had an improved OS and 
this difference approached statistical significance (p = 0.066, Figure 5.9). Cox 
proportional hazard regression analysis of OS in EBV-negative cases identified 
only age (p < 0.001) as independently prognostic. 
 
Table 5-3 Unadjusted log-rank comparisons of overall and disease-specific Kaplan-
Meier estimates of survival in EBV-negative cases by HLA-A*01:01 and HLA*02:01 
genotype.     
Factor 
Overall survival 
Disease-specific 
survival 
p-value p-value 
Presence of an HLA-A*01:01 allele 0.913 0.278 
Number of HLA-A*01:01 alleles 0.757 0.536 
Presence of an HLA-A*02:01 allele 0.066 0.239 
Number of HLA-A*02:01 alleles 0.181 0.496 
P-values are from the log-rank comparisons of overall and disease-specific Kaplan-Meier 
estimates of survival by a single variable as stated. A p-value of < 0.05 is considered 
significant.  
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Figure 5-9 Overall survival in EBV-negative cases by the presence or absence of the 
HLA-A*02:01 allele 
OS, overall survival. 
 
5.3.2.4 Analysis of EBV-negative cases- DSS  
Analysis of DSS in EBV-negative cases demonstrated that male sex (p = 0.003) 
and advanced stage disease (p = 0.023) were associated with poorer DSS (data 
not shown). Cox proportional hazard regression analysis of DSS in EBV-negative 
cases identified clinical stage (p = 0.014) as independently prognostic. 
5.3.2.5 Analysis of EBV-associated cases – OS 
HLA-A*02:01 carriers were under-represented in EBV+ve cases, 32.8% as 
compared with the 50.2% of EBV-negative cases (p = 0.001, by 2-sided Pearson 
CHI square analysis), as expected.  
EBV+ve cHL cases also demonstrated poorer OS with increasing age (p < 0.001), 
with no long term survivors in the older adult age group (Figure 5.10). Poorer 
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survival with advanced stage disease was also seen (p = 0.023, data not shown). 
There was no significant association with male sex or histological subtype and OS 
in EBV+ve cases.  
Inferior OS was observed with increasing number of HLA -A*02:01 alleles present 
(p = 0.017, Figure 5.11).  Patients with EBV+ve cHL who carried a copy of HLA-
A*02:01 demonstrated inferior OS which did not reach statistical significance (p = 
0.184, Figure 5.12). Data are summarised in Table 5.4.  
 
Figure 5-10 Overall survival in EBV-associated cases by age group 
OS, overall survival. Cases are stratified by ≤ 34 years old, 35-49 years old and ≥ 50 years 
old. 
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Figure 5-11 Overall survival in EBV-associated cases by number of A*02:01 alleles  
OS, overall survival. 
 
Figure 5-12 Overall survival in EBV-associated cases by presence or absence of an 
HLA-A*02:01 allele 
OS, overall survival 
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A previous preliminary analysis with shorter follow-up presented at ASH 2012 
(Farrell et al, 2012) demonstrated a significantly lower OS with the presence of 
HLA-A*02 (p = 0.04, Figure 5.13). The most likely reason for the loss of 
significance in the analysis with longer follow-up was a single death from 
cerebrovascular accident (stroke) at 192 months (> 16 years) from diagnosis in 
the HLA-A*02:01-negative group. 
 
Figure 5-13 Overall survival in EBV-associated cases by presence or absence of HLA-
A*02:01 in a prior analysis with shorter follow-up 
OS, overall survival. Data shown as presented at ASH 2012 (Farrell et al, 2012). These data 
included fewer cases (n = 385) with shorter follow-up compared to the present analysis. 
 
There was no statistically significant association between number of HLA-A*01:01 
alleles present and OS, although there was only one death in HLA-A*01:01 
homozygotes in the course of 192 months of follow up (91.7% OS at 192 months 
(n = 12), as compared with 61.8% in those with one HLA-A*01:01 allele (n = 43) or 
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58.1% in those with no HLA-A*01:01 allele (n = 78), Figure 5.14). Presence of an 
HLA-A*01:01 alleles was not significantly associated with OS in EBV+ve cHL. 
 
Figure 5-14 Overall survival in EBV-associated cases by number of HLA-A*01:01 
alleles  
OS, overall survival 
 
Cox proportional hazard regression analysis of OS in EBV-associated cases 
identified increasing age (p < 0.001), presence of HLA-A*02 (p = 0.010), and 
increasing number of HLA-A*02 alleles (p = 0.047) were independently associated 
with poorer OS. 
5.3.2.6 Analysis of EBV-associated cases – DSS 
Log-rank analysis of Kaplan-Meier estimates of DSS in EBV+ve cases (122 cases 
analysable) demonstrated reduced DSS with advanced stage disease (p = 0.007). 
Improved DSS was seen with fewer A*01:01 alleles, although this did not reach 
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statistical significance (p = 0.219, Figure 5.15). Patients with an A*02:01 allele (p 
= 0.088, Figure 5.16) or greater numbers of A*02:01 alleles (p = 0.200, Figure 
5.17) demonstrated poorer OS, although this did not reach statistical 
significance. In the Cox proportional hazard regression model of DSS in EBV+ve 
cases, only the presence of an HLA-A*02 allele was independently prognostic (p = 
0.039); advanced stage disease p = 0.769 in this model. 
 
Figure 5-15 Disease-specific survival in EBV-associated cases by number of HLA-
A*01:01 alleles  
DSS, disease-specific survival. 
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Figure 5-16 Disease-specific survival in EBV-associated cases by the presence or 
absence of the HLA-A*02:01 allele 
DSS, disease-specific survival. 
 
 
Figure 5-17 Disease-specific survival in EBV-associated cases by number of HLA-
A*02:01 alleles  
DSS, disease-specific survival 
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Table 5-4 Unadjusted log-rank comparisons of overall and disease-specific Kaplan-
Meier estimates of survival in EBV-associated cases by HLA-A*01:01 and HLA*02:01 
genotype.     
Factor 
Overall survival 
Disease-specific 
survival 
p-value p-value 
Presence of an HLA-A*01:01 allele 0.229 0.146 
Number of HLA-A*01:01 alleles 0.330 0.219 
Presence of an HLA-A*02:01 allele 0.184 0.088 
Number of HLA-A*02:01 alleles 0.017 0.200 
P-values are from the log-rank comparisons of overall and disease-specific Kaplan-Meier 
estimates of survival by a single variable as stated. A p-value of < 0.05 is considered 
significant (indicated in blue).  
 
5.3.3 Summary of Results 
In this study of 424 adults with cHL from Scotland and the North of England, the 
clinical variables of age, sex and clinical stage were confirmed as prognostic. 
Histologic subtype (i.e. MC or NS subtype), still regarded as important to some 
investigators and physicians, was not significantly associated with outcome in 
any analysis. In contrast, EBV-status of the cHL was predictive of OS in 
univariate analysis, but was not independent of age, due to the higher 
proportion of older adults with EBV+ve disease. DSS was not associated with EBV 
status of the disease, suggesting that causes of death other than cHL (e.g. other 
cancers) account for the excess overall mortality in EBV+ve cases. This may 
suggest that EBV positivity in older adult cHL is as a surrogate of immune 
competence, and merits further study. 
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The finding that HLA-A*02:01 was under-represented in EBV+ve cases as 
compared with EBV-ve cases supports the previously published finding that this 
allele is protective against developing EBV+ve cHL (Hjalgrim et al, 2010). 
Corroborating the findings of previous studies (Falk & Osoba, 1971; Hafez et al, 
1985), but in a study conducted in the modern era with PCR-based HLA typing 
and modern therapeutic interventions, improved DSS in carriers of HLA-A*01:01 
in all cases was observed.  
In the present study HLA-A*02:01 was associated with inferior overall and DSS in 
EBV+ve cHL. In adjusted Cox proportional hazard regression analysis of OS in 
EBV+ve cases, only increasing age, presence of HLA-A*02:01 and increasing 
number of HLA-A*02:01 alleles were independently prognostic of inferior 
survival, following adjustment for histological subtype, clinical stage, age and 
sex. 
In EBV-negative cases, the risk was in the opposite direction, with HLA-A*02:01 
being associated with improved OS, approaching statistical significance. 
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5.4  Discussion  
As HLA-A*02:01 is protective for developing EBV+ve cHL, we hypothesise that 
EBV+ve cHL arising in this 'protected' group is associated with greater biological 
or immunological dysfunction, resulting in poorer survival outcomes associated 
with HLA-A*02:01.  
The non-significant association of HLA-A*01:01 with improved DSS in all cases 
supports previous studies, but is currently unexplained. Risk of disease 
development in these patients may be due more to poor immune control 
associated with HLA-A*01:01 (see Chapters 3 and 4) and not to other factors, so 
one might expect a better response to treatment. 
Given the extremely poor outcomes seen in this study in HLA-A*02:01 carriers 
with EBV+ve disease (61.7% 10-year OS), it is possible that this group of patients 
is not currently being well-served by standard first-line therapy. HLA-A genotype 
may be helpful in identifying groups of patients who have inferior outcomes 
using standard therapy and may benefit from novel or cellular therapies.  
Given the differences in survival observed by EBV status of disease, and the 
effect of HLA on survival in EBV-stratified cohorts of patients, this study supports 
the importance of stratifying cHL cases by EBV status in future clinical studies. 
Although larger (n=424) than previously published studies of survival by HLA type 
in cHL (n = 52) (Hafez et al, 1985), DLBCL (n = 166) (Lu et al, 2011) or FL (n = 
165) (Lu et al, 2011), I should emphasise that the conclusions drawn on survival 
in EBV+ve cases are based on analysis of the 137 patients with EBV+ve cHL 
included in the study. These numbers are small in comparison to the clinical 
studies used to generate prognostic scores e.g. of the 5141 patients included in 
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the IPS study (Hasenclever & Diehl, 1998) one would expect approximately 1700 
EBV +ve cases, although it is noteworthy that EBV status was not included in the 
analyses in this paper. For this reason, larger studies within the context of 
clinical trials are required to extend these findings. It is hoped that the future 
research of the group will enable the analysis of survival by HLA in large 
prospective national clinical studies, in order that any differentials in outcome 
can be translated into clinical benefit for patients. 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6.  General Discussion  
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6.1  Introduction 
Over the last two decades, our knowledge of the pathophysiology of cHL has 
increased exponentially, improving our understanding of this heterogeneous 
disease. Epidemiological, molecular, microenvironmental and genetic findings 
are increasing our understanding of why some individuals develop cHL. Precisely 
how a ubiquitous virus such as EBV causes cHL in a minority of immune 
competent hosts remains an open question, although HLA type and the CTL 
response are likely to be central in this.  
Clinical developments mean that the vast majority of patients with cHL are now 
cured of their disease; however, late toxicities of therapy remain a significant 
cause of morbidity in survivors. In addition, whilst the majority are cured, 
approximately 15-20% of patients, many of whom are young adults, will die of 
their disease. Clinicians treating this disease recognise that some cHL behaves in 
a more recalcitrant manner, proving stubborn in the face of intensive therapy. 
Much remains to be done to improve outcomes for this group. 
The work of this thesis set out to address a number of specific questions 
regarding the role of HLA class I in the aetiology and clinical outcome of cHL. 
This Chapter summarises these findings and discusses the implications that this 
may have for further research in this area. 
6.2  Does the presence of an HLA-A*01:01 allele modify 
the magnitude of the CTL response to HLA-A*02:01-
restricted epitopes?  
Our findings suggest that overall HLA-A phenotype does not significantly affect 
the EBV-specific CTL response restricted through HLA-A*02:01. It was 
demonstrated that responses in HLA A*02:01/ A*x heterozygotes were greater 
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than in the other groups studied but these findings had to be disregarded for 
reasons of confounding, and adjusted analysis was not possible. In valid 
comparisons between HLA-A*02:01/A*01:01 heterozygotes and HLA-A*02:01 
homozygotes, no differences in CTL response as assessed by ELISPOT, CTL 
degranulation and IFN-γ secretion were demonstrated.   
Greater EBV CTL responses were observed in samples from female donors and 
with shorter time-to-processing. Differences by sex have not previously been 
reported with regard to EBV responses, but may go some way to explaining the 
higher prevalence of EBV-associated malignancies in men as compared with 
women. In addition, this finding has potential implications for biological and 
clinical studies examining the EBV-specific CTL response. If this study was to be 
repeated or extended in the future, it could be suggested that groups should be 
matched for sex, or restricted to one sex, and should include only samples 
processed on the same day as collection.  
The primary experimental question “Does the presence of an HLA-A*01:01 allele 
modify the magnitude of the CTL response to HLA-A*02:01-restricted epitopes?” 
was partly answered. Exploratory analysis of cytokine levels in response to 
stimulation with EBV peptides demonstrated significantly higher secretion of IL-
10 (with a nearly 10-fold difference), IL-17 and IL-5 in response to stimulation 
with EBV peptides in HLA-A*02:01/A*01:01 heterozygotes, compared to other 
HLA-A*02:01 carriers. This suggests a possible effect of HLA-A*01:01 which might 
begin to explain some of the HLA-associated differences in risk of developing 
EBV+ve cHL. It is possible that HLA-A*01:01 is associated with an inhibitory 
immune response in the face of EBV, either directly, or through LD with genes in 
the extended MHC encoding involved in the cytokine response. Although this 
  Chapter 6: Discussion 
273 
 
study was small and exploratory, the magnitude of the differences observed, 
particularly for IL-10, is provocative and warrants further investigation. 
6.3  Can any HLA-A*01:01-restricted EBV-specific CTL 
responses be detected or are any inhibitory cytokine 
responses detected?  
Using sensitive methodologies and a peptide prediction strategy, no HLA-
A*01:01-restricted CTL responses to EBV were detected in this study. This lack of 
response was observed in unstimulated BD-PBMCs and also following stimulation 
using EBV-infected LCLs to boost low-level memory-CD8 CTL responses.  
The lack of demonstrable HLA-A*01:01-restricted EBV-specific IFN-γ CTL 
response may in part explain the elevated risk of EBV+ve cHL associated with 
HLA-A*01:01.  
The critical CTL response to EBV, which is reflected in disease risk, may be 
important at any stage from primary EBV infection to establishment of EBV+ve 
cHL. However, one could hypothesise that the response to those peptides 
presented in the latency II programme are most important in the context of 
EBV+ve cHL. Our findings favour the idea that the critical response may be to 
latency II antigens. Responses to the latency II peptides are much more 
restricted in the range of HLA-types through which a response can be generated. 
In this context, lack of response through a single common allele (HLA-A*01:01) 
may become more important. Further studies elucidating the class I-restricted 
immune response to the latency II programme of EBV are merited. 
In the analysis of cytokine excretion in response to stimulation with EBV-infected 
LCLs in HLA-A*01:01 homozygotes and HLA-A*01:01/A*02:01 heterozygotes, 
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differences in levels of cytokine secretion were demonstrated. HLA-A*01:01 
homozygotes generated much higher levels of IL-6, a cytokine implicated in the 
pathogenesis of cHL, than HLA-A*01:01/A*02:01 heterozygotes following 
stimulation with autologous LCLs. Higher levels of IL-2 were also seen after 16 
days of stimulation in A*01:01 homozygotes. IL-2 is known to drive a Treg 
response, thus higher levels may contribute to a dampening of EBV-specific 
immunity contributing to development of cHL.  
Lower levels of secretion of IL-5 were also seen in HLA-A*01:01 homozygotes in 
comparison to A*01:01/A*02:01 heterozygotes. At first this is more difficult to 
explain as IL-5 is implicated in the proliferation and apoptosis resistance of HRS 
cells. However, in the context of the improved DSS seen in carriers of HLA-
A*01:01 (Chapter 5), this begins to make sense as lower levels in this group may 
suggest lower proliferation and increased apoptosis of the HRS cells. Functional 
studies to explore this should be performed.   
Whilst this study is small and exploratory, the cytokine profiles observed in 
response to stimulation with EBV are intriguing. Differential cytokine secretion 
in response to other viruses by class I HLA phenotypes has previously been 
described, although the mechanisms involved have not yet been explained. 
Further studies should be performed to validate these findings and to study the 
means by which this operates. 
6.4  Are HLA-A*01:01 and A*02:01 alleles a factor in 
determining clinical outcome in EBV+ve cHL?  
In this study of 424 adults with cHL from Scotland and the North of England, we 
demonstrated that HLA-A*01:01 and A*02:01 are factors in determining clinical 
outcome in cHL. 
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Corroborating the findings of studies performed in a previous era, improved DSS 
in all cases of cHL (EBV+ve and EBV-ve) was observed in carriers of HLA-A*01:01. 
Despite being reported now in a number of studies, this finding is currently 
unexplained. Risk of disease development in these patients may be due solely or 
predominantly to poor immune control associated with HLA-A*01:01 (see 
Chapters 3 and 4) in the absence of other risk factors, and therefore one might 
expect a better response to treatment. Alternatively, these results might 
suggest a more important role of class I HLA in the tumour microenvironment 
than is currently presumed. 
In the present study HLA-A*02:01 was associated with inferior OS and DSS in 
EBV+ve cHL. In adjusted analysis of OS, only increasing age, presence of HLA-
A*02:01 and increasing number of HLA-A*02:01 alleles were independently 
prognostic of inferior survival. As HLA-A*02:01 is protective for developing 
EBV+ve cHL, we hypothesise that EBV+ve cHL arising in this 'protected' group is 
associated with greater biological or immunological dysfunction, resulting in 
poorer survival outcomes associated with HLA-A*02:01.  
Given the extremely poor outcomes seen in this study in HLA-A*02:01 carriers 
with EBV+ve disease (61.7% 10-year OS), it is possible that this group of patients 
is not currently being well-served by standard first-line therapy. HLA-A genotype 
may be helpful in identifying groups of patients who have inferior outcomes 
using standard therapy and may benefit from novel or cellular therapies.  
Although larger than all previously published studies of survival by HLA type in 
lymphoma, at 424 patients, these conclusions are based on analysis of only the 
137 patients with EBV+ve cHL. These numbers are small in comparison to the 
clinical studies used to generate prognostic scores, e.g. the 5141 patients 
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included in the IPS study (Hasenclever & Diehl, 1998), although it is noteworthy 
that EBV status was not included in the analyses performed by this group. For 
this reason, larger studies within the context of clinical trials are required to 
extend these findings. It is hoped that the future research of the group will 
include the analysis of survival by HLA in the large prospective UK national 
clinical studies (e.g. NCRI RAPID and RATHL, discussed in Chapter 1) which have 
recently completed recruitment.  If studies of outcomes in such large 
prospective trials confirm differential outcome by HLA-type, this could generate 
hypotheses for targeting of therapy which could be translated into clinical 
benefit for patients. 
6.5  Concluding Remarks 
The work of this thesis sheds further light on the central questions which remain 
at the heart of cHL research, namely, why do some people develop EBV+ve cHL, 
and why do some patients continue to die of their disease when the majority are 
cured.  
A lack of a detectable HLA-A*01:01-restricted EBV-specific CTL response and 
differences in cytokine secretion in carriers of HLA-A*01:01 suggest biologically 
plausible mechanisms by which risk of developing cHL may be increased and 
merit further exploration.  
Differential DSS and OS were observed, with improved DSS in carriers of HLA-
A*01:01 in all cases, and inferior OS and DSS associated with HLA-A*02:01 in 
EBV+ve cases. These findings require confirmation, but potentially could explain 
some of the differences in outcome seen between individuals, and offer exciting 
possibilities for the targeting of therapy to improve clinical outcome.  
   
277 
 
Appendix 1: Suppliers 
Supplier Address 
Abbot Diagnostics Ltd. Abbott House, Vanwall Business Park, Vanwall Road, 
Maidenhead, Berkshire, SL6 4XF, UK 
AID Diagnostika GmbH  Ebinger Strasse 4, D-72479 Straßberg, Germany 
Alta Bioscience University of Birmingham, Edgbaston, Birmingham, B15 
2TT, UK 
Anachem Ltd. Anachem House, 1 & 2 Titan Court, Laporte Way, Luton, 
Bedfordshire, LU4 8EF, UK 
BD Biosciences Edmund Halley Road, Oxford Science Park, OX4 4DQ, 
Oxford, UK 
Beckman Coulter (UK) 
Ltd. 
Oakley Court, Kingsmead Business Park, London Road, High 
Wycombe, HP11 1JU, UK 
DAKO UK Ltd. Cambridge House, St. Thomas Place, Ely, Cambridgeshire, 
CB7 4EX, UK 
DJB Labcare Ltd. 20 Howard Way, Interchange Business Park, Newport 
Pagnell, Buckinghamshire, MK16 9QS, UK 
E-biosciences Ltd. 2nd Floor, Titan Court,3 Bishop Square 
Hatfield, AL10 9NA, UK 
Elkay Laboratory Products 
(UK) Ltd. 
Unit E, Lutyens Industrial Centre, Bilton Road, 
Basingstoke, Hampshire, RG24 8LJ, UK 
ENM Company 5617 Northwas Highway, Chicago, IL 60646-6135, USA 
Fisher Scientific UK Ltd. Bishop Meadow Road, Loughborough, LE11 5RG, UK 
Gambro BCT Lundia House, Unit 3 The Forum, Minerva Business Park, 
Peterborough, PE2 6FT, UK 
GE Healthcare UK Ltd. Amersham Place, Little Chalfont, Buckinghamshire, HP7 
9NA, UK 
Gen-Probe Life Sciences 
Ltd. 
Appleton Place, Appleton Parkway, Livingston, West 
Lothian, EH54 7EZ 
Gilson Scientific Ltd. 20 Charles St. Luton, Bedfordshire, LU2 OEB, UK 
Grant Inments 
(Cambridge) Ltd. 
Shepreth, Cambridgeshire, SG8 6GB, UK 
Graphpad Software Inc. 2236 Avendida de la Playa, La Jolla, CA 92037, USA 
Greiner Bio-One Ltd. Brunel Way, Stroudwater, Business Park, Stonehouse,GL10 
3SX, UK 
Haier Westgate House, Westgate Ealing, London, W5 1YY, UK 
Hawksley Marlborough Road, Lancing Business Park, Lancing, Sussex, 
BN15 8TN, UK 
HTZ Ltd. 3rd Floor, 55 Gower Street, London, WC1E 6HQ, UK 
IBM UK Ltd. UK Head Office, PO Box 41, North Harbour, Portsmouth, 
Hampshire, PO6 3AU, UK 
Invitrogen Ltd. 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 
9RF, UK 
Luminex B.V. Europe Krombraak 13-15, 4906 CR Oosterhout NB, The Netherlands 
Microsoft Corp. One Microsoft Way, Redmond, WA 98052-6399, USA 
Microzone Ltd. 4 Heath Square, Boltro Road, Haywarth Heath, West 
Sussex, RH16 1BL, UK 
Millipore (UK) Ltd. Suite 3 & 5, Building 6, Croxley Green Business Park, 
Watford, WD18 8YH, UK 
Miltenyi Biotec Ltd.  Almac House, Church Lane Bisley, Surrey, GU24 9DR, UK 
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Supplier Address 
MVE Biological Systems 2200 Airpost Industrial Drive, Suite 500, Ball Ground, GA 
30107, USA 
New Brunswick Scientific/ 
Eppendorf Ltd. 
Endurance House, Vision Park, Histon, Cambridge, CB24 
9ZR, UK 
Pall life sciences Walton Road, Farlington, Portsmouth, PO6 1TD, UK 
QIAGEN Ltd. QIAGEN House, Fleming Way, Crawly, West Sussex, RH10 
9NQ, UK 
R&D Systems Europe 19 Barton Lane, Abingdon Science Park, Abingdon, Oxon 
OX14 3NB, UK 
Royal Mail Royal Mail, FREEPOST SCO6274, 21 South Gyle Crescent, 
Edinburgh, UK 
Scientific Laboratory 
Supplies (SLS) 
Ruddington Lane, Wilford Industrial Estate, Nottingham, 
NG11 7EP, UK 
Sigma-Aldrich Company 
Ltd. 
The Old Brickyard, New Road, Gillingham, Dorset, SP8 
4XT, UK 
Thermo-Fisher Scientific 
Inc. 
81 Wyman Street, Waltham, MA 02454, USA 
Thomson Reuters 2141 Palomar Airport Road, Suite 350, Carlsbard, CA 
92011, USA 
vWR International Ltd. Unit 15, The Birches, Willard Way, Imberhorn Industrial 
Estate, East Grinstad, West Sussex, RH19 1XZ, UK 
Xstrahl Ltd. UK The Coliseum , Watchmoor Park  
Riverside Way , Camberley  
Surrey, GU15 3YL, UK 
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Appendix 2: SHARE study questionnaire
The SHARE study – Study of Healthy Adult Responses to EBV 
 
Study Questionnaire v2 10th July 2009  REC Ref: 08/S0709/149 
 
 
SHARE study number: 
 
 
Age:______________years  Sex: M/F 
 
Post code: _ _ _ _  _ (omit last two digits e.g., G61 1 or PA34 8) 
 
Have you ever had glandular fever (infectious mononucleosis) Yes/No 
 
If Yes: was this confirmed by a laboratory test    Yes/No 
 
 What age were you at diagnosis: ____________________________ 
 
Do you have any current symptoms of allergy    Yes/No 
 
 
Smoking 
Do you smoke cigarettes at all nowadays    Yes/No 
 
Have you ever smoked regularly      Yes/No 
 
What age were you when you started smoking:      _____________________
   
 
How many cigarettes do you/did you smoke per 
day:____________________ 
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Appendix 3: Amino Acid Code 
One-letter abbreviation Three-letter abbreviation Full name 
A  Ala Alanine 
C Cys Cysteine 
D Asp Aspartic acid 
E Glu Glutamic acid 
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I Ile Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Glu Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr  Threonine 
V Val Valine 
W Trp Tryptophan 
Y Tyr Tyrosine 
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Appendix 4: Gating strategy in CD107 flow cytometry 
 
 
 
Gating strategy used in the assessment of CTL degranulation by flow cytometry for CD107. 
Representative results from one donor p10098 shown. The anti-CD017 is present for the 
duration of stimulation and binds the CD107 normally only transiently expressed on the cell 
surface prevents its re-internalisation by endocytosis. a) Negative control: B-depleted 
peripheral blood mononuclear cells (BD-PBMC) with culture medium plus DMSO only. b) BD-
PBMC stimulated with EBV peptides, in this case peptide pool 2 (see Table 3.2) comprising 
latent peptides. Gate P1 comprises the positive events counted. The delta CD107 is defined 
as the change in CD107 expression following stimulation (P1 stimulated – P1 negative 
control). The gates used were the same for all stimulations and controls. 
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